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Abstract 
 
Mantle cell lymphoma (MCL) is a rare B cell neoplasm that accounts for 
approximately 4-8% of non-Hodgkin’s lymphomas (NHLs). The median age at 
diagnosis is 65 years with a male to female predominance of 3:1. It has also 
been demonstrated that female MCL patients have a greater response to 
therapy, especially immunomodulatory therapy compared to male MCL patients.  
The concept of cancer immunosurveillance is well described and it is perceived 
that females mount a greater immune response compared to males. In addition, 
although lymphomas are generally not perceived to be hormone controlled, 
epidemiological studies have demonstrated lower prevalence of lymphoma in 
females taking exogenous oestrogen. 
This aim of this thesis was to explore the gender difference observed in MCL. 
The study investigated the difference in the quantity of immune cells in the 
peripheral blood and lymph node biopsies of untreated male and female MCL 
patients. There was a significantly greater number of T cells in the peripheral 
blood of male MCL patients compared to the female MCL patients. Conversely, 
greater numbers of immune cells were observed in the lymph node biopsies of 
female MCL patients compared to male MCL patients. In addition, four NK cell 
activating receptors; NKp46, NKp44, NKp30 and NKG2D were examined to 
determine if their expression was different between the genders.  
The cell mediated cytotoxic function of the immune cells (PBMCs) from male 
and female MCL patients and healthy controls was also examined. Interestingly 
the healthy controls exhibited greater cytotoxicity compared to the MCL 
patients. PBMCs were incubated with oestrone (female hormone in 
postmenopausal women), lenalidomide and IL-2 to further investigate the 
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effects of these on the immune cells from male and female MCL patients. 
Incubation with IL-2 resulted in a significant increase in the cytotoxicity activity 
of male MCL patients but not female MCL patients in this cohort.  
The lymph node biopsies from MCL patients were examined for the presence of 
oestrogen receptors. Oestrogen receptor β was predominantly expressed on 
MCL cells in all the biopsies examined. This is an area that warrants further 
studies. 
This thesis provides some insight into the mechanisms that may influence the 
gender difference observed in MCL, however further studies are needed.  
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NCR Natural cytotoxicity receptors 
NF-ƙB Nuclear factor kappa-light-chain-enhancer of activated B cells 
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NK cells Natural Killer cells 
NKG2A Natural-killer group 2 member A 
NKG2C Natural-killer group 2 member C 
NKG2D Natural-killer group 2 member D 
NKT Natural Killer T cells 
NHL Non-hodgkins lymphoma 
ORR Overall response rate 
OS Overall survival 
PBMC Peripheral blood mononuclear cells 
PBS Phosphate buffered saline 
PD Progressive disease 
PerCP  Peridininochlorophyll-protein 
PFS Progression free survival 
PI Propidium Iodide 
PI3K Phosphatidylinositol-3-kinase 
PR Partial response 
RAE Retinoic acid early transcript 
RB Retinoblastoma 
SCID mouse Severe combined immunodeficiency mouse 
SCT Stem cell transplant 
SEM Standard error of the mean 
SFM Serum free media 
SHP-1 Src homology region 2 domain-containing phosphatase-1 
STWS Scott’s Tap water substitute 
TBI Total body irradiation 
TCR T cell receptor 
TRAIL TNF-related apoptosis-inducing ligand 
T regs T regulatory cells 
TTF Time to failure 
ULBPS UL16-binding proteins 
VEGF 
VLA4 
Vascular endothelial growth factor 
Very late antigen – 4 
WBC White blood cells 
  
  
  
  
 
  
18 
 
 
 
 
 
 
 
Chapter 1 
 
 
 
 
Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
19 
 
1.0. Mantle Cell Lymphoma 
 
Mantle cell lymphoma (MCL) is a B cell neoplasm that accounts for 
approximately 4-10% of non-Hodgkin’s lymphomas (NHLs) (McKay et al, 2012). 
The median age at diagnosis is 65 years with a male to female predominance 
of 3:1 (Chandran et al, 2012; McKay et al, 2012). Histologically it is 
characterised by an abnormal proliferation of mature B lymphocytes which are 
classically CD19+CD20+CD22+CD23-FMC7+CD5+CD10- (Pérez-Galán et al, 
2011; Campo et al, 2011). In involved lymph nodes, the malignant cells can 
reside in the mantle zone or be found in a nodular or diffuse growth pattern 
which are thought to represent progressive stages of tumour infiltration (Campo 
et al, 2011; Swerdlow et al, 2008). 
1.1. Clinical presentation and epidemiology of MCL 
The majority of the patients present with lymphadenopathy which is generally 
widespread at diagnosis. Eighty to ninety percent present with advanced-stage 
disease with or without B symptoms (fever, weight loss and night sweats) 
(Table 1). Extranodal involvement is common, especially bone marrow (in 
>65%), gastrointestinal tract, liver and spleen and 20-30% of patients present 
with a leukemic component (McKay et al, 2012).  A small subset of patients 
present with disease that is largely non-nodal and confined to the blood, bone 
marrow and spleen. They tend to exhibit a more indolent course than those with 
predominately nodal disease, although the clinical distinction cannot be relied 
upon to predict outcome (Hsi & Martin, 2014).  
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Stage Features 
I Involvement of a single lymph node region or lymphoid 
structure (e.g. spleen, thymus, Waldeyer’s ring) 
II Involvement of two or more lymph node regions on the 
same side of the diaphragm 
III Involvement of lymph regions or structures on both 
sides of the diaphragm 
IV Involvement of extranodal site(s) beyond that 
designated E 
For all stages 
 
A 
 
B 
 
 
No symptoms 
 
Fevers (>380C), drenching sweats, weight loss (10% 
body weight over 6 months) 
For stages I to III 
 
E 
 
 
Involvement of a single, extranodal site contiguous or 
proximal to known nodal site 
Table 1: Staging classification for MCL 
Table demonstrating staging classification used for MCL and non-Hodgkins lymphoma 
by the Ann Arbour classification. Adapted from (Armitage, 2005) 
  
1.2. Molecular Pathogenesis of MCL 
MCL is characterised by the t(11:14)(q13;q32) translocation and the 
overexpression of CCND1 that probably facilitates the transformation of the 
cells by deregulating the cell cycle (Bea, 2014). This translocation juxtaposes 
the CCND1 locus (encoding cyclin D1) on 11q13 to the enhancer of the IgH 
locus on 14q32, leading to upregulation of cyclin D1 mRNA and protein. The 
overexpression of cyclin D1 in MCL results in cell cycle dysregulation by 
facilitating G1 to S phase transition by the cyclin D1 forming a complex with the 
cyclin-dependent kinases CDK4 and CDK6. This complex formation initiates 
phosphorylation of the retinoblastoma (RB) protein (a major negative regulator 
of S phase entry), release of E2F transcription factors (such as cyclin E), and 
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formation of cyclin E/CDK2 complexes. These events produce irreversible 
inactivation of the RB protein and ultimately progress into S phase (Jares et al, 
2007). Rarely some cases of MCL are cyclin D1 negative and in such cases 
overexpression of cyclin D2 or D3 is demonstrated, suggesting that 
dysregulation of other cyclins may confer an alternative mechanism for MCL 
development (Swerdlow et al, 2008; Beà et al, 2013; Jares et al, 2007).   
The initial translocation event occurs at the pre-B cell stage in the bone marrow 
and appears to follow two molecular and clinical subtypes of MCL (Jares et al, 
2012). The most common form of MCL, the classical subtype, is derived from 
mature B cells that are limited to the mantle cell zone of the follicle and carry no 
or limited number of IGHV somatic mutations (Navarro et al, 2012). This 
subtype expresses the neural transcription factor SOX11 which are genetically 
unstable and accumulate alterations in regulatory genes, DNA damage 
response pathways and cell survival mechanism. These alterations result in 
aggressive tumour behaviour. The second subtype of MCL carries the IGVH 
with somatic mutation. These tumour cells are genetically stable and the SOX11 
expression is minimal or negative. This subtype tends to disseminate more to 
the peripheral blood and spleen than the lymph nodes (Fernàndez et al, 2010; 
Jares et al, 2012) (Figure 1). 
All mature B cells and mature B cell malignancies are negative for the 
expression of SOX11, but its presence in MCL highlights its relevance in the 
pathogenesis of MCL (Mozos et al, 2009) suggesting additional pathways for 
the development of MCL. SOX11 promotes tumour growth of MCL cells in vivo 
and regulates a broad spectrum of transcriptional program which includes B 
cells development by altering the terminal B cell differentiation of MCL 
(Vegliante et al, 2014).  
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Figure 1: Two different molecular subtypes of MCL.  
Two hypothetical models of different molecular subtypes of MCL. The naive B cell with the 
t(11;14) mutation colonizes the mantle zone of the lymphoid follicle and generates an in situ 
MCL lesion. Most MCLs evolve from these cells or cells in the marginal zone with no or limited 
IGHV somatic mutations. The tumours which express SOX11, are genetically unstable, and 
tend to accumulate alterations in genes dysregulating cell cycle, DNA damage response 
pathways, and cell survival mechanisms. Alternatively, some cells with the t(11;14) may enter 
the germinal center and undergo IGHV somatic hypermutations. These cells are genetically 
stable and do not express SOX11. The tumours derived from these cells tend to spread to the 
peripheral blood and spleen more than to lymph nodes. The disease seems to be stable for long 
periods of time, but some of these tumors may acquire mutations in genes such as TP53 that 
lead to disease progression. Adapted from (Jares et al, 2012) 
 
Other molecular events have also been described in addition to the major 
t(11;14)(q13;q32) translocation in MCL. The most common alterations further 
deregulating cell cycle in MCL involve the INK4a/CDK4/RB1 and 
ARF/MDM2/TP53 pathways (Jares et al, 2012). The CDKN2A locus (9p21), 
frequently deleted in MCL, connects both pathways encoding for the CDK 
inhibitor INK4a and the positive p53 regulator ARF. TP53 is commonly mutated 
gene in MCL (19-28%) and RB1 is also inactivated by point mutations or gene 
deletions in occasional cases. Gene amplification leads to the overexpression 
of CDK4, MDM2 and BMI1, that in turn represses the CDKN2A locus. These 
mutations and alterations further dysregulate the cell cycle (Jares et al, 2007).  
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MCL has deregulated cell signaling pathways in addition to the genetic 
alterations that have been demonstrated in recent promising results observed in 
clinical trials involving inhibition of the bruton’s tyrosine kinase (BTK) of the B 
cell receptor signaling pathway (Advani et al, 2013; Wang et al, 2013b; Shah et 
al, 2014). Furthermore, the microenvironment of MCL may also influence the 
development and studies have observed IL-6 influence in MCL development by 
activating STAT3 pathway as discussed below (Pérez-Galán et al, 2011; Jares 
et al, 2007; Zhang et al, 2012).  
1.3. MCL tumour microenvironment 
 
There has been limited data on the precise composition of the 
microenvironment in MCL. Extrapolating from other B cell lymphomas studies, it 
is somewhat possible to describe the microenvironment in MCL. 
The tumour microenvironment of B cell lymphomas contains variable numbers 
of immune cells, stromal cells, blood vessels and extracellular matrix (Scott & 
Gascoyne, 2014). The extent, composition and architecture of this environment 
is dependent on multiple factors which include genetic aberrations that are 
harboured by the malignant cells and their dependence on external stimuli for 
survival, proliferation and immune evasion (Coupland, 2011). 
Majority of MCL patients have advanced stage disease (Anne Arbour stages 
III/IV) and a large proportion of MCL patients have extranodal manifestation 
with a prevalence of circulating MCL cells in the bone marrow and 
gastrointestinal involvement (Campo & Rule, 2015; Shah & Rule, 2014). These 
clinical features suggest that MCL cells have a very active ‘homing’ function to 
lymph nodes and different tissue compartments. Lymphoma cell trafficking is a 
non-random, complex and regulated process which allows these cells to 
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migrate to tissues in response to stromal cell derived chemokine gradients 
(Scott & Gascoyne, 2014). B cell lymphoma cells retain the capacity of their 
normal counterparts for trafficking and homing (Scott & Gascoyne, 2014). MCL 
cells exhibit a high expression of chemokine receptors and adhesion molecules 
such as chemokine receptor 4 (CXCR4), CXCR5 and chemokine receptor 7 
(CCR7) and similarly on the endothelial cells of the high endothelial venules 
allowing them to move to lymph nodes and other tumour supporting areas 
(Kurtova et al, 2009). These receptors plus the adhesion receptor; very late 
antigen-4 (VLA4 / CD49d),  enables MCL cells to interact with accessory 
stromal cells, such as mesenchymal stromal cells and lymphoma-associated 
macrophages (LAM) (Trentin et al, 2004). Once the MCL cells are within the 
tumour supporting area, the chemokine and adhesion receptors establish 
contact between the LAM and stromal cells (Burger & Ford, 2011).  
1.4. B cells   
 
As MCL is a B cell disorder a brief review of normal B cells here would enable 
further understanding of the pathogenesis as to a degree, the composition of 
the microenvironment represents remnants of the normal lymphoid tissue, 
effaced or infiltrated by malignant cells and the host inflammatory response 
(Swerdlow et al, 2008; Scott & Gascoyne, 2014). The normal B cells originate 
from haematopoietic progenitor cells within the bone marrow and migrate to 
secondary lymphoid organs to complete their development (Cooper, 2015). This 
involves immunoglobulin VDJ gene rearrangement and differentiation into 
mature naïve B cells that express surface IgM and are often CD5+ (Kraus et al, 
2004) These naïve B-lymphocytes circulate and have a homing process toward 
the lymph nodes (Von Andrian & Mempel, 2003). Once they have migrated to 
the B cell zone of the lymph node follicle, they encounter antigens which are 
25 
 
presented by macrophages and dendritic cells (Bastista & Harwood, 2009). The 
B cells occupy the primary lymphoid follicles and follicle mantle zones until they 
encounter antigen whereupon they migrate into the centre of a primary follicle, 
undergo blastic transformation into centroblasts, and form a germinal centre 
(Victoria & Nussenzweig, 2012). The centroblasts matures into centrocytes 
within the germinal centre, resulting in somatic mutations of the immunoglobulin 
variable region gene and heavy chain class enabling the production of higher-
affinity IgG or IgA (Victoria & Nussenzweig, 2012). Final outcome of these 
centrocytes is to differentiate into either antibody-secreting plasma cells, which 
home back to the bone marrow, or memory B cells which reside in the follicle 
marginal zones (Delves et al, 2011; Cooper, 2015). 
The B cells major role in adaptive immunity is to produce immunoglobulins that 
recognise, bind and eliminate specific antigen (Scott & Gascoyne, 2014). Each 
individual B cell produces immunoglobulin of a single specificity which is also 
expressed on its surface in a membrane-bound form known as the B-cell 
receptor (BCR) (Kraus et al, 2004). Binding of antigen to the BCR either directly 
or indirectly (via CD4+ helper T cells) triggers B cell activation, clonal expansion, 
and the secretion of soluble immunoglobulin (antibodies) into the extracellular 
space (Delves et al, 2011; Cooper, 2015). B cells that bind antigen via BCR 
internalize and represent the antigen on major histocompatibility complex 
(MHC) class II with activation of nuclear factor-ƙB (NF-ƙB) directing the primed 
B cell towards the T cell – B cell border (McHeyzer-Williams et al, 2012). The 
interaction of B and T cells here provides a checkpoint that selects cells with 
high affinity BCR for further development in the germinal centre of the B cell 
follicle (Cooper, 2015). Immunophenotyping, histological analysis and gene 
expression profile of MCL  have identified characteristics that are reminiscent of 
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naïve B cells. Furthermore 15-40% of MCL cells also show somatic 
hypermutation indicating that they have passed through the germinal centre 
reaction possibly following T cell – B cell interaction (Jares et al, 2012).  
1.5. T cells in MCL microenvironment 
Cellular composition of MCL microenvironment has not been systematically or 
definitively analysed. It has been extrapolated from other B cell lymphoma 
studies suggesting that MCL has a similar microenvironment to follicular 
lymphoma to a certain extent (Scott & Gascoyne, 2014). This environment 
consists mostly (90-95%) of malignant MCL cells but other cells are also 
present such as CD4+, CD8+ T cells, T regulatory cells, follicular regulatory 
cells, macrophages, follicular dendritic cells and normal B cells are also present 
(Scott & Gascoyne, 2014). The expression of CD40 and responsiveness to 
CD40 ligand (CD154) suggest interaction with T cells which provide MCL cell 
survival and expansion (Burger & Ford, 2011). In addition B cell lymphomas 
have a high infiltration of CD4+ cells which include CD4+CD25+ T cells 
expressing CTLA4 and Foxp3 (intratumoral T regulatory cells) and follicular 
regulatory T cells further supporting their survival and suppression of 
immunoediting by cytotoxic T cells (Yang et al, 2006). Interestingly the 
interaction of  CD4+ T cells with lymphoma cells encourage them to develop into 
T regulatory cells (Yang et al, 2006). This process is mediated by the 
expression of molecules that are involved in co-stimulation of naïve T cells, 
including CD70, CD80 (B7-1) and CD86 (B7-2) (Yang et al, 2009). Furthermore 
it has been demonstrated that lymphoma cells have higher expression of CD70 
which supports the mechanism by which naïve T cells are encouraged to 
develop into T regulatory cells (Yang et al, 2006, 2009). In context of MCL and 
27 
 
its relation to T cells, a brief review of normal T cells below aids to appreciate 
their role in the microenvironment. 
1.6. The T cells   
T cell mediated immunity is central to the adaptive immune system. T cells are 
derived from the haematopoietic cells and each T cell lymphocyte expresses a 
unique T cell receptor on the surface as the result of developmental selection 
upon maturation in the thymus (Kared et al, 2014). The mature T lymphocytes 
leaving the thymus are also known as naïve T cells. They circulate through the 
blood and lymphatic system and reside in secondary lymphoid organs (spleen, 
lymph nodes, tonsils, gut and nasal lymphoid tissue plus mucosal lymphoid 
tissue) (Andersen et al, 2006). The naïve T lymphocytes have not encountered 
foreign antigens and thus are not activated. They reside in the spleen for a few 
hours and in the lymph nodes for approximately a day before leaving to enter 
another lymph node and repeating the cycle until its gets activated (Munoz et al, 
2014; Kared et al, 2014). Activation of T cells is an adaptive process whereby 
antigenic peptides are presented to the naïve T cells in secondary lymphoid 
tissue by antigen presenting cells (APC) such as the dendritic cells (DC), which 
are the most efficient antigen presenting cells (APC). Antigens presented to T 
cells are recognised through the T cell receptor (TCR) leading to activation of T 
cell immunity (Medzhtov & Janeway, 2000; Delves et al, 2011). 
1.7. The T cell receptor (TCR) 
 
The TCR consists of two heterogeneous polypeptide chains, an α and a β 
chain, linked by a disulphide bond which is expressed on the surface and is 
unique to each T cell (Wucherpfennig et al, 2010). Both these chains possess a 
variable (V) region, which recognises and binds specific antigen, and a constant 
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(C) region, which provides effector or signalling functions once antigen is 
bound. The V region of each TCR is encoded by different gene segments that 
are assembled within the developing lymphocyte by somatic DNA 
recombination, a process referred to as gene rearrangement (Medzhtov & 
Janeway, 2000). This enables the T cells to have a vastly diverse repertoire of 
highly specific TCRs, thus allowing majority of the antigens encountered within 
an individual’s lifespan to be recognised (Rossjohn et al, 2014).  
TCR with α and β chains also have additional accessory chains which are 
required for optimal T cell activation following antigen binding (Gras et al, 2008).  
These accessory chains; γ, δ and ε are part of the CD3 co-receptor (commonly 
used surface marker in the laboratory to identify T cells) and the ζ chain which 
is largely intracytoplasmic (Rudolph et al, 2006). The αβTCR T cells are 
subdivided into several groups on the basis of lineage markers and functional 
activities. Furthermore, two major surface co-receptor molecules, CD4 and 
CD8, define two separate T cell lineages with different functions (Gras et al, 
2008).  The CD4+ cells recognize antigens in the context of MHC class II 
molecules (only expressed on APC such as B cells, macrophages and DC) and 
produce cytokines as effector T helper cells. The CD8+ lymphocytes are 
activated by antigenic peptides presented by MHC class I molecules (expressed 
on all nucleated cells) and form effector cytotoxic T lymphocytes (CTL) 
(Rossjohn et al, 2014; Andersen et al, 2006; Doherty & Zinkernagel, 1997). 
The TCR recognizes antigenic peptides presented in the context of Major 
Histocompatibility Complex (MHC). MHC is a set of cell surface proteins 
required to recognise foreign molecules, thus determining histocompatibility. 
(Medzhtov & Janeway, 2000). The main function of MHC molecules is to 
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present and display antigenic peptides derived from intracellular proteins on the 
cell surface for recognition by appropriate T cells (Ku et al, 2009; Doherty & Ko, 
1997). The presented peptide can be either self or non-self, thus regulating 
normal cells from being attacked by the immune system. Class I MHC 
molecules have a heavy polypeptide chain linked to a smaller polypeptide 
called a β2-microglobulin subunit so can only be recognized by CD8 co-
receptors (Doherty & Zinkernagel, 1997). Class II MHC molecules consist of α 
and β polypeptide chains with no presence of β2-microglobulin so can be 
recognized by CD4 co-receptors (Neefjes et al, 2011). The MHC class I and II 
molecules are polygenic and there are three MHC class I α-chain gene, HLA-A, 
HLA-B and HLA-C which result in at least three different class I proteins (Pende 
et al, 2002). Similarly there are three different types of MHC class II α and β 
genes expressed; HLA-DQ, HLA-DP and HLA-DR, thus resulting in at least 3 
different class II molecules but much more when polymorphisms are taken into 
account (Rossjohn et al, 2014; Trowsdale & Knight, 2013). The different types 
of class I and class II molecules all exhibit the same basic structure and all 
participate in presenting peptides to T cells but, because of significant 
differences in their peptide groove each presents a different range of peptides 
to the immune system (Trowsdale & Knight, 2013).  
 In 1996, Zinkernagel and Doherty were awarded the Nobel Prize in Medicine 
for demonstrating that CD8+ T cells could only recognize virally infected target 
cells if they expressed a particular set of MHC molecules (Doherty & 
Zinkernagel, 1997). The MHC molecules are able to present a vast range of 
peptides. It is estimated that there are up to 250,000 of each HLA class I 
molecule on the surface of a cell (Parham & Ohta, 1996). Similarly, naïve CD4+ 
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cells are activated by their TCR recognition of peptides presented by MHC class 
II, which has a more restricted expression pattern.  
The classical expression of antigen by MHC class I molecules essentially have 
three processes; first , the proteasomal degradation of endogenous proteins to 
peptides in the cytosol; second the translocation across the endoplasmic 
reticulum and third, the presentation of the antigen by assembly of the MHC 
with its β2-microglobulin  molecule (Crotzer & Blum, 2009; Chapman, 2006). 
MHC class I also present exogenously processed peptides to cytotoxic T cells 
and this is referred to as the alternative pathway. Antigen Presenting Cells 
(APC) and dendritic cells are generally involved with the alternative pathway, 
presenting peptides to the effector T cells using a similar mechanism to the one 
described above (Shen & Rock, 2006). 
The type of MHC class expression on tumour cells and cell lines can be 
demonstrated by flow cytometry. This is an effective method of investigating the 
expression of MHC-class expression on various cells (Schietinger et al, 2010; 
Manning et al, 2008). In relation to MCL, Drenou et al, have demonstrated 
reduced expression of MHC on mantle cell lymphoma cells by flow cytometry 
after studying mantle cell lymphoma cells from patients as part of a larger study 
encompassing B cell lymphomas (Drenou et al, 2002). 
1.8. T helper cells (Th) 
T helper cells play critical roles in orchestrating the adaptive immune 
responses. Their function is mainly through secreting cytokines and chemokines 
that activate and/or recruit target cells (Zhu & Paul, 2015).  The activated CD4+ 
T helper cells can be further distinguished by their cytokine profile. They are 
subdivided into Th1, Th2, Th17 and regulatory T cells (T regs) based on their 
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effector function and the production of specific cytokines (figure 2.0) (Tato & 
O’Shea, 2006).   
The three most relevant subsets for this thesis and MCL; Th1, Th2 and T 
regulatory cells will be discussed in more detail below and later in this chapter. 
Th1 and Th2 cells 
The Th1 cells produce mainly IFN-γ, but also IL-2 and lymphotoxin-α (LTα). The 
Th1 cells enhance pro-inflammatory cell mediated immunity by stimulating 
cytotoxic T cells and have been shown to induce delayed-type hypersensitivity 
and B cell production of opsonizing isotypes of IgG (Williams et al, 2006).  
The Th2 cells produce and secrete IL-4, IL-5, IL-6, IL-10, IL-13 and IL-25 and 
encourage non-inflammatory immediate immune responses. They have also 
been shown to be essential in B cell production of IgG, IgA and IgE. IL-4 has a 
positive feedback effect for Th2 cell differentiation and is a major mediator for 
IgE class switching in B cells (Zhu & Paul, 2015). IL-5 recruits eosinophils and 
affects mast cells and lymphocytes. IL-9 induces mucin production in epithelial 
cells and IL-10 suppress Th1 cell proliferation and can suppress dendritic cell 
function (Trinchieri, 2007).  IL-25 (also known as IL-17E) is also a Th2 cytokine. 
IL-25, signalling through IL-17RB, enhances the production of IL-4, IL-5, and IL-
13 (Fort et al, 2001). IL-25 can induce the production of chemokines including 
RANTES (CCL5) and eotaxin (CCL11) that recruit eosinophils (Zhu & Paul, 
2015). 
The development of these subsets of T helper cells from naïve T cells is 
dependent on the particular cytokines present in the microenvironment. Th1 
development prevails in the presence of IFN-γ and IL-12 whilst Th2 
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development predominates in the presence of IL-4. The resulting Th1 or Th2 
population will subsequently produce more IFN-γ or IL-4 respectively providing 
a positive feedback loop for further Th1 or Th2 cell production. This enables 
maintenance of the CD4+ T cell subtype most suited to the immune response 
required (Geginat et al, 2014; Zhu & Paul, 2015). Figure 2 below summarizes 
CD4 T cells, including their unique cytokine production and cytokines critical for 
their final development and maturation including some of their functions. 
 
Figure 2: Summary of CD4 T helper cell fates 
Their functions, their unique products (as shown in red) and cytokines critical for their final 
determination (shown in black bold print). Adapted from (Zhu & Paul, 2015). 
 
Cytotoxic T cells  
Cytotoxic T cells develop from naïve CD8+ cells and their role is to monitor all 
cells of the body, ready to destroy any that are thought to be a threat to the 
body (Andersen et al, 2006). Cytotoxic T cells can be easily activated by the 
antigen MHC class I complex and undergo dramatic clonal expansion 
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(Andersen et al, 2006; Doherty & Ko, 1997).  Cytotoxic T cells are efficient 
effector cells due to their ability to destroy more than one target cell, whilst 
sparing innocent ‘bystanders’. Destruction of the target cells require cell contact 
to be established and antigen recognition before initiating the release of 
cytolytic granules into the synapse (Von Andrian & Mackay, 2000). Cytotoxic T 
cells do not require a co-stimulatory signal upon antigen recognition in order to 
kill the target cells (Andersen et al, 2006; Delves et al, 2011). 
There are two major cytotoxicity pathways that have been described. One is a 
calcium dependent perforin/granzyme mediated apoptosis and the second is 
calcium independent Fas ligand/Fas-mediated apoptosis. Both pathways are 
initiated via the TCR signalling (Andersen et al, 2006).   
Perforins and granzymes are transported into the target cell as one complex 
and granzymes induce apoptosis via the caspase-dependent and independent 
mechanisms. Perforin appears to enable transfer of granzyme via pores it 
forms. The Fas-mediated apoptosis is initiated by binding of the Fas molecule 
(CD95) on the target cell via the Fas ligand (CD95L) or TRAIL on the effector 
cells, which subsequently initiates the caspase dependent apoptosis in the 
target cell (Andersen et al, 2006).  
1.9. Activation of T cells 
Naïve T cells received two separate signals to become activated. The first 
signal is provided through engagement of the TCR with its MHC-bound 
antigenic peptide (Von Andrian & Mackay, 2000). The second, or co-
stimulatory, signal is provided by interaction between various accessory 
molecules on the surface of APCs and T cells (Smith-Garvin et al, 2009). The 
best-characterised co-stimulatory pathway involves the binding of CD28 on T 
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cells to B7-1 (CD80) or B7-2 (CD86) on APCs although many other co-
stimulatory pathways interactions, such as OX40/OX40L and CD27/CD70 have 
been identified (Figure 3)(Sharma et al, 2011). Once activated by both signals 
the T cells rapidly proliferate and differentiate to produce large number of 
effector T cells. This process is also critically aided by the production of IL-2 by 
the activated T cells. Conversely in the absence of co-stimulation the T cell 
which has recognised the antigen via the TCR only, is either clonally deleted or 
functionally inactive (Kared et al, 2014). Once activated the effector cells do not 
require co stimulation and can be activated by the antigen alone (Von Andrian & 
Mackay, 2000; Sharpe & Abbas, 2006; Kared et al, 2014).  
Activation of T cells is restricted by inhibitory signals. This is achieved by the 
upregulation of cytotoxic T lymphocyte-associated protein 4 (CTLA4) following 
the initial stimulation of T cells by B7-CD28 interaction. CTLA4 has a greater 
affinity to B7 and therefore out-competes CD28 thus initiating inhibitory signals 
for the T cells (Figure 3B) (Sharma et al, 2011; Andersen et al, 2006). In 
addition other inhibitory signals are initiated by programme cell death 1 (PD1) 
and its interaction with PD1 – ligand on the APC (Myklebust et al, 2013; 
Greenwald et al, 2005). 
In the context of MCL, a recent study by Wang et al, demonstrated the 
expression of B7-H1 on MCL which resulted in inhibition of T-cell proliferation 
induced by the tumour cells, impaired generation of antigen-specific T-cell 
responses, and mantle cell lymphoma cells being rendered resistant to T-cell-
mediated cytolysis (Wang et al, 2013). 
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Figure 3: T cell activation 
A: The initial T cell activation begins with TCR and interaction with antigen bound on 
the MHC found on the antigen presenting cell (APC), but additional co-signals are 
provided by the interaction between CD28 and B7.  
B: T cell activation is limited by cytotoxic T lymphocyte-associated protein 4 (CTLA4) 
which is upregulated following initial activation. CTLA-4 has a higher affinity to B7 and 
out-competes CD28 for binding to B7 on the APC. Later inhibitory signals as provided 
through programmed cell death 1 (PD1) which binds to PD1 ligand (PD1L) and other 
regulators are also present such as T cell immunoglobulin and mucin domain 
containing protein 3 (TIM3) and V domain immunoglobulin suppressor of T cell 
activation (VISTA). Adapted from (Sharma et al, 2011). 
 
1.10. The regulatory T cells (T regs) 
The majority of the T regulatory cells appear within the CD4+ T cell subset and 
their primary role is to suppress the immune response mounted against self and 
foreign antigens.  Therefore they are critical in the maintenance of peripheral 
tolerance and prevention of autoimmune disease (Corthay, 2009). The exact 
mechanism by which T regulator cells exert their function is not fully described 
however immunosuppressive cytokines such as TGF-β, IL-10 and IL-35 play an 
important role. Presently, the T regulatory cells have the following functions 
described (Corthay, 2009): 
Early Co-inhibitory 
signal 
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 Prevention of autoimmune diseases by establishing and maintaining 
immunologic self-tolerance via inhibitory cytokines such as IL-10, TGF-β, 
IL-35 (Collison et al, 2007). 
 Suppression of allergy and asthma. 
 Metabolic disruption e.g. via IL-2 consumption. 
 Induction of maternal tolerance to the foetus. 
 Suppression of pathogen-induced immunopathology  
 Modulation of dendritic cell maturation and / or function. 
T regulatory cells are classified into two types; natural and induced. The natural 
T regulatory cells develop in the thymus express surface CD4 and CD25 (IL-
2Rα), and are positive for the intracellular transcription factor forkhead box P3 
(Foxp3) that is essential for their development, survival and function (Curotto de 
Lafaille & Lafaille, 2009). They represent approximately 10% of the CD4+ 
population (Kelley & Parker, 2010). Inducible T regulatory cells are generated in 
the periphery from CD4+CD25-Foxp3- cells in response to certain antigenic 
stimuli and in the presence of TGF-β and IL-10, or in the absence of co-
stimulation especially in the mucosal tissues (Josefowicz et al, 2012; Curotto de 
Lafaille & Lafaille, 2009). Furthermore, within the population of the inducible T 
regulatory cells there is additional heterogeneity which include the T regulatory 
1 (Tr1) and T helper 3 (Th3) cells which depend on IL-10 and TGF-β for their 
suppressive actions respectively (Broere et al, 2011).  
The inhibitory effect exerted by all T regulatory cells can also be via the TCR 
stimulation.  Upon activation their function may be mediated via direct cell 
contact through inhibitory molecules such as cytotoxic T lymphocyte-associated 
antigen 4 (CTLA4) or via secretion of IL-10 and TGF-β (Lindqvist & Loskog, 
2012). IL-10 can suppress Th1 and Th2 cells by influencing the production of 
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IL-2 (Steinbrink et al, 2002), TNF-α and IL-5 and indirectly by down-regulating 
MHC and co stimulatory molecules on the APC (Lindqvist & Loskog, 2012).  
T regulatory cells are identified by the following markers; CD4+, CD25+, CTLA-4, 
glucocorticoid-induced tumour necrosis factor receptor family related gene 
(GITR), lymphocyte activation gene-3 (LAG-3), CD127 and Foxp3. However, 
these markers are not specific for T regulatory cells as all of them are either up 
or down regulated depending on the activation of the CD4+ cells and are also 
present on other cells such as CD8+ T cells (Corthay, 2009). Nonetheless, 
Foxp3 remains a reliable marker for T regulatory cells and CD127 low / dim can be 
used as an alternative marker for Foxp3 if cell permeabilisation is to be avoided 
(Simonetta et al; Liu et al, 2006). CD127 is an IL-7 receptor which is down 
regulated in a subset of CD4+ cells in the peripheral blood. Lui et al, have 
demonstrated that majority of these cells are Foxp3+  including, those 
expressing low levels or no CD25. A combination of CD4, CD25 and CD127 
resulted in highly purified population of T regulatory cells and hence allowed the 
CD127 biomarker to identify T regulatory cells (Liu et al, 2006).  
 
1.11. Macrophages in MCL microenvironment 
 
Macrophages have been postulated to have an important presence in MCL 
tissue. However their specific role in the pathogenesis remains to be described 
(Burger & Ford, 2011). High numbers of macrophages have been shown to 
correlate to more aggressive disease characteristics and it has been suggested 
that they are central to MCL survival (Kurtova et al, 2009). Macrophages 
present antigens to B cells and the rapid in vivo delivery of immune-complexes 
to marcophages in the lymph node subcapsular sinus including their capture by 
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follicular B cells has been demonstrated by multiphoton intravital microscopy of 
lymph nodes (Junt et al, 2007). They also express TNF family members, B cell 
activating factor (BAFF) and a proliferation inducing ligand (APRIL) that provide 
survival signals to MCL cells via the receptors BCMA, TACI and BAFF-R on 
MCL cells (Rodig et al, 2005) thus providing additional support for growth and 
survival. This mechanism of action with normal B cells and malignant cells by 
macrophages could be similar to events that occur in the microenvironment of 
MCL with macrophages and malignant MCL cells (Burger & Ford, 2011).   
1.12. Stromal Cell in MCL microenvironment 
Another potentially important cell is the mesenchymal stromal cell (MSC), which 
is also found in the microenvironment of MCL. In lymphomas stromal cells 
create a microenvironment that initially attracts malignant cells, allowing for 
early survival and subsequently contributing to tumour growth (Gascoyne et al, 
2010). MCL cells adhere to MSC cells by adhesion receptors CXCR4 and VLA-
4. Blocking of CXCR4 (by plerixafor a CXCR4 antagonist) and VLA-4 (by 
natalizumab a VLA-4 antagonist) disrupts the adhesion interactions and 
releases the MCL cells from their microenvironment thus making the cells more 
susceptible to anti-MCL therapy (Kurtova et al, 2009; Burger & Ford, 2011). 
MCL cells have a high affinity for MSC and have been shown to induce drug 
resistance probably because of the interaction with the MSC cells resulting in a 
protective environment (Kurtova et al, 2009). Cross talk between stromal and 
MCL cells involve many soluble mediators including interleukin (IL)-6, IL-7, IL-4, 
IL-8, vascular growth factor, CXCR4 and insulin growth factor 1 (Coupland, 
2011). Zhang et al demonstrated survival and chemotherapy resistance with IL-
6 in MCL.  They exposed MCL cells to neutralizing autocrine IL-6 or IL-6 
receptor antagonist which resulted in MCL cell growth inhibition and enhanced 
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rate of spontaneous apoptosis and sensitivity to chemotherapy drugs (Zhang et 
al, 2012). This provides further evidence of stromal’s interaction with malignant 
MCL cells.  
1.13. Other survival and growth signals in MCL microenvironment 
Again the exact characteristics and details of survival and growth signals have 
not been fully detailed in MCL. However it has been demonstrated that B cells 
require an intact B cell receptor (BCR) for survival (Kraus et al, 2004; Burger & 
Buggy, 2013). It is a key factor in promoting clonal expansion in various 
malignancies such as MCL, chronic lymphocytic leukaemia and diffuse large B 
cell lymphoma via activation of downstream kinases (Pérez-Galán et al, 2011; 
Pighi et al, 2011; Ponader & Burger, 2014). MCL cells have been found to have 
constitutive activation of Spleen tyrosine kinase (Syk)  and PKCβ II which are 
signal components downstream of BCR (Herman et al, 2011). Pighi et al, 
demonstrated BCR associated kinases including Syk and Btk as the most 
abundant phosphor-proteins in MCL by phospho-proteomic analysis (Pighi et al, 
2011), suggesting that BCR signalling plays a central role in disease 
maintenance and progression, although the mechanism and possible antigens 
involved in BCR stimulation remains obscure.  
The BCR is made up of antigen-specific membrane Ig paired with Ig-α / Ig-β 
heterodimers (CD79α/CD79β). Once the antigen has engaged the BCR it 
induces phosphorylation of immunoreceptor tyrosine-based activation motifs 
(ITAM) in the cytoplasmatic tails of Ig-α and Ig-β with subsequent activation of 
tyrosine kinases the Src-family kinases (Lyn, Fyn, Blk and Lck) and the Syk as 
shown in figure 2. These then activate Btk downstream, which in turn activats 
phospholipase-Cγ (PLCγ), enabling calcium mobilization and activation of the 
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NF-ƙB and MAP kinase pathways promoting cell proliferation and survival 
(Burger & Buggy, 2013; Shah et al, 2014; Advani et al, 2013).  New targeted 
drugs have been recently developed that block the downstream Btk and inhibit 
cell survival and proliferation (Wang et al, 2013b). Additionally it has been 
demonstrated that there is an initial lymphocytosis due to the ‘off target’ effects 
on the adhesion receptors such as CXCR4 and CXCR5. This causes the 
interference of the external stimuli from BCR and disruption of the lymphoma-
stromal interaction in the microenvironment thereby releasing the MCL cells out 
of the ‘fertile’ microenvironment to less suitable environment which results in a 
short survival (Advani et al, 2013; O’Brien et al, 2014; Shah et al, 2014; Chang 
et al, 2013). 
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Figure 4: A simplified B cell receptor signalling pathway 
The BCR is activated as an antigen is attached, initiating the phosphorylation of CD79a 
and CD79b (within the cytoplasmic tails of their immunoreceptor tyrosine kinase 
activation motifs (ITAMs), by the tyrosine kinases Lyn and Fyn. Btk, BLNK, PI3K 
amongst others are recruited to the membrane and Syk in turn is recruited and 
phosphorylates Btk and multiple other substrates including PI3K. Phosphorylated Btk 
activates signals downstream to induce activation of NF-κB which is involved in B cell 
proliferation and survival. Btk also activates other molecules which are involved in B 
cell survival and proliferation. The irreversible inhibition of Btk by ibrutinib stops the 
Btk’s downstream cascade of signals which in turn inhibits or affects B cells 
proliferation, motility, differentiation and survival.  Adapted from (Shah et al, 2014).   
 
 
Immununity and immune cells as shown above have a significant role in tumour 
microenvironment as discussed above (Dunn et al, 2002). The role of immune 
surveillance on tumour cells is further discussed below. 
1.14. Immune surveillance of tumours 
The immune system has three primary roles in the prevention of tumours (Dunn 
et al, 2004): 
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1. Elimination of virus infected cells to protect the host from virus-induced 
tumours for example secondary lymphomas driven by Epstein Barr virus 
(EBV) infections and HTLV driven T cell lymphomas. 
2.  Removal of pathogens in a timely manner to prevent an inflammatory 
environment conducive to tumour genesis. 
3. Identification and removal of cancerous cells or stressed cells on the 
basis of their expression of tumour specific antigens or molecules 
induced by stress. 
Immune surveillance is a process by which the immune systems identifies 
cancerous or precancerous cells and eliminates them before they cause harm. 
This concept that was first proposed half a century ago and has now been 
further refined by incorporating evidence of tumour genesis in a functioning 
immune system resulting in a more complete explanation termed as tumour 
immunoediting (Dunn et al, 2004). 
The immunoediting concept is divided into three phases; elimination, equilibrium 
and escape (Dunn et al, 2004). The elimination phase has the same concept 
that is described in immune surveillance whereby the immune system detects 
and eliminates cancerous cells. This phase can be complete with removal of all 
cancerous cells or incomplete with the removal of only a small proportion of 
cancerous cells. The incomplete removal of cancerous cells results in a 
temporary state of equilibrium whereby the cancerous cells remain dormant or 
continue to evolve by facilitating further DNA changes and modulating the 
antigens they present.  At this stage the immune system is sufficiently keeping 
the cancerous cells in control, but if the immune system fails to completely 
eliminate these cells, this can result in cancerous cells developing variants by 
selection that are able to resist, avoid or suppress  the immune system and 
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eventually lead to the escape phase and proliferation of the cancer (Swann & 
Smyth, 2007). 
The evidence of immunoediting is present in both animal and human models of 
cancer (Dunn et al, 2002). In mouse models the elimination of specific 
components of the mouse’s immune system via gene-targeted mice has led to 
these mice developing cancers (Shankaran et al, 2001). For example, mice 
lacking in T cell and NK cell cytotoxic effector pathway due to the lack of 
perforin, which is used by cytotoxic T cells and NK cells to form membrane 
pores on target cells have been shown to develop spontaneous lymphomas 
with time (Street et al, 2002). The lymphomas that developed in these mice 
were transplanted into wild type (WT) immunocompetent mice and were 
rejected by their intact immune system, particularly cytotoxic T cells (Smyth et 
al, 2000). Furthermore B cell lymphomas in mice lacking both perforin and β2-
microglobulin are rejected by either NK cells or T cells following transplantation 
to WT mice supporting the notion of MHC-class I molecule expression on 
cancer cells will influence and mediate the effector cells involved (Street et al, 
2004). In addition there have been many other studies using gene targeted 
mice to knock out certain aspects of the immune system including loss of 
immune cells and production of cytokines to demonstrate and support immune 
surveillance. This has been reviewed in more detail elsewhere detailing 
evidence of immunoediting in mice models (Swann & Smyth, 2007). 
In humans, a number of clinical observations have provided supporting 
evidence of cancer immune surveillance.  In immunosuppressed patients there 
is higher risk of malignancy. Immunosuppression to prevent transplant rejection 
is associated with up to a hundred fold increase in certain malignancies among 
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which lymphomas predominate (Penn, 1988; Opelz & Döhler, 2004). 
Additionally immunocompromised patients with acquired immunodeficiency 
such as in HIV patients are more  prone to cancers (Ponce et al, 2014; Yanik et 
al, 2013).  
The number of T cells and NK cells present in patients with lymphoma, have 
been associated with prognosis. In Follicular lymphoma which is a B cell 
lymphoma, a study reported by Shafer et al, demonstrated an inferior overall 
survival of patients with follicular lymphoma who exhibited low NK cell count 
(CD3-CD56+ +/- CD16) in the peripheral blood (Shafer et al, 2013). In addition 
the number of absolute lymphocytes have also been observed to predict 
outcomes in follicular lymphoma (Siddiqui et al, 2006). More recently Nygren, et 
al reported on the number of T cells surrounding MCL in lymph node biopsies. 
They observed a lower number of T cells (CD3+CD4+ and CD3+CD8+) within the 
biopsies correlated to poorer outcomes (Nygren et al, 2014). 
Multiple myeloma has been studied to demonstrate evidence of immunoediting 
due to the presence of the premalignant state known as monoclonal 
gammopathy of undetermined significance (MGUS). MGUS can be easily 
identified and interestingly T cells from the bone marrow of patients with MGUS 
mount strong responses to autologous premalignant cells, which is not detected 
in patients with multiple myeloma (Dhodapkar et al, 2003). Furthermore, certain 
low grade lymphomas can remain stable for long periods of time without 
progression such as follicular lymphoma and in-situ mantle cell lymphoma 
supporting the possibility of the immune system maintaining some equilibrium 
(Hsi & Martin, 2014; Swann & Smyth, 2007; McKay et al, 2012). 
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In general there is varying evidence supporting immunoediting in humans. 
Further evidence to support the involvement of the immune system in 
eliminating cancerous cells has been demonstrated by immunomodulatory 
drugs such as lenalidomide which is discussed later (Acebes-Huerta et al, 2014; 
Richardson et al, 2010; Dauguet et al, 2010). These are a few examples from 
many studies that support the concept of immunoediting and immune 
surveillance in cancer. 
1.15. Immune escape of tumours 
Although the immune system prevents or restricts tumour growth, it is 
eventually overwhelmed or evaded allowing the tumour to proliferate. There are 
a number of mechanisms by which the cancerous cells can escape elimination 
by the immune system some of which include, modified antigens presented by 
cancerous cells leading to T cell inactivity (Schwartz, 2003), expression of T cell 
inhibitory molecules such as B7-H1, HLA-G or HLA-E by cancerous cells, such 
as the expression of B7-H1 in mantle cell lymphoma (Wang et al, 2013a), 
tumour antigen loss or modification of MHC molecules (Drenou et al, 2002) and 
presence of suppressive T regs (Swann & Smyth, 2007).  
As previously discussed, loss or reduction of MHC class I and II is commonly 
observed across many lymphoma types. Certain mechanisms have been 
proposed in relation to the reduction in MHC expression. One such event is the 
deletion of chromosome 6 resulting in reduced MHC class II at a protein level 
which has been evident in B cell lymphoma found in the central nervous system 
and testes (Riemersma et al, 2000). In addition, high grade B cell lymphomas 
lose MHC II as part of their partial differentiation towards the plasma cell stage 
(Wilkinson et al, 2012). Next generation sequencing efforts in B cell lymphomas 
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have demonstrated recurrent mutation in β2-microglobulin, a part of the MHC 
class I molecule that is necessary for cytotoxic T cells to recognize tumour cells. 
Large proportion of lymphomas show disruption of β2-microglobulin  surface 
expression with half of them containing genetic mutation or deletions (Challa-
Malladi et al, 2011). Although the lack or reduced MHC class I would be 
expected to escape cytotoxic T cell attack, NK cell would normally be expected 
to detect these cells. However these tumours show loss of CD58, a ligand for 
C2-receptor which is involved in the recognition and destruction of cells by both 
NK and cytotoxic T cells (Scott & Gascoyne, 2014). 
The increase in number of T regulatory cells and tumour associated 
macrophages in the tumour microenvironment of lymphomas have shown to be 
associated with worse outcomes and tumour progression (Ame-Thomas et al, 
2012; Qian & Pollard, 2010). T regulatory cells as discussed above have been 
shown to inhibit proliferation of the infiltrating cytotoxic T cells. During tumor 
initiation, macrophages create an inflammatory environment that is mutagenic 
and promotes growth. As tumours progress to malignancy, macrophages 
stimulate angiogenesis, enhance tumour cell migration and invasion, and 
suppress antitumor immunity which can be typically observed in  a subtype of 
macrophages termed as M2 (Qian & Pollard, 2010; D Foey, 2015). In the 
context of MCL the importance in pathogenesis and/or disease progression has 
not been systematically studied or characterised as described earlier. It has 
been shown that higher number of macrophages have been linked to more 
aggressive disease (Argatoff et al, 1997). These findings suggest that 
macrophages may play an important (yet ill defined) role as lymphoma-
associated macrophages as described in other lymphomas and cancers 
(Farinha et al, 2005; Condeelis & Pollard, 2006). 
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Cancer cells can become resistant to cytotoxicity due to the mutation in the 
gene encoding for FAS and TRAIL receptors and expansion of immature 
myeloid cell population can lead to significant T cell suppression.  Therefore 
cancerous cells can alter the tumour microenvironment and skew the immune 
response such that tumour growth, rather than elimination is favoured (Swann & 
Smyth, 2007). The interaction between tumours and the immune system is 
extremely complex and although there is greater understanding of this process 
there are still many aspects that remain unexplained.  
 
1.16. Treatments options for MCL 
There is no standard curative therapy for MCL. Although, almost all patients 
respond to initial therapy the majority have incomplete responses and often 
relapse. The natural course of MCL is characterised by multiple relapses with 
increasing chemo-resistance over time. The clinical course and response to 
therapy is heterogeneous. Some patients having a very aggressive presentation 
and succumb to MCL in a relatively short period of time, whilst other patients 
have an indolent clinical course. Most clinical trials demonstrate a median 
duration of response of 1.5 to 3 years and the median overall survival (OS) of 4-
6 years (Vose, 2013).  The choice of initial treatment is largely made based on 
the patient’s age and fitness (Campo & Rule, 2015), however there are 10-30% 
of the patients presenting with clinically indolent MCL  where initial therapy can 
be safely deferred without negatively impacting on their OS which can be up to 
12 years (Martin et al, 2009; Eve et al, 2009; Hsi & Martin, 2014).  
1.17. First-line therapy for young and fit patients 
For young fit patients (generally <65 years) with no significant morbidity the aim 
should be to proceed with cytarabine (AraC) based high-dose therapy followed 
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by consolidation with an autologous stem cells transplant in first remission 
(Shah & Rule, 2014; Campo & Rule, 2015; McKay et al, 2012). Ara-C has been 
shown to have excellent cytotoxic activity in MCL, with improved overall 
response (ORR) and complete responses (CR) (Khouri et al, 1998; Ritchie et al, 
2007; Forbes et al, 2013; Geisler et al, 2012b).  High dose-AraC (HD-AraC) was 
first used in the dose intense hyper-CVAD regimen (hyper-fractionated 
cyclophosphamide, vincristine, doxorubicin, dexamethasone [steroids are used 
in the treatment of lymphomas due to their activation of apoptosis by death-
inducing genes and repression of transcription factor activity, thereby inhibiting 
the transcription of growth / survival genes (Greenstein et al, 2002)]) with good 
results (Khouri et al, 1998) and as MCL is a CD20 expressing neoplasm, the 
addition of rituximab, an anti-CD20 monoclonal antibody, to this regimen 
produces higher CR rates of 87-92% (Ritchie et al, 2007). CD20 is a pan B cell 
specific differentiation antigen that is expressed on mature B cells and in most 
B-cell non-Hodgkin’s lymphomas, but not on early B-cell progenitors or late 
mature plasma cells (Tedder et al, 1988). CD20 is part of a multimeric cell-
surface complex that regulates calcium transport and is involved in the 
regulation of B-cell activation and proliferation (Beers et al, 2010). However, 
studies involving disruption of the gene encoding CD20 in mice do not 
demonstrate a critical function for this molecule in B-cell development or the 
generation of immune responses (Uchida et al, 2004). Rituximab is a chimeric 
monoclonal antibody (incorporating human immunoglobulin G1 heavy-chain 
sequences and murine immunoglobulin variable regions) that recognizes the 
human CD20 antigen (Reff et al, 1994).  Rituximab can cause the death of 
lymphoma cells by several mechanisms which include redistribution of CD20 
into large lipid rafts in the plasma membrane and to have a strong complement-
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dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity but 
has a minimal direct antitumor effect. However the exact mechanism is still 
debated (Weirda et al, 2010). Other mechanism of action on lymphoma cells is 
by binding of the antibody to CD20 which may activate the complement 
cascade through C1q, leading to cell death or deposition of complement 
proteins on the cell membrane, a phenomenon known as complement-
dependent cytotoxicity. Antibody-coated cells may be killed by immune cells 
expressing Fcγ receptors through antibody-dependent cell-mediated 
cytotoxicity. Finally, antibody binding to CD20 may have direct antiproliferative 
effects or may actively induce cell death (apoptosis)(Maloney, 2012). These 
effects appear to be additive and possibly synergistic when anti-CD20 antibody 
therapy is combined with chemotherapy. 
However, R-hyper-CVAD regimen is associated with significant toxicity (Merli et 
al, 2012). Subsequent studies incorporated the HD-AraC derived from hyper-
CVAD regimens.  The MCL2 study (Geisler et al, 2012b),used  R-CHOP 
(rituximab (R), cyclophosphamide, vincristine, doxorubicin and prednisolone) 
alternating with R + HD-AraC followed by autologous stem cell transplant. ORR 
was 96% and CR was 54%. The 6 year overall, event-free and progression free 
survival (PFS) was 70%, 56% and 66% respectively. Other combination 
chemotherapy regimens which include R and / or HD-AraC are shown below in 
Table 2. 
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Induction Consolidation N OR (CR) % Median 
response 
Median 
OS 
Ref 
R-Hyper-CVAD / 
R-MA 
- 97 97(68) 64% - 3 yrs 
FFS 
82% 3-year (Romaguera 
et al, 2005) 
 
R-Hyper-CVAD - 49 86 (55) 4.8 yrs PFS 6.8 yrs (Bernstein 
et al, 2013) 
 
R-Hyper CVAD - 60 83 (72) 61% 5yrs PFS 73% 5yrs (Merli et al, 
2012) 
 
Hyper-CVAD/HD 
MTX & 
cytarabine 
TBI, high dose CY, 
autologous/ 
allogenic SCT 
 
45 93.5/38 
 
72% 3yr EFS 92% 3yr (Vandenber
ghe et al, 
2003) 
R-CHOP x 3 + HD-
Ara-C x 1 
BEAM ASCT 
 
 
60 70/64 36% 4-yr FFS 66% 4 yr 
FFS 
Van’t Veer 
et al 2009 
R-maxi-CHOP x 3 
/ R-HD-Ara-C x 3 
BEAM / BEAC 
followed by R-in 
vivo purged ASCT 
 
160 96/54 56% 6 yr EFS 70% 6 yr (Geisler et 
al, 2012a) 
R-CHOP vs CHOP Dexa BEAM, TBI HD 
CY followed by ASCT 
vs IFN maintenance 
62/63 
vs 60 
97/34 – 92/33 
vs 75/7 -75/8 
 
PFS: 20 vs 19 
months, TTF : 
28 vs 14 
months 
76% vs 76% 
2 yrs, 59% 
vs 46% 5yr 
(Dreyling et 
al, 2014) 
 
R-CHOP x 6 vs R-
CHOP x 3 / R-
DHAP x 3 
RCHOP : 
DexaBEAM, HD CY, 
TBI followed by 
ASCT 
RCHOP/RDHAP : 
HD-Ara-C 
Melphalan- ASCT 
 
497 P-I  90/24 
vs 94/39 
After ASCT 
97/63 vs 
97/65 
TTF: 
49months vs 
NR : RD after 
ASCT 
48months vs 
NR 
79% vs 80% 
3 yr 
(Hermine et 
al, 2012) 
R-DHAP –rituximab, dexamethasone, cytarabine, ciplatin ; MA-methotrexate; TBI-total body irradiation; SCT –stem 
cell transplant; CY-cyclophosphamide; IFN- interferon alpha; OR-overall response; CR-complete response; PFS-
progression free survival; OS-overall survival; Ref – reference; FFS-failure free survival; TTF-time to failure; BEAM- 
carmustine, etoposide, cytarabine, melphalan; Dexa- dexamethasone; ASCT – autologous Stem cell transplant; P-I 
– post induction; HD AraC- high dose cytarabine; N- number of patients; NR- not reported. 
Table 2: Intensive frontline therapy in MCL 
Table illustrates current intensive front-line therapies available for MCL. Table lists 
clinical trials conducted for these intensive treatments. 
 
1.18. First line therapy for elderly or unfit patients  
The majority of patients diagnosed with MCL are elderly (figure 1.1). High dose 
cytarabine and consolidation with an autologous stem cell transplant is not 
suitable for these patients due to the increased toxicity (McKay et al, 2012). 
There is no generally accepted standard front line therapy for this group of 
patients. However, incorporating Rituximab to standard chemotherapy regimes 
provides better results with improved OS (median survival 27 vs 37 months in 
chemotherapy alone versus rituximab and chemotherapy, respectively)(Schulz 
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et al, 2007; Griffiths et al, 2014). Overall, this group of patients receive a 
combination of rituximab with chemotherapy as shown in Table 3.    
 
Chemotherapy N Median 
age 
ORR(CR) 
% 
Median PFS 
Months/ % 
Median 
OS 
 
Ref 
 
R-Chlorambucil 
 
20 
 
64yrs 
 
95 (90) 
 
84%  
 
3yr 95% 
 
(Sachanas 
et al, 2011) 
 
R-B  
vs. 
 R-CHOP 
 
94 
 
70yrs 
93 (40) 
Vs. 
91 (30) 
22 
Vs 
35 
 
N/A 
 
(Rummel et 
al, 2013) 
 
 
R-CHOP Vs R-FC 
 
 
 
 
 
R-B-AraC 
560 
 
 
 
 
 
40 
 
70yrs 
 
 
 
 
 
70yrs 
87/50 vs 78/52 
 
 
 
 
 
100/95 for 
treatment naïve 
80/70 for relapsed 
 
R vs IFN : 
57%vs26% at 
4 years 
 
 
 
95% 2 year –
untreated 
70% 2 year 
relapsed 
treated 
 
64 vs 40 
(R vs IFN; 
87%vs 
57%- 4 
years) 
 
NR 
(Kluin-
Nelemans 
et al, 2012) 
 
 
 
(Visco et al, 
2013) 
N – number of patients; ORR-Overall response rate; CR-complete response rate; PFS- progression free survival; OS-
overall survival; Nr – not reached; na – not applicable; IFN – interferon-alpha; R-rituximab; FC- fludarabine and 
cyclophosphamide; R-B – rituximab and bendamustine; R-CHOP- rituximab and cyclophosphamide, vincristine, 
doxorubicin and prednislone; AraC – cytarabine. N/A – not available; yrs- years 
Table 3: Therapy for elderly and unfit patients 
Table illustrates therapy options for elderly and unfit patients.  
 
1.19. Therapy in relapsed or refractory MCL and novel agents 
There is no standard treatment for patients which relapse. Alternative 
combinations of immuno-chemotherapy may be used to those that have been 
used in front line therapy. In the majority of cases the responses and remission 
are inferior to front line therapy. In some younger and fit patients allogenic stem 
cell transplant can be considered and  a recent study reported on a 2 year OS 
of 46% in patients who have relapsed after an autologous stem cell transplant, 
with patients relapsing after 1 year from an autologous stem cell transplant 
having better outcomes (Dietrich et al, 2014).     
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As with other haematological malignancies novel agents have transformed the 
treatment of MCL by targeting certain key molecules and/or signalling pathways 
involved in tumour genesis. There are four novel agents that have been 
licensed in relapsed and refractory MCL (Table 4). Ibrutinib is the most recent 
drug to gain its licence in both USA and Europe for the treatment of relapsed 
MCL. It was approved in the USA by the Food and Drug Adminstration (FDA) 
for use after 2nd line therapy in relapsed MCL. Ibrutininb is an orally available 
small molecule that inhibits the Bruton tyrosine kinase (Btk). Btk itself is a 
member of the TEC family of non-receptor tyrosine kinases (Burger & Buggy, 
2013).  It is a key signal protein lying downstream of the B- cell receptor (BCR) 
where it is recognised to be activated by BCR-linked signal molecules such as 
LYN and SYK (Baba et al, 2000). It is also activated by other important signals 
encountered by the B lymphocytes, including growth factors, chemokines, 
cytokines, integrins and Toll like receptors placing it at a key point in the control 
of signals between the B lymphocyte and its microenvironment. Btk is principally 
found within the cytoplasm and activation causes translocation to the 
membrane. Once activated Btk phosphorylates phospholipase Cγ2, triggering 
secondary messengers that activate NF-ƙβ. These signal process is critical for 
the regulation of apoptosis, promotion of cell survival and further B-cell 
development (Niemann & Wiestner, 2013; Rinaldi et al, 2006; Mohamed et al, 
2009). Therefore inhibiting Btk will lead to early cell death by switching off and 
altering the survival pathway. The pivotal phase II trial recruited 111 patients 
with relapsed/refractory MCL. The ORR was 68% with 47 and 21% achieving 
partial response (PR) and complete response (CR) respectively. The PFS was 
13.9 months in this cohort of patients (Wang et al, 2013b). Ibrutinib is the most 
active single agent in relapsed / refractory MCL (Wang et al, 2013b). 
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Interestingly, off target effects of ibrutinib can affect the Interleukin 2-inducible 
kinase (ITK) resulting in the inhibition of this kinase. This causes inhibition of 
Th2 cells after TCR stimulation which is specific for Th2-polarised CD4 T cells 
which inhibits the T cell response to parasites such as leishmaniasis (Dubovsky 
et al, 2013). However, Ibrutinib also affects other TEC family kinases (TFK) 
which includes Btk, ITK, BMX and RLK. Ibrutinib inhibits TFK in other cells such 
as macrophages, neutrophils, dendritic cells and mast cells, therefore effectively 
inhibiting their function resulting in susceptibility to infections and lower counts 
of these cells (Berglof et al, 2015). Ibrutinib is a new drug and many ‘off’ target 
effects are slowly coming to light as further studies and more clinical experience 
is gathered.  
Bortezomib is a highly selective and reversible inhibitor of the 20S proteasome. 
In the context of MCL it has the capacity to block proteasomal degradation of 
IƙBα (thus inhibiting NFkB activation) as well as the cyclin-dependent kinase 
inhibitor p27 (Piperdi et al, 2011; Pham et al, 2003). The PINNACLE trial, in 
which bortezomib gained its FDA approval in USA, recruited 155 relapsed 
refractory MCL and reported a 33% ORR with 8% CR with 6.5 months PFS 
(Goy et al, 2009).  
Temsirolimus is a selective inhibitor of the mammalian target rapamycin 
(mTOR) kinase which forms part of the pathway that regulates the translation of 
cyclin D1 from cyclin D1 mRNA. The OPTIMAL study recruited 162 relapsed 
refractory MCL patients and had a ORR of 22% and CR rate of 2% with 
duration of response of 7 months (Hess et al, 2009).  
 
 
54 
 
Treatment 
No. 
Patients 
ORR CR 
Median DOR 
Median 
PFS 
Median 
(months) (months) OS (months) 
Ibrutinib 111 68% 21% 17.5 13.9 Not reached 
Bortezomib 155 33% 8% 9.2 6.5 23.5 
Lenalidomide 134 28% 8% 16.6 4 19 
Temsirolimus 122 22% 2% 7.1 4.8 12.8 
CR: Complete Response. DOR: Duration of Response. ORR: Overall Response Rate.  
OS: Overall Survival. PFS: Progression-free Survival. 
Table 4: Single agent therapies approved for relapsed and refractory MCL 
 
In contrast to the above agents that target specific molecules, pathways or 
cellular components important in MCL tumour genesis, the immunomodulatory 
drug lenalidomide is believed to act by multiple mechanisms targeting both the 
malignant cell and tumour microenvironment.  Lenalidomide got FDA approval 
on the back of the EMERGE trial which recruited 134 relapsed and refractory 
MCL patients and reported an ORR and CR of 28% and 8% respectively with a 
PFS  of 16.6 months (Goy et al, 2013).  
Lenalidomide is a second generation synthetic derivative of glutamic acid and a 
thalidomide analogue. Thalidomide was marketed in the 1950s as a sedative 
drug but became a popular treatment for morning sickness in early pregnancy 
due to its concomitant antiemetic properties. Its withdrawal in the 1960s was 
secondary to congenital malformations like phocomelia. Following an 
observation in 1965 that thalidomide administration improved the inflammatory 
lesions of erythema nodosum leprosum (ENL) in a patient suffering from sleep 
difficulties the use of thalidomide continued (Sheskin, 1980) and eventually 
gained FDA approval for its use in ENL. The research into its mechanism of 
action unravelled an immunological and immunomodulatory effect. Thalidomide 
was used in several disease states associated with immune activation and it 
was apparent that thalidomide was a drug with a wide range of clinical 
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application and was especially used to treat in multiple myeloma (Singhal et al, 
1999). 
The efficacy of thalidomide as a single agent in MCL is limited to two case 
studies of patients with relapsed disease who achieved durable partial 
remission following treatment (Damaj et al, 2003; Wilson et al, 2002).  A study 
investigating the use of thalidomide in 19 patients with heavily pre-treated 
lymphoma was disappointing with only 1 response overall (in a patient with 
gastric marginal zone lymphoma) and no responses in 3 patients with MCL (Pro 
et al, 2004). A further study in patients with 16 relapsed MCL reported by 
Kaufmann et al demonstrated a more favourable response with thalidomide and 
rituximab in combination. They achieved an overall response of 81% with 31% 
complete responses and a median progression free survival of 20.4 months 
(Kaufmann et al, 2004). This resulted in clinical evidence of activity of 
thalidomide in MCL. Furthermore, Richardson et al demonstrated significant 
activity of thalidomide and lenalidomide in-vitro on MCL cell lines resulting in 
immunomodulatory anti-lymphoma activity by enhancing peripheral blood 
mononuclear cell mediated cytotoxicity (Richardson et al, 2010).   Despite the 
benefits of thalidmode, its long-term use was also marred by significant side 
effects of constipation, somnolence, thrombosis and peripheral neuropathy.  
Subsequently, lenalidomide was developed to have enhanced 
immunomodulatory and anti-tumour activity compared to thalidomide whilst 
possessing a better side effect profile especially with regards to neuropathy and 
thrombosis. It evolved from adding an amino group (NH2) at the position 4 of the 
phthaloyl ring and removal of carbonyl group (C=O) of the 4-amino-substituted 
phthaloyl ring (Bartlett et al, 2004)(figure 9.0). 
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Figure 5: Chemical structure of thalidomide and lenalidomide 
Lenalidomide developed from the thalidomide back bone as described above. Amino 
group NH2 was introduced at the position 4 of the phthaloyl ring as shown above. 
Adapted from (Kotla et al, 2009). 
 
1.20. Mechanism of action of lenalidomide 
In vitro and in vivo experimental studies have demonstrated lenalidomide to 
work through multiple mechanisms, including direct tumour cytotoxicity, 
inhibition of angiogenesis and osteoclastogenesis, and disruption of stromal 
cell-derived signals from the tumour microenvironment (Chanan-Khan & 
Cheson, 2008).  
Immunomodulation 
The immune system is comprised of cellular (macrophages, dendritic cells, NK 
cells, T cells and B cells), and humoral components (antibodies, cytokines). The 
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immune system can prevent development of cancers by eliminating or 
suppressing oncogenic viral infections, altering the inflammatory milieu 
conducive to tumour genesis, and by immune surveillance; identifying and 
destroying cancerous cells before they can cause harm (Dunn et al, 2004; 
Swann & Smyth, 2007).  
The immunomodulatory properties of lenalidomide have been demonstrated by 
its clinical efficacy in multiple myeloma, chronic lymphocytic leukemia (CLL) and 
myelodysplatic syndrome by the alteration of cytokine production, regulating T 
cell stimulation and enhancing the NK cell cytotoxicity. 
Influencing cytokine production 
Cytokines are soluble proteins produced by a variety of haematopoietic and 
non-haematopoietic cells and are critical for the innate and adaptive immune 
responses. Cytokines can influence the cells by gene activation, growth, 
differentiation and expression of surface molecules. The harmonisation 
between cellular and humoral (cytokines, antibodies) interactions enables 
tumour elimination.  
Lenalidomide inhibits the production of TNF-α, IL-1, IL-6, IL-12 and increases 
the production of anti-inflammatory cytokine IL-10 from human peripheral blood 
mononuclear cells (PBMCs) (Corral et al, 1999). Modulation of these cytokines 
within the nodal microenvironment likely influences inflammatory responses, 
supports tumour growth and metastasis, and contributes to chemoresistance. 
Zhang et al demonstrated IL-6 to be protective towards MCL cells (Zhang et al, 
2012). IL-6 receptor ligation initiates a downstream kinase signalling cascade 
(such as STAT3, Ras, phosphoinositide 3-kinase/Atk) to promote tumour 
genesis. In some MCL cells, IL-6 secretion provides an autocrine growth signal. 
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Bone marrow stromal cells secrete high levels of IL-6 and PBMCs secrete both 
IL-6 and the soluble gp80 IL-6 receptor subunit (Zhang et al, 2012). Because 
both stromal cells and PBMCs can be found in the MCL microenvironment, they 
may provide a paracrine source of IL-6 for supporting MCL growth. Consistent 
with this hypothesis, IL-6/gp80 knockdown effectively allows chemotherapy-
induced apoptosis to occur on exogenous addition of IL-6 or gp80, rather than 
supporting tumor growth and proliferation. Therefore the ability of lenalidomide 
to reduce IL-6 and this STAT3 activity may provide mechanisms for reducing 
signalling within the MCL microenvironment resulting in MCL growth retardation 
and promoting apoptosis (Chanan-Khan & Cheson, 2008). 
Lenalidomide also stimulates production of IL-2, IFN-γ and TNF-α. This allows 
T-cell proliferation in the absence of CD28 stimulation (Hayashi et al, 2005a; 
Corral et al, 1999). Because T-cell receptor and costimulatory signals are 
required for IL-2 production, these observations suggest that lenalidomide may 
activate costimulatory signals normally triggered by CD28. In addition 
lenalidomide increases tyrosine phosphorylation of CD28 in the intracellular 
domain of T cells in absence of costimulatory molecules, and stimulates NF-ƙB 
activation downstream from CD28 (LeBlanc et al, 2004). It also promotes 
nuclear translocation and binding of nuclear factor of activated T cells and 
activator protein-1 to the IL-2 promotor, a process dependent on PI3K signalling 
that enhances IL-2 production (Hayashi et al, 2005a). 
TNF-α is a highly pleiotropic cytokine produced by monocytes and 
macrophages and is important in protective immune responses against 
infections. However, in certain haematological malignancies high levels of TNF-
α have been implicated in the proliferation of these neoplasms (Kotla et al, 
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2009). Studies have demonstrated increased levels of TNF-α in CLL patients 
and treatment with lenalidomide significantly reduced the TNF-α levels thus 
suggesting its importance in tumour genesis (Chanan-Khan et al, 2006).    
T cell modulation 
T cell activation is via peptide fragments presented by the antigen presenting 
cells (APCs) to the T cell receptor (TCR). However, this alone is not sufficient to 
generate an effective response and therefore a secondary interaction with B7 
molecule on APC and CD28 on the T cell surface enables co stimulatory signal 
that aids in T cell proliferation, differentiation and survival with cytokine and 
cellular response (Sharpe & Abbas, 2006). Lenalidomide acts on the T cells via 
B7-CD28 co stimulatory pathway, highlighted by the ability of lenalidomide to 
overcome the inhibitory effects of CTLA-4-Ig ( a competitive inhibitory of B7) 
(Leblanc et al, 2004). Leblanc et al demonstrated increased activity of T cells 
when incubated with lenalidomide in the presence of CTLA-4-Ig compared to T 
cells incubated only with CTLA-4-Ig (Leblanc et al, 2004). Although the exact 
mechanism for this is not clear due downstream pathways being integrally 
connected, however directly inducing tyrosine phosphorylation of CD28 on the 
T cells results in activation of downstream targets which include PI3K, MAPK 
and others resulting in activation of classic T cell transcription factors such as 
AP-1, NFAT-1 and NF-ƙB that induces secretion of IL-2, TNF-α and IFN-γ 
(McDaniel et al, 2012). Furthermore, as lenalidomide increases secretion of 
IFN-γ and IL-2 it leads to T cell proliferation and increase in the NK cell activity 
via an increase in the transcription activity of AP-1 and NFAT2, which are key 
regulators of the IL-2 gene (Dredge et al, 2002b; Hayashi et al, 2005b). 
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Influencing Natural Killer (NK) cells 
NK Cells are an important part of the innate immune system. They do not 
require specific antigens to respond to cancerous cells and are able to kill the 
cells directly via the antibody dependent cell mediated cytotoxicity and natural 
cytotoxicity as discussed above. 
Davies et al demonstrated increased cell cytotoxicity activity on multiple 
myeloma cells was largely due to the NK cells. This study demonstrated 
reduction of myeloma cell death on depletion of NK cells in-vitro. Furthermore 
incubation with thalidomide increased the NK cell numbers and IL-2 levels but 
the T cells numbers remained unchanged (Davies et al, 2001). Furthermore 
Hayashi et al, demonstrated an increase in NK cells when cultured with 
immunomodulatory drugs (thalidomide and lenalidomide) for 5 days and also 
enhanced ADCC activity of NK cells when incubated with immunomodulatory 
drugs (Hayashi et al, 2005b). Although these drugs stimulate NK-mediated 
cytotoxicity, the exact mechanism is not fully understood. It is believed the 
enhanced numbers and function of NK cells is secondary to the IL-2 production 
by the co stimulated T cells (Hayashi et al, 2005b; Davies et al, 2001). This was 
demonstrated by inhibition of the NK cell cytotoxicity by the IL-2 receptor being 
blocked by the monoclonal antibody. Additionally Hayashi et al, also 
demonstrated lack of phosphorylation of signalling molecules 
(ERK/P38MAPK/AKT/PKC) in NK cells suggesting lack of direct activation by 
immunomodulatory drugs (Hayashi et al, 2005b). 
Lenalidomide as discussed above has been shown to have a significant 
influence on NK cells. A further expansion on the background of NK cells and 
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relevant activating receptors below would aid to understand their relevance with 
MCL and immunomodulation with lenalidomide. 
The immune system can generally be divided into the innate and adaptive 
immune system (Medzhtov & Janeway, 2000; Gajewski et al, 2013). The first 
line defence is by the innate immune system against invading pathogens but is 
not antigen-specific and does not produce long-term immunological memory. 
The cells involved are neutrophils, macrophages and natural killer (NK) cells, all 
of which recognise pathogen-associated surface molecules and respond by 
direct elimination of the pathogen (Vivier et al, 2011). The adaptive immune 
responses are mediated by B and T lymphocytes in response to specific antigen 
and ultimately generate long-term immunological memory. Adaptive immunity 
can further be subdivided into cell-mediated immune responses, which are 
driven by T lymphocytes, and humoral (or antibody-mediated) responses, which 
are driven by B lymphocytes (Corthay, 2014; Medzhtov & Janeway, 2000). 
Although the two immune systems have distinctive roles there is considerable 
overlap between innate and adaptive immunity with the two arms working in 
synergy to optimise immune activity. 
1.21. Natural Killer (NK) cells 
 NK cells are effector lymphocytes of the innate immune system that mediate 
two major functions; recognition and lysis of tumour and virus-infected cells and 
production of immunoregulatory cytokines. They develop from the same 
progenitor cells as T and B cells in the bone marrow and mature in secondary 
lymphoid tissue (Caligiuri, 2008).  NK cells referred to throughout this thesis will 
be related to human NK cells unless otherwise stated.  
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NK cells are derived from the haematopoietic cells in the bone marrow; 
CD34+CD45RA+ progenitor cells go onto develop into NK cells which are 
immunophenotypically identified as CD3-CD56+. The absence of CD3 excludes 
T cells and CD56 is the 140-kDa isoform of neural cell adhesion molecule 
(NCAM) a glycoprotein found on NK cells and a minority of T cells (Lanier et al, 
1989).  
There are two phenotypically and functionally distinct subsets of NK cells 
distinguished by their expression of CD56 on the surface; CD3-CD56bright and 
CD3-CD56dim. The CD3-CD56bright NK cells are described to be the more 
immature cells predominantly located in the secondary lymphoid tissue or the 
decidual tissue of pregnant women and make up approximately 5-15% of the 
total NK cells (Fauriat et al, 2010). These cells are primarily cytokine producers 
when responding to infected or malignant cells (Fehniger et al, 2003), but have 
little or no ability to spontaneously kill target cells. The CD3-CD56bright NK cells 
produce cytokines which activate nearby APCs and T cells to bridge the gap 
between the innate and adaptive immune systems.  The CD3-CD56dim NK cells 
are described to be the more mature of the NK cells and make up 
approximately 90% of the NK cells in the peripheral blood. They mediate a 
predominantly cytotoxic response which can spontaneously lyse susceptible 
target cells, but produce significantly fewer cytokines compared to the CD3-
CD56bright cells (Caligiuri, 2008; Takahashi et al, 2007). These cells have the 
ability to directly kill target cells through mechanisms similar to cytotoxic T cells 
(perforin, granzyme, FasL, TRAIL) and owing to their surface expression of 
CD16 (FcγRIIIa; a type III receptor for IgG), can also mediate antibody-
dependent cellular cytotoxicity (ADCC). This is achieved by binding of CD16  to 
the Fc portion of immobilised immunoglobulin (usually IgG subclass 1 and 3) on 
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target cells that trigger NK cell activation, degranulation and perforin/granzyme 
release (Vivier et al, 2011; Chan et al, 2012). 
1.22. NK cell mechanism of actions 
NK cells are rapidly activated to spontaneously attack certain abnormal cells in 
the body, especially tumour and virus-infected cells. The NK cells predominantly 
target cells that have down regulated expression of MHC-class I, which is 
expressed on nearly every health cell in the body (Vivier et al, 2011). The loss 
or altered expression of MCH-class I is a common mechanism by which tumour 
cells can evade recognition by the TCR of the cytotoxic T cells and thus the NK 
cells can fill this potential void in the immune system by eliminating unhealthy 
cells that have evaded the T cells. This simplistic overview of the NK cells 
eliminating malignant or infected cells with lost or down regulated MHC-class I 
molecules forms the ‘missing-self’ hypothesis (Ljunggren & Karre, 1990). 
However, the immune process involving NK cells is far more complex, and 
although the detection of the expression of MHC-class I remains important in 
the activation of NK cells to kill target cells, NK cells also act through activating 
and inhibiting receptors and ligands (Vivier et al, 2011, 2012a). In addition to 
the ‘missing-self’ hypothesis, the balance between inhibitory and activating 
signals allows the NK cell to mount an immune response (Kumar & McNerney, 
2005). 
Activation of NK cells requires direct contact with the target cells and the 
formation of the immune synapse. Following initial contact, adhesion molecules 
expressed on the NK cell (eg. LFA-1) and target cell (eg. ICAM-1), interact with 
each other to further strengthen the association. NK receptors subsequently 
home in at the synapse site to execute a detailed surveillance of the ligands 
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expressed by the target cell. In the absence of inhibitory signals, activation is 
triggered within the NK cell that leads to cytotoxicity. Once the NK cells has 
completed its function it detaches from the target cell (Caligiuri, 2008; Orange, 
2008).  
 
Figure 6: NK cell 'missing-self' hypothesis 
 [A & B] Tolerance; It is recognised that NK cells have both activating and inhibitor receptors 
which are in balance and thus NK cells may receive an activating signal which is in balance with 
the inhibitory signals form the ligated MHC-binding receptor resulting in no lysis of the normal 
healthy cell.  Intact inhibitory signal will result in no response from the NK cells. 
[C] Missing self; loss of MHC-binding inhibitory signals from the lack of MHC-class I expression 
in target tumour cells will shift the balance and activate the NK cells as the inhibitory signals 
are no longer held in check.  
[D] Balance of signals; NK cells may be activated by stressed cells which upregulate activating 
ligands for NK cells thus overcoming the inhibitory signals delivered by the MHC-class 1 
molecules. Therefore activation of NK cells leads to direct cell mediated cytotoxicity or 
indirectly through production of cytokines. However if the balance of inhibitory and activating 
signals are stable then it results in no response. 
Adapted from (Vivier et al, 2011) 
 
Stressed cell  
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1.23. NK cell receptors 
As described above, NK cell activation is regulated by the balance and 
integration of the signals triggered by ligands binding to different activating and 
inhibitory surface receptors. The inhibitory receptors on NK cell are mostly 
those that recognise MHC-class I molecules on the surface of the target cells 
(Seidel et al, 2012). Inhibitory receptors on NK cells include immunoglobulin-like 
transcript (ILT) 2 receptors, the killer immunoglobulin-like receptors (KIRs) and 
the CD94-natural-killer group 2 member A (NKG2A) receptor (Moretta & 
Moretta, 2004).  
The activating receptors on NK cells include natural-killer group 2 member D 
(NKG2D), activating KIRs, NKp80, CD94/NKG2C, DNAX accessory molecule, 
2B4 and natural cytotoxicity receptors (NCRs); NKp30, NKp44 and NKp46 (also 
known as NCR3, NCR2 and NCR1 respectively) (Koch et al, 2013). The major 
receptors responsible for NK cell activation are NKp46, NKp30, NKp44 and 
NKG2D. These activating receptors play an important role in NK mediated 
killing of most tumours and more over the surface density of these receptors 
correlates with the magnitude of the cytolytic activity against NK- susceptible 
target cells (Moretta & Moretta, 2004). 
The three NKp46, NKp30 and NKp44 NCRs activating receptors and NKG2D 
activating receptor are the most relevant in context of MCL and will be 
discussed in more detail below. 
The natural cytotoxicity receptors (NCRs) 
The NCRs are type I membrane proteins comprising of an ectodomain with one 
(NKp30 and NKp44) or two (NKp46) immunoglobulin-like domains connected to 
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a transmembrane-spanning a-helix via a short stalk domain. NCRs belong to 
the immunoglobulin superfamily. They all comprise an extracellular ligand-
binding domain, which binds to the cellular and exogenously derived ligands, a 
transmembrane domain, and a short cytosolic domain. These group of 
receptors lack functional intracellular signalling domains and therefore associate 
with appropriate adaptor proteins via a charged residue in their transmembrane 
domain  (Hudspeth et al, 2013; Moretta et al, 2001) (figure 4.0). NCR signalling 
pathways involve the immunoreceptor tyrosine based activation motif (ITAM) 
dependent signalling molecules serving to activate several intracellular  
signalling pathways involving protein kinase 70 (ZAP70) and spleen tyrosine 
kinase (SYK) which phosphorylate transmembrane adapter molecules leading 
to activation of several signalling molecules like phosphatidylinositol 3-kinase 
(PI3K) and phospholipase C (PLC) among others which are necessary for NK-
mediated cytokine production and/or cytotoxicity (Koch et al, 2013). It has been 
described that the NCR can activate each other through phosphorylation of the 
adapter molecules in different NCRs, thus increasing their efficiency. However, 
the exact mechanism for activation with different ligands is not known and 
currently under investigation. 
NKp30 
NKp30 is associated with ITAM to initiate signalling. ITAM also contains the 
adapter proteins CD3ζ and its heterodimers have the γ-chain of the high affinity 
Fc receptor for IgE (FcεRIˠ). In malignantly transformed cells, the NKp30 
receptor recognises the tumour antigen B7-H6 and BCL-2 associated 
athanogene 6 (BAG 6). B7-H6 is thought to be a tumour specific antigen 
because it expression has not been found on healthy cells in steady state. 
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Detection of B7-H6 leads to eradication of the tumour cells by the NK cells 
(Brandt et al, 2009).  In contrast, BAG 6 is found on the plasma cells of the 
immature dendritic cells and can trigger NK cells to kill these immature dendritic 
cells (Koch et al, 2013). Elimination of these immature dendritic cells is thought 
to select out a more immunogenic subset of dendritic cells during a protective 
immune response. 
NKp44 
NKp44 is coupled with a dimer of the ITAM-containing adaptor DNAX-activation 
protein 12 for downstream signalling. NKp44 is only detected after activation of 
the NK cells (Rosental et al, 2011). The extracellular domain of the NKp44 
adopts a positively charged V shape groove on one site for a yet unknown 
ligand on tumour cell. However in the presence of tumours this receptor had an 
increase in expression which correlated to the level of cell mediated cytotoxicity 
(Moretta et al, 2001).   
NKp46 
NKp46 is deemed as the most specific marker for NK cells (Walzer et al, 2007). 
It is associated with CD3ζ and also with the γ-chain of the high affinity Fc 
receptor for signalling. The ectodomain of NKp46 comprises of two 
immunoglobulin-like domains which may be the ligand binding sites (Arnon et 
al, 2006). The identity of the ligand expressed on the tumour cells to activate 
NKp46 remains unknown. However, as with the other NCRs it plays an 
important role in tumour elimination. 
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NKG2D Receptor 
NKG2D is a C-type lectin-like transmembrane activating receptor. It is present 
on the majority of the NK cells and also on cytotoxic T cells. NKG2D recognises 
two families of ligands; MHC-class I chain-related protein A (MICA) and B 
(MICB), and the UL16-binding proteins (ULBPs) (Champsaur & Lanier, 2010). 
These ligands are typically present  on many tumours, whilst rarely expressed 
on healthy cells (López-Soto et al, 2014).  Ligand engagement of NKG2D 
triggers the phosphorylation of the signalling adapter protein DNAX-activating 
protein of DAP10 and recruitment of either phosphatidylinositol-3-kinase (PI3K) 
or a Grb2-Vav1 complex to engage full activation (Coudert et al, 2005). Sole 
activation of NKG2D receptor in inactivated NK cells is unable to trigger 
activation of the NK cell and needs co-activation signal from other receptors 
such as 2B4 or NKp46 receptor. The result of NKG2D activation leads to NK 
cells’ secretion of cytokines and exocytosis of cytotoxic granules (López-Soto et 
al, 2014; Lanier, 2003).  
The NCRs and NKG2D have other ligands capable of activating the NK cells 
through these receptors. However the majority of the ligands that have been 
identified are associated with virally infected cells as opposed to tumour cells. 
Notably many tumour related ligands remain unknown and there is currently 
ongoing research to identify them. 
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Inhibition of Angiogenesis by lenolidomide 
Vascular endothelial growth factor (VEGF) and its receptors are required for the 
formation of blood vessels during carcinogenesis (D’Amato et al, 1994).  
Thalidomide and the newer immunomodulatory drug; lenalidomide have been 
shown to significantly decrease the expression of angiogenic factors VEGF and 
Interleukin-6 (IL-6) in multiple myeloma; thereby reducing angiogenesis and 
hence contributing to clinical activity in multiple myeloma (Gupta et al, 2001). 
The newer IMiDs like lenalidomide were found to be 2–3 times more potent 
compared to thalidomide in antiangiogenic activity in various in-vivo assays 
(Dredge et al, 2002a). These properties have been found to be independent of 
the immunomodulation exerted by lenalidomide.  The exact mechanism in MCL 
has not been fully elicited. However, a recent study has demonstrated that 
lenalidomide can reduce and inhibit the recruitment of the lymphoma-
associated macrophages which are known to produce VEGF, therefore 
reducing lymphangiogenesis (Song et al, 2013; Kerjaschki, 2005)   
 
1.24. MCL epidemiology  
Like other NHLs the incidence of MCL increases with age with a median age at 
presentation being 65 years (Smith et al, 2015; McKay et al, 2012). This in-part 
could be as a result of immunosenescence, a complex process in which 
immunological function is impaired and or remodelled and is believed to be a 
major contributory factor to the increased frequency of morbidity and mortality 
among elderly (Caruso et al, 2013). This relationship with age and immunity 
was explored by analysing 356 healthy Japanese ranging from 20 years to 90 
years. This study showed reduction of number of T and B cells and proliferation 
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of T cells with age. The rate of decline was greater in males compared to 
females (Hirokawa et al, 2013).  
The annual incidence of MCL in UK is estimated to be up to 513 (males 331 
and females 181) new cases per year (based on data from 2004-2012) and age 
standardised incidence rates is 0.86 per 100,000 population (males; 1.5 per 
100,000 and females; 0.6 per 100,000 population)(Smith et al, 2015).  
There is a higher incidence of MCL in males than in females (Chandran et al, 
2012; McKay et al, 2012; Morton et al, 2006). This is in keeping with reports of 
higher incidence of lymphomas in men compared to women in general (Nelson 
et al, 2001; Morton et al, 2006). The precise reason for this is not known 
however epidemiological data in female has shown an association between 
reproductive hormonal factors and oral contraceptive to reduce the risk for NHL 
(Nelson et al, 2001; Lee et al, 2008a). Lee et al reported on an epidemiological 
study which demonstrated that women who were on menopausal hormone 
therapy for greater than 5 years were associated with a reducing risk of all 
NHLs (Odds Ratio (OR) 0.68, 95% CI; 0.48,0.98). Additionally they also 
reported on oral contraceptive pill use and pregnancy reduced the risk of all 
NHLs (OR 0.68, 95% CI; 0.49,0.94 and OR 0.81, 95%CI: 0.55) (Lee et al, 
2008a). This study correlated to results from an earlier study which had 
demonstrated similar results. Nelson et al, reported on women who used oral 
contraceptives, (oestrogen based) had a significantly lower risk of NHLs (OR 
0.47; 95% CI, 0.26 to 0.86) than women who had never used these 
compounds. They also reported on postmenopausal women who used hormone 
replacement therapy (primarily oestrogen) had a lower risk of NHLs compared 
to those that did not. Furthermore postmenopausal women were at a greater 
risk of NHLs compared to premenopausal (Nelson et al, 2001). This has alluded 
71 
 
to the fact that oestrogen may have a protective effect with regards to the NHLs 
and may be involved in a mechanism by which NHLs are either supressed or 
eliminated. Although the precise mechanism is not fully described several 
studies recently have shown oestrogens could potentially influence overall 
survival of NHLs in women. 
Lymphomas are not generally perceived as hormone-controlled. However, as 
mentioned above, epidemiological studies suggest their potential role in NHLs 
and this has led to further studies with oestrogen and lymphoma. A study 
reported by Yakimchuk et al showed that grafted T-cell lymphomas grew faster 
in male mice than in female mice and that female protection was abolished by 
ovariectomy resulting in increasing size of the lymphoma. The tumour size 
could be subsequently reduced by treatment with oestrogen beta agonists such 
as diarylpropionitrile (DPN). This at least in part resulted in lymphoma apoptosis 
and inhibition of proliferation (Yakimchuk et al, 2011a). They also reported the 
expression of oestrogen receptor beta (ERβ) in the peripheral blood 
mononuclear cells of patients suffering from chronic lymphocytic leukaemia 
(CLL- B lymphocyte cell disorder). They demonstrated 69% of the patients with 
CLL were positive for ERβ compared to only 17% of the healthy controls 
(p<0.001). This suggested that oestrogen receptors are potentially important in 
this B cell malignancy and could be a therapeutic target (Yakimchuk et al, 
2012a). It is still questionable whether hormone sensitivity of lymphomas reflect 
primarily the sensitivity of tumour itself or rather the sensitivity of the 
microenvironment or both.  
Interestingly , a recent study involving 1821 patients with CLL demonstrated a 
better 10 year survival in female patients compared to male patients. 
72 
 
Additionally more female patients (83%) responded better to therapy than their 
male (71%; p<0.0001) counterparts (Catovsky et al, 2014). In addition a study 
reported by Eve, et al, demonstrated a significantly better response to 
lenalidomide in female patients compared to male patients with relapsed / 
refractory MCL (Eve et al, 2012). Lenalidomide modulates the immune system 
to be effective, this may suggest a better immune response in females. Female 
hormones may also be influential. However the authors were not able to 
conclude on the precise mechanism of the observed differences in the 
response rate of female MCL patients compared to the males. Furthermore, this 
pattern of response has also been described in patients with other subtypes of 
NHL; diffuse large B cell lymphoma and follicular lymphoma where patients 
treated with immunochemotherapy that is, combination chemotherapy with 
rituximab, the progression free survival has been observed to be significantly 
better in the female patients (Riihijärvi et al, 2011).  
Further studies are needed to correlate these differences in relation to the 
genders and whether oestrogens have a role. To further illustrate the activity of 
oestrogens, a general overview of oestrogens and its receptors is portrayed 
below. 
1.25. Oestrogen and Oestrogen Receptors 
Oestrogens have widespread biological actions. There are predominately three 
naturally occurring oestrogens; 17-β- oestradiol (E2), oestrone (E1) and oestriol 
(E3) (Gruber et al, 2002). Oestradiol is the predominant oestrogen during the 
reproductive years. The primary sources of oestradiol in women are the theca 
and granulosa cells of the ovaries and the luteinised derivatives of these cells. 
The theca cells secrete androgens that diffuse to the granulosa cells to be 
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aromatized to oestrogens. Oestrone and oestriol are primarily formed in the liver 
from oestradiol. In males the aromatisation of oestrogens and androgens occur 
in the testes and secondary tissues (Gruber et al, 2002).  
Serum oestradiol levels steadily rise at the onset of puberty in girls to 
approximately 15 to 35pg per millilitre (Gruber et al, 2002). During menstrual 
cycles oestradiol production varies cyclically with the highest rate of production 
and concentration being in the pre-ovulatory phase (Mihm et al, 2011). 
Oestradiol production and serum concentration are lowest pre-menstrually. In 
the perimenopausal period there is a steady decline in ovarian oestradiol 
production and in postmenopausal women serum oestradiol levels are minimal 
and most oestradiol is formed by extragonadal conversion of testosterone 
(Mihm et al, 2011). In peripheral tissues, the production of different oestrogens 
and their interconversion depend on the local expression and activity of 
aromatase, 17β-hydroxysteroid dehydrogenases and oestrone sulfatases 
(Cutolo et al, 2012). Oestrone is the predominant oestrogen in postmenopausal 
women (Table 5). During the reproductive periods control of oestrogen 
production is exerted by gonadotrophins, however in postmenopausal women 
little is currently known on the factors that control the oestrogen production 
(Gruber et al, 2002). 
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Phase 
 
17-β-Oestradiol 
 
Oestrone 
 
Oestriol 
 Serum 
Concentration 
(pg/ml) 
Serum 
Concentration 
(pg/ml) 
Serum 
Concentration 
(pg/ml) 
 
Follicular 
 
40-200 
 
30-100 
 
3-11 
Preovulatory 250-500 50-200 - 
Luteal 100-150 50-115 6-16 
Premenstrual 40-50 15-40 - 
Postmenopausal <20 15-80 3-11 
Table 5: Serum concentrations of oestrogens in normal women 
 Adapted from (Gruber et al, 2002) 
There are a significant number of physiological actions of oestrogens ranging 
from stimulation of growth and differentiation of primary and secondary sex 
organs, influence of mood and behaviour, arterial dilatation, cardio-protection, 
maintenance of bone density to neuro-protection. The specific nuclear action of 
oestrogen is determined by the type of hormone and the subtype of oestrogen 
receptor involved (Nilsson & Koehler, 2005). Given the widespread role of 
oestrogens in human physiology it is not surprising that oestrogens are 
implicated in the development and progression of numerous diseases which 
include but not limited to various types of cancers (such as breast, ovarian, 
colorectal, prostate cancers), osteoporosis, neurodegenerative diseases, 
cardiovascular disease and autoimmune diseases among others. In many of 
the diseases oestrogen mediates its effects through the oestrogen receptors as 
exhibited in its normal physiological function (Nilsson & Koehler, 2005).  
Oestrogens influence the maturation of both T and B lymphocytes (Grimaldi et 
al, 2001; Ackerman, 2006). They decrease B cell lymphopoiesis by down-
regulating IL-7 production by bone marrow stromal cells and also reduce the B 
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cell receptor signal strength (Grimaldi et al, 2002) resulting in escape from 
negative selection. Exposure to oestrogen decreases the number of developing 
thymic CD4+ / CD8+ T cells and promotes T cell lymphopoiesis in the liver 
allowing cells to escape negative selection, potentially leading to the 
accumulation of autoreactive cells (Pauklin et al, 2009). This is supported by the 
increase in Bcl2 expression which enhances cells survival (Verthelyi, 2001). 
Oestrogens also promote Th2 responses, resulting in increased levels of IL-4, 
IL-5 and IL-10 (Ackerman, 2006). This also results in proliferation of B cells and 
their maturation. Interestingly oestrogens promote elevated levels of CD4+ T 
cells in females and females show a pre-ponderance towards Th2 immune 
responses and B cell activation, whereas males predominately generate Th1 
CD4+ and CD8+ lymphocytes (Ghazeeri et al, 2011).  Oestrogens modify the 
functional capacity of T regulatory cells. They increase the expression of 
perforin in both the natural and induced T regulatory cells thereby enhancing 
cell death in the target associated effector T cells (Valor et al, 2011). The 
oestrogens also increase the suppressive function of T regulatory cells by 
inducing production of the regulatory cytokines IL-10 and TGF-β (Pennell et al, 
2012). Oestrogen inhibition of T cell response is thought to be due to the 
oestrogen stimulation via the ERα present on the T cells resulting in an increase 
in the Foxp3 expression thus converting the CD4+CD25-  into the regulatory T 
cells largely seen in pregnant females in the uterus, but can also occur in the 
lymph nodes and peripheral blood (Polanczyk et al, 2004; Yakimchuk et al, 
2013) . Although there is a significant influence of oestrogens on the immune 
cells its effects are numerous and it continues to be an area of study and 
research. 
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1.26. The oestrogen receptors  
Oestrogens induce cellular changes through several different mechanisms. 
Central to this mechanism is the protein to which oestrogens binds; the 
oestrogen receptor (ER)(figure 10.0)(Deroo & Korach, 2006). In the ‘classical’ 
mechanism oestrogens diffuse into the cell and binds to the ER which is loosely 
bound in its cytoplasmic or nuclear location and is attached to receptor- 
associated proteins. These proteins serve to stabilise the receptor when the ER 
is in an inactivated state or mask the DNA binding domains of the receptors. 
Once the oestrogen binds to the receptor, the receptor dissociates with the 
attached proteins and the oestrogen – receptor complex moves to the nucleus, 
where it binds to the DNA and initiates transcription. Transcription is catalyzed 
by RNA polymerase II and requires the assembly of various proteins, including 
the TATA-box–binding protein (TBP) and other associated factors at a TATA 
box(Deroo & Korach, 2006). This recruitment of the co-regulatory proteins to the 
promoter increases or decreases mRNA levels associated with protein 
production and physiological response.  ER also interact with nuclear kappa B 
and activating protein-1 (AP1) to influence cellular proliferation (Nilsson & 
Koehler, 2005). 
Oestrogens can also act through ‘nongenomic’ mechanisms either through the 
ER located in or next to the plasma membrane or through non-ER plasma 
membrane associated proteins, resulting in cellular responses such as 
increased levels of calcium, nitrogen oxide (NO) and activation of kinases as 
mentioned below. Non-nuclear actions of ER tend to have rapid results (Nilsson 
& Koehler, 2005). The gene activation occurs through second-messengers 
downstream of growth signalling pathways such as epidermal growth factor 
receptor (EGFR), the insulin-like growth factor (IGFR) and the G protein 
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coupled receptor (GPCR) pathways. This alters intracellular kinase and 
phosphatase activity, resulting in altered phosphorylation of ER (Weigel & 
Zhang, 1998). ER regulates genes via protein-protein interactions with other 
transcription factors, such as c-Fos/c-Jun B (AP-1) and nuclear factor-ƙB (NF-
ƙB), resulting in alteration to cell division, angiogenesis, and survival (Barone et 
al, 2010). The kinases that get phosphorylated include Akt, extracellular 
regulated kinase (Erk) 1 / 2 mitogen-activated protein kinase (MAPK), p21-
activated kinase 1 (PAK-1), PI3K and protein kinase A (PKA) (Likhite et al, 
2006; Wang et al, 2002). These phosphorylation events are complex and 
interdependent leading to alteration in gene signalling.  
The precise gene products related to ER stimulation is still being studied. 
However in ovarian epithelial cells it has been shown that stimulation of the 
ERα upregulates the anti-apoptotic Bcl-2 gene (Choi et al, 2001). In relation to 
ERβ in-vitro study has shown pro-apoptotic signalling in ovarian cancer 
mediated by upregulation of FasL, a pro-apoptotic protein ligand (Sapi et al, 
2002).  
In the context of lymphoid malignancy a study reported by Yakimchuk, et al 
demonstrated increased apoptosis when selective ERβ agonist 
diarylpropionitrile (DPN) is used on murine lymphoma cells in vivo (Yakimchuk 
et al, 2011a). Although ERβ has a generally pro-apoptotic effect and ERα an 
anti-apoptotic effect, the responses are cell and ligand dependent and correlate 
to a certain degree to the ER subtype expression. 
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Figure 7: Diagrammatic illustration of oestrogen action with ER. 
In the “classical” pathway of oestrogen action (i), oestrogen or other selective ER 
modulators (SERMS) bind to the oestrogen receptor (ER), a ligand-activated 
transcription factor that regulates transcription of target genes in the nucleus by binding 
to the oestrogen response element (ERE) regulatory sequences in target genes and 
recruiting co-regulatory proteins (CoRegs) such as coactivators. Rapid or 
“nongenomic” effects of oestrogen may also occur through the ER located in or near to 
the plasma membrane (ii), which may require the presence of “adaptor” proteins, which 
target the ER to the membrane. Activation of the membrane ER leads to a rapid 
change in cellular signaling molecules and stimulation of kinase activity, which in turn 
may affect transcription. Lastly, other non-ER membrane-associated oestrogen-binding 
proteins (EBPs) may also trigger an intracellular response (iii). Adapted from (Deroo & 
Korach, 2006). 
 
There are two subtypes of oestrogen receptors; oestrogen receptor alpha (ERα) 
and beta (ERβ) (Mueller & Korach, 2001) and several isoforms and splice 
variants of each subtype are described (Deroo & Korach, 2006). The most 
common splice variants of ERα are expressed in multiple tissues and arise from 
deletions of internal exons, resulting in truncated proteins lacking segments of 
the DNA-binding domain (DBD) or hormone-binding (ligand-binding) domain 
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(LBD) of the receptor (Cheng et al, 2005). ERs are composed of three 
functional domains; the NH2-terminal domain (NTD), the DNA-binding domain 
(DBD) and the COOH-terminal ligand-binding domain (LBD) (Figure 8). The 
NTD encompasses a ligand independent activation function (AF1) domain 
involved in transcriptional activation of target genes and with only 16% similarity 
between ERα and ERβ (Jia et al, 2015). The DBD is highly conserved between 
ERα and ERβ with 97% amino acid identity and mediates sequence-specific 
binding of ERs to DNA sequences in target genes denoted estrogen-responsive 
elements (EREs). In contrast, the LBDs of ERα and ERβ show a 59% overall 
amino acid sequence identity yet the ligand-binding pockets of the two subtypes 
show only minor differences in structure. There are 3 ERα isoforms due to 
alterantive splicing of the ER-mRNAs. ERα∆3 lacks exon 3, which encodes part 
of the DNA-binding domain (Price et al, 2001). ERα36 lacks both AF-1 and AF-
2 and the last 138 amino acids are replaced with a unique 22 sequence (Shi et 
al, 2009). ERα46 lacks the amino acid including AF-1 and was first described as 
a dominant negative inhibitor of ERα activity in osteoblasts (Denger et al, 2001). 
As described for ERα, wild-type ERβ (ERβ1) possesses both a DBD (C domain) 
and an LBD (E domain). ERβ2 codes for a variant that contains an additional 18 
amino acids in the LBD, while ERβ3 lacks exon 3. ERβ4 contains both of these 
variations. ERβ5 lacks exon 5, and in ERβCX, the COOH-terminal 61 amino 
acids are replaced by a unique sequence of 26 amino acids (Moore et al, 1998). 
ERβ4 is truncated at both the N and the C termini. In humans, variants lacking 
exon 2, exon 4, exon 6, and exon 7 also exist (Deroo & Korach, 2006). 
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Figure 8: The Structures of the ER isoforms 
The NH2- terminal domain (NTD) in blue, DNA-binding domain (DBD) in orange, and 
the COOH-terminal or ligand-binding domain (LDB) in green. The NTD contains a 
ligand-independent activation function (AF1) region which is responsible for recruitment 
of co-regulatory proteins. Adapted from (Jia et al, 2015) 
 
ERs are members of the nuclear hormone- receptor superfamily and have 
several functional domains. These two receptors vary in their structure and their 
encoding genes are on different chromosomes.  The DNA-binding domains of 
the two ERs are similar, but the receptors are heterogeneous in their binding 
domains to the ligands. As a result some oestrogens bind to the two receptors 
with different affinities as shown in Table 6 (Gruber et al, 2002).    
Ligand Oestrogen Receptor α 
Ki (binding affinity) 
Oestrogen Receptor β 
Ki (binding affinity) 
17-β-Oestradiol 100 100 
Oestriol 14 21 
Oestrone 60 37 
Binding affinity Ki Values range from Ki  0 to 100, with higher values indicating greater binding 
affinity. 
Table 6: Binding affinity of the different ligands for ERα and ERβ 
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The tissue distribution of ERs varies between the two receptors. Granulosa cells 
and developing spermatids contain mostly ERβ and this receptor is also found 
in other tissues such as kidney, intestinal mucosa, lung, bone marrow, bone, 
brain, endothelial tissue and prostate (Leitman et al, 2010; Shim et al, 2006). In 
contrast, endometrium, breast-cancer cells, ovarian stroma mostly contain ERα. 
It is thought that on both the ERs the conformation of the ligand-binding domain 
changes in different ways when different ligands bind resulting in variations of 
the transcriptional effects. For example oestradiol activates transcription when 
bound to ERα but exerts a suppressive effect when bound to ERβ. Although the 
specific effects of the various subtypes of ERs is still under investigation there is 
remarkable variation on its effect on various tissues and cells they are present 
on (Henderson et al, 2003; Deroo & Korach, 2006).  
Furthermore, it has been suggested that ERα and ERβ elicit opposite effects on 
proliferation and apoptosis. Oestrogens via the ERα stimulate proliferation of 
the breast, uterus and developing prostate, thus increasing the risk of tumour 
progression in these tissues (Morani et al, 2006; Imamov et al, 2004). In 
contrast ERβ have exhibited a suppressive effect on proliferation of the 
prostate, colon, mammary glands, lung and bone marrow stem cells 
(Yakimchuk et al, 2013).  
Currently there is no precise data on the exact splice variants present on 
lymphoma cells or MCL. The area of research is growing and of much interest.  
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1.27 Oestrogen Receptors on lymphocytes 
Both ERα and β have been identified on immune cells. However, the 
expressions of the two subtypes differ in the immune subsets. CD4+ T cells 
have a higher expression of ERα compared to ERβ and CD8+ T cells have a 
low expression of both the ERs (Pierdominici et al, 2010). NK cells have both 
receptors expressed but in low levels (Phiel et al, 2005). B cells exhibit higher 
expression of ERβ compared to ERα which is in line with several human 
leukaemia / lymphoma cell lines representing chronic lymphocytic lymphoma, 
Hodgkin’s disease, Burkitt’s lymphoma and multiple myeloma (Phiel et al, 2005; 
Yakimchuk et al, 2013).  
Thus oestrogens via their ERs have an important impact on lymphocytes, which 
may explain, in part, the development of gender bias in disease prevalence and 
immune response.  The oestrogens can influence the cell signalling pathways 
including nuclear factor-ƙB and interferon regulatory pathways as mentioned 
above. Although much of the oestrogen effects on the immune system is 
thought to be dose dependent (Dorak & Karpuzoglu, 2012). 
There are limited studies specifically in MCL in relation to oestrogens and ERs. 
However, due to the gender differences in the incidence of MCL and the 
response rate to certain therapies like lenalidmide, it is an area of increasing 
research. 
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1.28. The Main aims of this thesis 
 
1) To investigate the quantitative difference in the immune cell subsets and 
expression of NK cell activating receptors between untreated male and female 
patients with MCL. 
 
2) To investigate the difference in the immune response and function following 
exposure to lenalidomide and oestrone between untreated male and female 
MCL patients. 
 
3) To look at the expression of oestrogen receptors on primary MCL cells and 
the distribution of selected immune cell subsets in lymph nodes of primary MCL 
in both male and female patients. 
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Chapter 2 
 
 
 
 
Materials and Methods  
85 
 
2.0. Source of study subjects 
 
 A total number of 6 male patients (median age 64 years) and 5 female patients 
(median age 62 years) diagnosed with Mantle Cell Lymphoma (MCL) and 11 
healthy, age matched ( > 50 years) volunteers (5 males and 6 females) were 
selected and recruited by either myself  and with the help of the haematology 
research team at Derriford Hospital, Plymouth, UK.  Patients were recruited 
during their scheduled visit to the specialized Haematology Trials Clinical and 
age and sex matched healthy volunteers were recruited from the staff at the 
haematology and pathology laboratories or the haematology ward at Derriford 
Hospital (details of the patient are provided in Table 7 and 8). Informed consent 
was obtained from each patient and healthy volunteer prior to the 
commencement of the described studies and usage of patient materials was in 
accordance with the approval from the local Ethical Committee ; South West 
(REC ref: 09/H0203/59 - ethical approval was for 5 years from September 2009) 
and Cambridge (REC ref: 14/EE/1251 ethical approval from October 2014 on 
going with a minimum approval of 5 years).   All patient material used in this 
study was from untreated MCL patients. 
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Male Patients 
Patient Age 
(years) 
Stage of 
MCL 
WBC 
(x10
9
/L) 
Lymphocyte 
(x10
9
/L) 
MIPI 
prognostic 
score 
Clinical 
presentation 
MP001 59 IV 9.4 4.8 5.7- im Indolent 
MP002 56 IV 9.3 1.9 5.9-im Aggressive 
MP003 70 IV 41 37.3 6.6-high Indolent 
MP004 70 III 7.9 2.7 6.1-im Aggressive 
MP005 64 IV 18 15 6.3-high Indolent 
MP006* 77 IV 10 6.7 6.6-high Aggressive 
Female Patients 
FP001 68 IV 5.4 2.3 5.8-im Aggressive 
FP002 60 IV 10.9 4.9 5.8-im Aggressive 
FP003 43 II 7.7 2.0 4.7-low Indolent 
FP004 68 IV 20.8 19.1 6.8-high Aggressive 
FP005 62 IV 27.9 22.9 6.2-high Indolent 
MCL- mantle cell lymphoma; WBC- white blood cells: MIPI-mantle cell lymphoma 
international prognostic index; indolent disease- not requiring treatment > 1 year; 
aggressive disease- needing immediate therapy based on symptoms; * patient was 
recruited  and only used for peripheral blood analysis of immune subsets; im- 
intermediate group in MIPI prognostic 
Table 7: Table to show the patient characteristics 
These patients were used for the experiments in the chapters 3 and 4. Staging of MCL 
is in accordance to the Ann-Arbour staging of lymphoma (Table 1 chapter 1) .  
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Male Patients 
Patient Age 
(Years) 
Stage of 
MCL 
WBC 
(x109/L) 
Lymphocyt
e 
(x109/L) 
MIPI Clinical 
nature 
IHM-1 56 IV 9.3 1.9 5.9-im Aggressive 
IHM-2 70 III 7.9 2.7 6.1-im Aggressive 
IHM-3 77 IV 10. 3.0 6.5-high Aggressive 
Female Patients 
IHF-1 68 IV 9.0 2.6 6.1-im Aggressive 
IHF-2 60 IV 10.9 4.9 5.7-im Aggressive 
IHF-3 65 IV 7.0 2.0 5.8-im Aggressive 
MCL- mantle cell lymphoma; WBC- white blood cells: MIPI-mantle cell lymphoma international 
prognostic index; indolent disease- not requiring treatment > 1 year; aggressive disease- 
needing immediate therapy based on symptoms; im- intermediate score on MPI 
Table 8: Patient characteristics relating to IHC and immunofluorescence 
Patient used for IHC and immunofluorescence described above were different to the 
cohort of patients described in table 7. This was subject to availability and access to 
diagnostic materials from patients. Staging of MCL described here is the same as that 
described above in table 7. 
 
2.0a. General information on Materials 
 
All sterile plastic-ware was purchased from Sarstedt (Leicester, UK) or Fisher-
Scientific (Loughborough, UK), and all general laboratory reagents (eg. 
Phosphate buffered saline, PBS) were purchased from Sigma-Aldrich 
(Gillingham, UK) or Life Technologies (Paisley, UK) unless otherwise stated. 
2.1. Preparation of Charcoal Dextran Stripped Heat inactivated Foetal 
Bovine Serum 
Principle 
Dextran coated charcoal is used to absorb free hormones and leave hormones 
that are bound to a carrier (or antibody). It is typically used to reduce oestrogen 
levels in foetal bovine serum and in particular dextran coated charcoal is used 
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to strip hormones from serum instead of charcoal alone, because there is less 
loss of protein. 
Method 
Heat Inactivated Foetal Bovine Serum (HI-FBS) (Sigma Aldrich, Gillingham, UK) 
used throughout was stripped of hormones with dextran coated charcoal 
(Sigma Aldrich, Gillingham, UK). 10g of dextran coated charcoal was added to 
500mls of HI-FBS and was mixed gently for a minimum of 12 hours at 40C in 
the Innova 42 Incubator Shaker (New Brunswick Scientific, Eppendorf, 
Stevenage, UK). After the 12 hours had elapsed, the HI-FBS with charcoal 
dextran was left to stand for one hour at 40C before being aliqouted into 50ml 
polypropylene Falcon Centrifuge tubes and centrifuged at 41g  (Heraeus 
Labofuge 400R :15cm radius, ThermoScientifc, Hemel Hempstead,UK) for 1 
minute. This solution was placed in the sterile Stericup and Steritop filtration unit 
(Millipore, Watford, UK) which had a filtration membrane pore size of 0.22µm 
and under gentle suction HI-FBS with dextran coated charcoal was filtered to 
remove the dextran coated charcoal. The filtered charcoal stripped HI-FBS (CS-
HI-FBS) was stored at -200C until use. The dextran coated charcoal stripping of 
HI-FBS was performed under sterile conditions in a class II microflow biological 
safety cabinet. 
2.2. Preparation of cell culture reagents 
1X RMPI 1640 Medium without L-glutamine and without phenol red 
supplemented with 10% CS-HI-FBS, 2mM L-glutamine, 100U/mL penicillin and 
100µg/ml streptomycin was prepared before use and stored at 40C (referred to 
as complete culture medium [CCM] here after). Serum free media (SFM) was 
prepared by supplementing 1x RMPI 1640 Medium without glutamine and 
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without phenol red with 2mM L-glutamine, 100U/mL penicillin and 100µg/ml 
streptomycin. All culture reagents were prepared using heat-sterilised 
equipment and in a class II culture hood using aseptic techniques. 
2.3. Cell Culture  
Cell culture procedures were performed in a Class II microflow biological safety 
cabinet (Microflow II MDH M51424/2, Astec, Hampshire, UK) using aseptic 
techniques. All cells were incubated and grown in HERAcell 240i incubator 
(Thermo Scientific, Hemel Hempstead, UK) with 95% air / 5% CO2 humidified 
atmosphere at 37oC.   
2.4. Granta 519 and K562 cell culture 
2.4.1. Granta 519 cell line (Granta 519 target cells) 
The Granta 519 cell line was purchased from DSMZ (Leibniz-Institute DSMZ- 
German Collection of Microorganisms and cell culture, Braunschweig, 
Germany). It was originally derived from a peripheral blood sample taken in 
1991 from a 58-year-old Caucasian woman who had recently been diagnosed 
with stage IV cytologically high-grade B-cell. G519 cells are characterised 
immunophenotypically as IgM+ IgD+ CD5- CD10- CD19+ CD22- CD23+ FMC7+ 
(representing differentiation-associated antigens present on mature B lymphoid 
cells) and carry a complex karyotype with multiple chromosomal 
rearrangements including t(11:14)(q13:q32). They express high levels of cyclin 
D1 mRNA with concurrent biallelic deletions of the genes encoding the cyclin-
dependent kinase inhibitors p16 (CDKN2A) and p15 (CDKN2B), all of which is 
consistent with cell cycle dysregulation at the level of G1. Despite CD5 
negativity of the cell line, immunophenotyping of involved bone marrow at the 
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time of the patient’s initial diagnosis five months earlier was positive for CD5 
surface expression. This factor, together with the presence of a 
t(11:14)(q13:q32), strongly suggests a blastic transformation of MCL and the 
Granta 519 cell line is thus widely accepted as such (Amin et al, 2003). 
2.4.2. K562 cell line (K562 target cells) 
K562 cell line was a kind gift from Dr. Sarah Richardson. K562 cells are the first 
human myelogenous leukemia line to be established. The line is derived form a 
53 years old female with chronic myeloid leukemia in blast crisis. These cells 
are positive for the BCR:ABL fusion gene and are an erythroleukaemic line. 
They lack the MHC complex required to inhibit NK activity and also lack any 
trace of Epstein-Barr virus or herpes virus. K562 cell lines are widely accepted 
as being highly sensitive to immune cell, especially NK cell mediated death and 
used in vitro (Sirianni et al. 2005).  
2.4.3. Storage and revival of Granta 519 cells and K562 cell lines 
For long term storage, Granta 519 cells and K562 cells were first counted and 
then centrifuged (Labofuge 400R, Newport Pagnell, UK) at 670g for 5 minutes. 
Supernatant was discarded and the cell pellets were re-suspended in freezing 
media (90% HI-FBS / 10% dimethyl sulfoxide (DMSO) (Sigma-Aldrich, Poole, 
UK)  to achieve a cell density of 5 - 10 x 106 cells/ml. 1ml of the total cell 
suspension was aliquoted into 1.8ml cyrovials and placed into a polystyrene 
container “Mr FrostyTM” (ThermoScientific, Hemel Hempstead, UK) containing 
isopropyl alcohol and placed in a -80°C freezer for 1 day to reduce the 
temperature by 1 degree/min.   The frozen cryovials were then transferred to a 
liquid nitrogen dewar (Taylor-Wharton LS300, Borehamwood, UK) for long term 
storage between -2100C and -1950C.  
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Revival of the frozen Granta 519 and K562 cell lines was performed by rapidly 
defrosting the cells by immediately incubating in a 370C water-bath for 1 to 2 
minutes. Cells were then dispensed and seeded into T75 tissue culture flasks 
containing 25ml of pre-warmed (370C) CCM. After seeding, G519 and K562 
cells were left in the incubator for 24 hours after which time the media was 
completely replaced with fresh CCM. Cells were subsequently re-fed with fresh 
CCM every 72-96 hours and discarded after they reached a maximum passage 
of 25. A maximum of 25 passages was chosen as higher passage potentially 
increased genetic mutations and could affect the cell line susceptibility to drugs 
and cell cytotoxicity. Both G519 and K562 cells were grown in suspension and 
were non-adherent cells. All cells were disinfected with Virkon 1% w/v solution 
(Antec international, Sudbury, UK) for a minimum of 4 hours prior to disposal. 
2.5. Isolation and storage of Peripheral Blood Mononuclear Cells (PBMCs) 
Approximately 24 to 30 mls of peripheral venous blood was collect in 4mls BD 
Vacutainer Ethylenediaminetetraacetic acid (EDTA) tubes (Becton Dickinson, 
Oxford, UK) from each participant for the isolation of PBMCs and for flow 
cytometry as described below in section 2.6.  
The PBMCs were isolated within 4 hours of collecting venous blood using 
routine isolation methodologies.  Venous blood was transferred into a sterile 
50ml polypropylene Centrifuge tube (Sarstedt, Leicester, UK) and an equal 
volume of warmed PBS was added.  This was gently mixed and layered onto 
10-12ml of lymphoPrepTM solution (Axis-Shield, Dundee, UK). LymphoPrep is 
an iso-osmotic solution with a density of 1.077 g/ml which allows cells of higher 
density to pass through during centrifugation. The layered blood was 
centrifuged (Labofuge 400R, Newport Pagnell, UK) at 670g for 30 minutes 
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without brakes. Following centrifugation the mononuclear cells and lymphocytes 
(density gradient <1.077g/ml) that were unable to pass though the medium 
were retained at the top.  The red cells and multinuclear cells (density gradient 
>1.077g/ml) settled at the bottom, resulting in the separation of cells into layers 
as illustrated in Figure 9.  The centrifugation resulted in separation into 4 layers 
(phases).  Two thirds of the uppermost layer, composed of serum, was 
discarded. The opaque interface, containing mononuclear cells (PBMCs), above 
the LymphoPrepTM, was aspirated and placed into a 15ml centrifuge tube. The 
PBMCs were washed twice in 10ml of PBS and in the final wash PBMCs were 
resuspended in 10mls PBS and centrifuged at 670g for 10 minutes followed by 
resuspension in 10ml of CCM.  
 
Figure 9: Diagrammatic representation of PBMC isolation 
This diagram displays the layer formation with Ficoll-Haque method to isolate PBMCs 
from peripheral blood over LymphoPrepTM (Thorsby & Bratlie, 1970; Richardson et al, 
2010).  
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Freshly separated PBMCs were counted using a Neaubaeur haemocytometer . 
Briefly, 10ul from the final solution was placed onto the counting chamber of the 
haemocytometer and all cells within the 4 quadrants were counted. This 
corresponded to 1 x104 cells/10ul. The number of cells counted per ml was 
multiplied by factor 100. 5-10 million cells/ml were then suspended in 90% CS-
HI-FBS / 10% DMSO and kept in Mr FrostyTM at -800C for 24 hours before being 
transferred to liquid nitrogen for long term storage.    
2.6. Flow Cytometry 
 
Principles of flow cytometry 
 
Flow cytometry makes use of the principles of light scattering by particles 
crossing a beam of light, and excitation light from fluorochromes attached to 
specific molecules or proteins expressed by cells, to identify, analyse, and/or 
sort different populations of cells. 
The process begins by single cells passing through one or multiple laser light 
beam and momentarily breaks the laser beam. The cells cause the light beam 
to scatter or the fluorochromes to emit light of particular wavelengths. This 
scattered light or fluorescence light from the fluorochrome is collected by a 
confocal lens and funneled onto a light detector which converts it into an 
electrical signal and subsequently it is digitalised to display the analysis of the 
cells.  The light scattered in the forward direction, forward scatter signal (FSC) 
will give information about the size and shape of the cell. The side scatter signal 
(SSC) gives information about the granularity of the cell. As FSC and SSC are 
unique for each type of particle, the combination of the two can help identify 
different types of cells. 
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In addition, the use of fluorescent dyes that bind to extracellular or intracellular 
components can provide additional information about the cell. When cells, 
labelled with fluorescent dyes which are specific for an antibody, traverse the 
laser beam, the fluorescent molecules are excited to a higher energy state, 
causing them to emit light energy. The use of multiple fluorochromes, each with 
similar excitation wavelengths and different emission wavelengths (or ‘colours’) 
allows cells properties to be measured simultaneously and identify specific 
antigens on the cells to enable identification of specific cells. For example the 
following flourochromes; fluorescein isothiocyanate (FITC) has a emission 
wavelength of 512nm, allophycocyanin (APC) has an emission wavelength of 
660nm and phycoerythrin (PE) approximately 700nm emission can be 
combined as each of their wavelength have minimal cross over on each other 
and emit light of different color and wavelength for the flow cytometry to identify 
individually without each emission overlapping / ‘spilling’ over each other and 
hence unable to read the identified the specific antigens on the cells of interest. 
Additionally, they have a narrow emission spectra and therefore helps to reduce 
this ‘spill’. 
When the emission spectra of flourochromes overlap the proportions of 
overlapping signal needs to be subtracted from the adjacent channel, a process 
called ‘compensation’. Compensation is unique to each combination of 
flourochromes utilized in a single tube. To perform compensation each antibody 
emission is acquired by the flow cytometery individually and the spillage 
between the flourochromes is subtracted by the software on the flow cytometry 
(FACSDiva, BD Immunocytometry Systems, San Jose, CA, USA). Due to the 
usage of the multicolour flow cytometry (FACSCanto, BD Immunocytometry 
Systems, San Jose, CA, USA ) (6 channel lazer) for the experiments outlined 
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below the inbuilt computer software mathematically creates a matrix from single 
flourochrome controls and optimizes the compensation. This is more accurate 
than the manually performed compensation in flow cytometers with multiple 
lazers. Compensation can be performed visually by subtracted spillage 
manually, but there is greater chance of false positivity as it is operator 
depended. 
For experiments described in this thesis, flow cytometry was used for the 
following purposes: 
1) To identify and quantitate different immune lymphocyte subsets in 
peripheral blood using fluorochrome-conjugated monoclonal antibodies 
directed against various cell surface or intracellular antigens  (section 
2.6.1) 
2) To quantitate the mean fluorescence of activating receptors on NK cells, 
by using fluorochrome-conjugated monoclonal antibodies, before and 
after NK cell stimulation (section 2.6.1). 
 
3) To differentiate between viable and apoptotic target (G519 cells and K562 
cells) and effector cells (PBMCs and Isolated NK cells) with the use of 
fluorescent dyes such as propidium iodide (PI) and 7-amino-actinomycin 
D (7-AAD)  (section 2.7). 
 
4) To quantitate target cells (G519 cells and K562 cells) and effectors cells 
(PBMCs and isolated NK cells) (section 2.7) 
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5) To identify MCL cells in the isolated PBMC cell population from MCL 
patient samples (section 2.6). 
2.6.1. Determination of T / NK / T regulatory cell numbers and NK cell 
activating receptors by flow cytometry 
Flow cytometry was performed on a Becton Dickinson (BD) FACSCanto (BD 
Immunocytometry Systems, San Jose, CA, USA).  Flow cytometry was utilised 
to determine the expression and quantification of T (CD3, CD4, CD8), Natural 
Killer (NK)(CD16, CD56)and T regulator cells (CD4 ,CD25,CD127). In addition, 
expression of NK cell activating receptors (NKp46, NKp30, NKp44 and NKG2D) 
was evaluated. All antibody reagents were purchased from BD Biosciences, 
Oxford, UK unless otherwise stated (Table 9). 4ml of venous whole blood 
collected in BD Vacutainer K2EDTA tube (Becton Dickinson, Oxford, UK) was 
used for flow cytometry to identify and enumerate the above mentioned immune 
cells of patients in their peripheral circulation (figure 12.0 and 13.0). Results 
were presented as the mean of cell number with regards to quantification and 
mean of mean fluorescence intensity (MFI) with +/- standard error of the mean. 
CD3 is a T cell co-receptor; CD4 is a glycoprotein found on surface of T cells; 
CD8 is a transmembrane glycoprotein co-receptor for T cells; CD45 is 
lymphocyte common antigen is a receptor-linked protein tyrosine phosphatase 
that is expressed on all leucocytes; CD16 low affinity Fc receptor; CD25 alpha 
chain of the IL-2 receptor; CD127 is an IL-7 alpha receptor. 
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Source Specificity Conjugate Clone Isotype 
 
T cells 
enumeration 
 
Becton 
Dickinson 
San Jose, 
CA, USA 
 
CD3 
CD4 
CD8 
CD45-LCA 
 
 
FITC 
APC 
PE 
PerCP 
 
SK7 
SK3 
SK1 
2D1 (HLe-1) 
 
IgG1mouse 
IgG1mouse 
IgG1mouse 
IgG1mouse 
 
NK cells 
enumertion 
 
Becton 
Dickinson 
San Jose, 
CA, USA 
 
CD3 
CD56-NCAM 
CD16-FcγRIIIA 
CD45-LCA 
 
FITC 
PE 
APC 
PerCP 
 
SP34 
NCAM16.2 
3G8 
2D1 
 
IgG3mouse 
IgG2bmouse 
IgG1 mouse 
IgG1 mouse 
 
NK cell 
activating 
receptors 
analysis 
 
Becton 
Dickinson 
San Jose, 
CA, USA 
 
 
CD3 
CD56-NCAM 
CD45-LCA 
CD335-NKp46 
CD337-NKp30 
CD336-NKp44 
CD94-NKG2D 
 
FITC 
PE 
PerCP 
APC 
Alexa Fluor 647 
Alexa Fluor 647 
APC 
 
SP34 
NCAM16.2 
3G8 
9E2/NKp46 
p30-15 
p44-8.1 
1D11 
 
IgG3 mouse 
IgG2bmouse 
IgG1 mouse 
IgG1 mouse 
IgG1 mouse 
IgG1 mouse 
 
For Tregs 
analysis 
 
Treg Cocktail 
BD 
 
Becton 
Dickinson 
San Jose, 
CA, USA 
 
CD4 
CD25- IL-2Rα 
CD127- IL-7Ra 
CD45- LCA 
 
PE 
Cy7 
FITC 
PerCP 
 
SK3 
2 A3 
HiL-7R 
3G8 
 
IgG1 mouse 
IgG1 mouse 
IgG1 mouse 
IgG1 mouse 
Table 9: Flow cytometry antibodies for T, NK, T regulatory cells and NK 
cell activating receptors 
LCA- lymphocyte common antigen; NCAM- natural cell adhesion molecule;  
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2.6.2. T cell enumeration 
T cell analysis was performed by staining with BD Multitest IMK kit for T cells 
analysis according to the manufacturer’s protocol. Briefly, 50µl of 
anticoagulated whole blood was placed in BD Trucount tubes (Becton 
Dickinson, Oxford, UK) with 20µl of the monoclonal antibody combination: 
FITC-CD3/PE-CD8/PerCP-CD45/APC-CD4 (Table 9). After 20 minutes 
incubation in the dark and at room temperature, 1ml of Quicklysis solution 
(Cytognos, Salamanca, Spain) was added to each tube prior to a further 15 
minute incubation in the dark at room temperature. Quicklysis solution was used 
to lyse red cells. Cells were acquired and analysed using FACSDiva software 
version 6.1.3 (BD Biosciences) to determine absolute cell counts of CD3+CD4+, 
CD3+CD8+ (T cells) lymphocyte subsets. A minimum of 20,000 CD45+ 
lymphocyte events per sample were collected and analysed (Figure 10 & 11).  
2.6.3. NK cell enumeration 
NK cells analysis was performed using similar methods as for T cells analysis 
mentioned above. In brief, 50µl of anti-coagulated whole blood was placed in 
BD Trucount tubes with 20µl of the following antibody combinations: FITC-
CD3/PE-CD56/PerCP-CD45 and 5ul of APC-CD16 (Table 9). Cells were 
acquired and analysed using FACSDiva software version 6.1.3 to determine 
absolute NK cell count (CD3-CD56+CD16+)  and NK cell subsets counts (CD3-
CD56bright CD16dim (involved in cytokine mediated cell cytotoxicity) and CD3-
CD56dimCD16bright (direct cell death). A minimum of 20,000 CD45+ lymphocyte 
events per sample were collected and analysed (Figure 12 & 13).  
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2.6.4. T regulatory cell enumeration 
T regulatory cell (T regs) analysis was performed by adding 20µl of PerCP-
CD45 and T reg antibody cocktail CD4/CD25/CD127 (Table. 9) to 50µl of 
anticoagulated whole blood placed in BD Trucount tubes.  Cell acquisition and 
analysis was done using BD FACSDiva software version 6.1.3. A minimum of 
20,000 CD45+ lymphocyte events per sample were collected and analysed 
(figure 12.0 & 13.0)(Hardy et al, 2013).  
2.6.5.  Formula for cell count calculation using flow cytometry beads 
BD Trucount Tubes were used to determine the absolute counts of various 
population of cell in the blood as mentioned above. The whole blood with the 
appropriate monoclonal antibody reagent is placed into the Trucount tubes, the 
lyophilized pellets in the tube dissolves, releasing a known number of 
fluorescent beads. The absolute number (cells/µL) of positive cells or cells of 
interest in the sample can be determined by comparing cellular events to bead 
events. Using the formula below the absolute cell count can be determined 
(Nantakomol et al, 2010; Hardy et al, 2013).  
# of events in region containing cell   X # of beads per test*       = absolute count of cell 
# of events in absolute count bead region  test volume  (cells/µl) 
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Figure 10: Flow plot representation of cell acquisition and quantification 
Flow plots cell acquisition and quantification of immune cell subsets in the peripheral 
blood of subjects on the FACSCanto flow cytometer and analysed by FACSDiva 
software version 6.1.3. 
A. Flow plot represents initial gating on peripheral blood. Forward and side scatter 
were used to identify the lymphocyte population as outlined. 
B. CD45+ lymphocytes were gated to identify the cells of interest including the bead 
count for quantification. 
C. CD3+ and CD3- cells were identified in the CD45+ populations and gated as shown. 
D. Flow plots represent NK cells CD3-CD56+ cells and subsets of NK cells were 
identified and counted CD3-CD56dimCD16bright (P5) and CD3-CD56brightCD16dim (P4). 
E & F. Flow plots represent CD3+ T cells and subsets T helper cells (CD3+CD4+) 
identified in Q2 and Cytotoxic T cells (CD3+CD8+) identified in Q2-1. 
G & H. Flow plots represent CD4+CD25+CD127dim T regulatory cells. 
These flow plots are representative for all flow plots analysed in this project.   
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Figure 11: Flow plots representing isotype controls 
Isotype controls for antibodies used in the identification and quantification of 
immune subsets as shown in figure 10.  
A. Forward and side scatter is used to identify the lymphocytes and are gated for 
further analysis. 
B, C, D, E and F plots represent isotype control demonstrating no fluorescence or slip 
over of fluorescence. PerpCP-Cy5, FITC-A, APC and PE are all represented 
respectively.  
Flow cytometry was performed on FACSCanto flow cytometer and analysis of the flow 
plot was on FACSDiva software version 6.1.3. 
2.6.6. NK cell activating receptor expression 
NK cell activating receptors analysis was perfomed by mixing 20 µl of PerCP-
CD45/FITC-CD3/ PE-CD56/APC-NKp46/Alexa Fluor 647-NKp44/APC-NKG2D 
and 5µl of Alexa Fluor 647-NKp30 (conjugate antibodies) to 50µl of 
anticoagulated whole venous blood (Table. 8.0). Cell solutions containing the 
aforementioned antibody combinations were processed using the BD 
FACSCanto flow cytometer and analysed with the BD FACSDiva software 
version 6.1.3.  In all samples tested, a minimum of 10,000 CD45+ lymphocyte 
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events were collected and analysed (figure 12.0). Results were expressed in 
mean fluorescence intensity (MFI). 
 
Figure 12.0: Flow plots to illustrate the analysis of NK cell activating receptors 
NK cell activating receptors; NKp46, NKp30, NKp44 and NKG2D on the NK cells; CD3-
CD56+ in the peripheral blood of the subjects.  
Plot A & B. Flow plots represent the identification of lymphocytes by forward and side 
scatter and CD45+. 
Plot C. Flow plot represents the NK cells; CD3-CD56+, which are gated on as shown. 
Plots D, E, F and G. Flow plots represent NKp46, NKp30, NKp44 and NKG2D 
activating receptors expression on NK cells respectively. They are analysed on both 
the CD56dim (P4) and CD56bright (P5) expressing NK cells.  
Quadrants shown on D exhibit positivity Q3 is the positive quadrant which positive of 
CD56 and the receptor as shown. Q4 positive for CD56 but not the respective receptor. 
These flow plots are representative of all flow plots analysed in this study. 
Flow cytometry was performed on FACSCanto flow cytometer and analysis was on 
FACSDiva software version 6.1.3. 
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2.6.7. Cell viability and cell death analysis by flow cytometry  
Principle 
Live cells have impermeable membranes to cationic dyes such as Propidium 
Iodide (PI) and 7-aminoactinomycin D (7-AAD).  However, these dyes are 
capable of entering apoptotic cells due to their plasma membranes being 
compromised. Referring to the PI dye, upon entry of PI, it labels the cells by 
binding to the DNA and intercalating between the bases. Once bound, it 
fluorescence is enhanced by at least 20 fold. Flow cytometry can be used to 
distinguish live, viable cells (unstained / PI-negative) from dead / apoptotic cells 
(stained / PI-positive). 
Method 
 
Cell lines (Granta 519 and K562), PBMCs and isolated NK cells viability was 
determined by incubating pre-treated cells with 10µg/ml of PI (Sigma Aldrich, 
Gillingham, UK) for 10 minutes at 40C. Cell viability was then analysed using a 
BD Accuri C6 flow cytometer and CFlow software (BD Biosciences, Oxford, 
UK). A minimum of 10,000 events was recorded and the results were presented 
as a percentage of PI-negative (live / viable) cells. The viability of PBMCs, was 
assessed after 24 hours incubation in CCM. Isolated NK cell viability was 
assessed immediately after the completion of NK cell isolation from PBMCs 
(see section 2.9). For all cell groups used in the experiments described here the 
viability was >90%, except for NK cell isolation, were by the viability was less 
than 50% therefore these cells were not used in any experiments. This in turn 
also resulted in very low number of NK cells to carry out any further viable 
experiments. 
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2.6.8. CD5+/CD19+ quantification of MCL cells in PBMCs from patient 
samples by flow cytometry 
MCL patients can have circulating MCL cells in the peripheral blood and often 
at diagnosis there are a large numbers of MCL cells circulating. Therefore, 
effector cell used here from MCL patients had less than 5% dual CD5 
(T1,TP67) / CD19 (B4 BCR co-receptor) positive cells. This is to limit the MCL 
cells affecting the cytotoxicity assay. Typically B cell loose and gain antigens as 
they develop and mature. In the development of MCL the CD5 and pan B cell 
antigens such as CD19 and CD20 are present together on the cells to 
demonstrate the typical immunophenotype of MCL (CD19+, CD20+, CD5+, 
CD45+,cyclin D1+, CD23-, surface Igbright). In normal subjects B cells with a dual 
CD5 and CD19 antigens can range from 3.6 to 20% of B cells (Gupta et al, 
2004). Thus a 5% cut off was used to ensure that there is minimal impact from 
native MCL cells and also allow for inclusion of patients with MCL. The quantity 
of MCL in the isolated PBMC was confirmed by incubating 20µl of BD 
OncomarkTM (CD5, CD10, CD19)(BD Biosciences, Becton Dickinson, San Jose, 
CA, USA)(Table 10) antibody with 50µl of isolated PBMCs (approximately 5 x 
105 cells) in FACS buffer for 20 minutes in the dark at room temperature, prior 
to analysis by flow cytometry on the BD FACSCanto flow cytometer (as per 
manufacturer protocol). A minimum of 10,000 lymphocyte events were gated 
according to their forward and side light scatter properties.  Analysis was 
presented as a percentage of dual staining CD5/CD19 cells using FACSDiva 
software version 6.1.3 (Figure 13). Results were presented in percentage of 
cells CD5+CD19+. 
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Source Specificity Conjugate Clone Isotype 
 
Becton Dickinson 
San Jose, CA, USA 
BD 
Oncomark
TM 
CD5 
CD10 
CD19 
 
FITC 
PE 
PerCP-Cy5.5 
 
L17F12 
HI10a 
SJ25C1 
 
IgG2aKappa 
IgG1 Kappa 
IgG1 Kappa 
Table 10: Flow cytometry antibodies for quantification of MCL cells in PBMCs. 
 
 
 
Figure 13: Flow plots to represent analysis of isolated PBMCs to identify MCL 
cells 
PBMCS from MCL patients analysed by flow cytometry to identify MCL cells in the 
PBMC with CD5+ and CD19+ dual fluorescence. 
A. Forward and side scatter plot to identify the cells of interest (P1 gating). 
B. Example of a flow cytometry plot demonstrating the presence of MCL cells in 
patient PBMC with cells positive for CD5+CD19+ in Q2 as shown. 
C. Example of a flow cytometry plot demonstrating the absence of MCL cells in patient 
PBMC with no cells positive for CD5+CD19+ cells in Q2 as shown here. 
These plots are representative for all the analysis done on patients samples to identify 
any presence of MCL cells in the PBMC. 
 
2.6a. Statistical Analysis 
Results from 5 male and female healthy age matched controls and 3 male and 
female MCL patients were analysed (unless otherwise stated). All effector 
(PBMC) and target cells exhibited a >90% viability. Cytotoxicity activity of the 
effector cells was measured by the percentage cell death of K562 cells and 
Granta 519 mantle cell lymphoma cells. The analysis was performed on 
GraphPad version 6 and the results are presented as the percentage mean 
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difference of cell death +/- standard error of the mean (SEM). Two way ANOVA 
with sidak post hoc multiple comparison analysis was performed on the 
cytotoxicity results and one way ANOVA with post hoc Dunns comparison was 
performed on the results of the enumeration of  NK, T , T regulatory cells and 
NK activating receptors between the groups. The results were presented as the 
mean total +/- standard error of the mean (SEM). Mann-Whitney U test was 
performed when comparing mean of two groups. 
2.6.9. Quantification of T and NK cells with their subsets, T regulatory 
cells and expression NK cell activating receptors analysis in PBMC cells 
post incubation after treatment with oestrone, IL-2 and lenalidomide in 
various combinations 
To determine the proportions of immune subsets and NK cell activating 
receptors on PBMCs after subjecting isolated PBMCs to various treatments, as 
described in section 2.7 below, flow cytometry was performed as described 
above in section 2.6. In brief, a minimum of 5 x 105 cells from each treatment 
arm of the PBMC were taken after they had been washed in PBS and re-
suspended in FACS buffer. Approximately 1.25 x 105 cells were incubated with 
the same quantity of antibodies for T cells, NK cells, T regulatory cells and NK 
activating receptors, as described in section 2.6 (Table 9), for 20 minutes in the 
dark at room temperature and subsequently analysed. Flow cytometry analysis 
was on the BD FACSCanto using BD FACSDiva software version 6.1.3. 
Minimums of 10,000 CD45 positive lymphocyte events were gated according to 
the side and forward scatter property and CD45+ fluorescence. Results were 
presented as the mean cell count with +/- standard error of the mean. 
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2.7. Cell mediated cytotoxicity assay  
 
Principle 
 
The characteristics of cell-mediated cytotoxicity were used to determine the 
efficiency of cell mediated cytotoxicity between males and females. This 
involves cytolysis of target cells (e.g. malignant cells) by effector cells (e.g. 
cytotoxic T cells and/or NK cells). The method of assessing this process was 
labelling the target cells with a green fluorescent cell staining dye such as 
carboxyfluorescein succinimidyl ester (CFSE) and then co-culturing the target 
cells with unlabeled effector cells. After a period of incubation, the dead cells 
were labelled with a red fluorescent dye such as 7-AAD. Flow cytometry can be 
used to distinguish live (green signal only cells) from dead (dual green and red 
signal) target cells (Richardson et al, 2010). 
Carboxyflourescein diacetate succinimidyl ester (CFDA-SE) is non-fluorescent, 
is highly cell permeable due to its acetate groups and once within the cell 
cytoplasm, intercellular esterases remove its acetate groups and coverts the 
molecule to the fluorescent ester, CFSE (Quah & Parish, 2010). CFSE is 
retained within the cell by covalent coupling via its succinimidyl group to 
intracellular molecules, notably lysine residues and other amine sources. Due to 
the covalent coupling CSFE can be retained in the cell for prolonged periods 
with no dye transfer to adjacent cells (Quah & Parish, 2010).  7-AAD does not 
pass through intact cell membranes such as in live / viable cells. Apoptotic cells 
have compromised cell membranes and 7-AAD can readily enter apoptotic cells 
to bind to the DNA (Marin et al, 2003; Lotze & Thomson, 2005). Its fluorescence 
once excited is deep red; 440 nm excitation and 650nm emission spectrum 
therefore it can be utilised with the green fluorescence of CSFE; 494nm 
excitation and 519nm emission spectrum (Marin et al, 2003). 
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2.7.1. Target cell generation 
An aliqout of Granta 519 and K562 cells taken from T75 culture flasks was 
washed twice in warmed SFM. 10 x 106 G519 and K562 cells were labelled with 
6µM-9µM of CFDA-SE (Life Technologies, Paisley, UK) and incubated for 
15minutes in the dark at 370C/5% CO2. The reaction was stopped by adding 
equal volumes of CS-HI-FBS for 3 minutes after which the G519 and K562 cells 
were washed in PBS to remove unincorporated CFDA-SE and re-suspended in 
CCM.  
2.7.2. Effector cell generation 
Stored PBMCs from male and female age matched control subjects and MCL 
patients were removed from the liquid nitrogen dewars and thawed for 1-2 
minutes in a water bath (Grant JB2, Grant Instruments, Cambridge, UK)  at 
370C. They were suspended in warmed CCM and incubated at 370C / 5% CO2 
for a minimum of one hour. PBMCs were subsequently, washed twice in PBS, 
counted and re-suspended at 2.5 x 106 cells /ml in CCM before being placed 
into 24-well flat bottom plates (1ml/well). The PBMC cells in the wells were 
either vehicle control (referred to as control / untreated [DMSO 1ug/ml]) or 
treated with 40pg/ml oestrone, 100U/ml IL-2, 2µM lenalidomide and a 
combination of 40pg/ml estrone,100U/ml IL-2 and 2µM lenalidomide. The 
PBMCs were incubated at 370C / 5% CO2 for 24 hours. Additional PBMCs from 
control subjects were either untreated controls or treated with DMSO 1µg/ml 
(vehicle control), 100U IL-2/ml plus 40pg/ml oestrone and 100U IL-2/ml plus 
2µM lenalidomide. The concentration of DMSO used throughout the cytotoxicity 
assay was never more than 0.1%. Due to the limited numbers of PBMCs 
isolated, the vehicle control was used as the control and any effect of DMSO 
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being used as a carrier vehicle was evaluated by comparing ten untreated 
controls with 10 vehicle controls (DMSO1µg/ml).  
Following 24hours incubation non-adherent PBMCs were collected, washed in 
PBS and pelleted by centrifugation. They were re-suspended in CCM prior to 
counting. A minimum of 1.25 x 105 PBMCs cells were analysed for viability by 
flow cytometry using PI, after 24 hour incubation as described in the above 
section 2.5.1. 10,000 gated events were recorded and analysed. 
2.7.3. Treatment with drugs, hormones and cytokines  
Lenalidomide 
Lenalidomide was kindly provided by Celgene (San Diego, CA, USA). Primary 
stock solutions of Lenalidomide (20µM) were prepared by dissolving the 
compound in DMSO as per manufacturer instruction and stored at -20oC until 
use.    
Oestrone 
Oestrone was purchased from Sigma- Aldrich (Dorset, UK). Primary stock 
solutions of Oestrone were prepared by dissolving the compound in DMSO (as 
per manufacturer instruction (stock solution 20mg/ml)).  Further stock solutions 
were prepared by diluting the primary stock in CCM to make a working solution 
of 20ng/ml.  This is referred to as the working stock solution herein and stored 
at 40C.  
Interleukin-2 (IL-2)  
IL-2 was purchased from PeproTech EC.Ltd (London, UK). IL-2 was initially 
dissolved in 100mM acetic acid and then a working stock of 10,000U/ml in 
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RPMI with 0.1%BSA was made up and stored at 40C. All preparation was done 
using sterile techniques and solutions. 
Fresh working stocks were prepared every 4-6 weeks. 
2.7.4. Cell mediated cytotoxicity assay 
Following generation of target and effector cells, the target cells were re-
suspended at 5 x 104 cells/ml and plated into a 96 well flat bottom plate at 5x103 
cells per well.  The effector cells were re-suspended in CCM at 2.5 x 106 
cells/ml per treatment and plated into the 96 well flat bottom plate containing the 
target cells at ratios of 1:50, 1:25 and 1:12.5, target to effector cells. 
The treated PBMCs were re-suspended at 2.5 x 106/ml CCM with 40pg/ml of 
oestrone. Following four hour incubation at 370C / 5% C02, cell death was 
determined by staining target cells with 1μg/ml of 7-AAD (Invitrogen, Paisley, 
UK) and incubating for 10 minutes at 4oC. Analysis of the mean cell death 
represented by 7-AAD and CSFE positive cells was performed by flow 
cytometry. G519 and K562 cells were gated according to forward and side light 
scatter properties and 1,000 CFSE-labelled events were collected and analysed 
for each sample (Figure 14). All experiments were performed in triplicate.  
Results were presented as the mean with standard error mean. 
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Figure 14: Flow cytometry plots exhibiting acquisition of cell death data in the 
cell mediated cytotoxicity experiments 
A. Initial flow plot to illustrate the gating on all cells according to the FSC and SSC (P1) 
(effector and target cells). 
B. CSFE labelled target cells were gated in M1 as shown. 
C. Dead target cells with dual CFSE and 7-AAD staining were presented in quadrant 3 
–upper right (Q3-UR#). 
This graph is representative for all results acquired from the flow cytometry analysis 
during the cell mediated cytotoxicity experiments.  
 
2.8. Direct cytotoxicity of oestrone and lenalidomide on Granta 519 MCL 
cell line and K562 cells 
To determine the direct effects of oestrone and lenalidomide on MCL, pre-
treated Granta 519 cells were transferred from T75 flask and then washed with 
sterile PBS. The Granta 519 cells were counted by haematocytometer as 
described in section 2.1 and 2.5x106cells/ml were suspended in CCM. Cells 
were then placed in 24-well flat bottom plate and left either untreated (CCM 
alone, control), or treated with DMSO (vehicle control), oestrone (40pg/ml, 
80pg/ml or 400pg/ml), 2µM of lenalidomide and a combination of 40pg/ml 
oestrone with 2µM of lenalidomide. The treated Granta 519 cells were left for 24 
and 48 hours at 370C / 5% CO2 prior to analysis.   
After the relevant incubation time the treated G519 cells were placed in a 96-
well flat bottom plate (5 x 105 cells per well) and incubated with 10µg/ml of PI 
for 10 minutes at 40C prior to analysis by BD Accuri C6 flow cytometer and 
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CFlow software. The results were presented as a percentage of PI-negative 
(live / viable) cells. All treatment arms were tested in triplicates and the mean 
cell viability was determined (Results chapter 4, section. 4.3). 
K562 target cells were incubated with oestrone as described above and 
analysed for direct cytotoxic effect of oestrone. K562 target cells were incubated 
for 0, 24 and 48 hours with the same concentrations of oestrone as described in 
section 2.6, above with Granta 519 cells (Results chapter 4, section 4.3). 
2.8. Immunohistochemistry and Immunofluorescence for identification of 
immune cell subsets (NK, T and T regulatory cells) and Oestrogen 
Receptor α (ERα) and β (ERβ) 
 
Principle  
Immunohistochemistry (IHC) is a widely used technique that combines 
histological, immunological and biochemical techniques for the identification of 
specific tissue components by means of a specific antigen/antibody reaction 
tagged with a visible label. The fundamental concept of IHC is to demonstrate 
antigens (proteins and carbohydrates complexes within or on the surface of a 
cell that can bind to a specific antibody) within tissue sections by means of 
specific antibodies. There are two types of antibodies used in IHC, monoclonal 
and polyclonal. Polyclonal antibodies have binding affinity to multiple epitopes 
of target antigens which is prone to cross reaction with non-target antigens. 
Monoclonal antibodies tend to have an affinity to a single epitope thus 
producing a more specific and cleaner staining result. All antibodies used here 
were monoclonal antibodies. The tissue section is exposed to the primary 
antibody and once the antigen-antibody binding occurs a secondary antibody is 
introduced which binds onto the primary antibody enhances the staining 
intensity. To detect the cell or cells of interest following the antigen-antibody 
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binding of the primary and secondary antibodies, the secondary antibody has 
an enzyme, Horseradish Peroxidase (HRP) which allows for the chromogenic 
substance to attach and thus demonstrate a coloured histochemical reaction 
visible by light microscopy.  3,3'-diaminobenzidine (DAB) is used as a 
chromogen and it is oxidized in the presence of peroxidase and hydrogen 
peroxide resulting in the deposition of a brown, alcohol-insoluble precipitate at 
the site of enzymatic activity. This enables specific identification and 
visualization of cell or cells and tissue structures that are of interest which have 
unique antigens that can be targeted by specific antibodies.  
Immunofluorescence (IMF) using the same principles as does IHC. It differs by 
a fluorescently tagged secondary antibody which is visualized on a 
fluorescence microscope with a near monochromatic light which is filtered to a 
specific wavelength. The specimen is illuminated with the selected wavelength, 
which gets absorbed by the fluorochrome, causing it to emit light of a longer 
wavelength.  
Method 
All histological samples were from the Department of Haematology, Derriford 
Hospital, Plymouth, UK and the specimen slides were prepared in the 
Pathology Department, Derriford Hospital, Plymouth, UK. IHC and 
immunofluorescence work was performed at the University of Exeter Medical 
School, Institute of Biomedical and Clinical Science, Exeter, UK with kind 
permission and guidance from Prof. Noel Morgan and Dr. Sarah Richardson. 
Some IHC work was also performed with Mr. Phillip Edwards at the Pathology 
Department, Derriford Hospital, Plymouth. 
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All histological samples used here were formalin fixed and paraffin embedded 
(FFPE). Removal of wax was carried out by immersing sample slides in Histo-
clear (National Diagnostics, Hessle, UK) for two five minute immersions and 
subsequently rehydrated with varying concentrations of alcohol (100%, 90%, 
70% Methanol each for 1 minute). 
Formalin induces molecular modifications of proteins (antigens) which may 
result in the antibody losing its ability to bind to the antigen. Therefore, antigen 
retrieval was carried out by Heat-Induced epitope retrieval (HIER) method which 
utilises heating the specimen to >1000C causing a disruption to the crosslinks 
between formalin and antigen, thus allowing the retrieval of the antigen. 
Specimens are heated in various pH retrieval buffers (Citrate pH 6, EDTA pH6; 
table M4) which further aid in retrieving the antigen by facilitating the breakage 
of the crosslinks.  HIER was carried out by placing rehydrated slides into a 
pressure cooker with 1 litre of antigen retrieval buffer and heating in a 
microwave oven for 20 minutes on high power. It was allowed to cool for a 
further 20 minutes prior to adding the block. 
5% normal goat serum (Vector laboratories, Peterborough, UK) was used 
(incubated for 5 minutes) as a block to prevent non-specific binding of the 
antibodies. Primary antibodies were subsequently added onto the specimen 
slides. The primary antibodies used; for MCL cell identification were mouse anti-
human CD20 and rabbit anti-human cyclin D1, for NK cells identification were 
mouse anti-human CD56 and rabbit anti-human CD3, for T regulatory 
identification were mouse anti-human Foxp3 and rabbit anti- human CD3 and 
for ERβ identification was the mouse oestrogen receptor antibody. Further 
details of the antibodies used are described in table 10.0. Oestrogen receptor 
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beta antibody was incubated overnight in the dark at 40C. The remainder of the 
primary antibodies, were incubated for 1 hour in the dark.  
Specimens that were stained to identify NK cells (CD56+, CD3-), T regulatory 
cells (CD3+,Foxp3+), T cell (CD3+) and MCL cells (CD20+, Cyclin D1+) using the 
indirect immunofluorescence technique, are described below. 
ERα and ERβ identification was done using the indirect IHC technique. Slides 
were incubated with primary antibody at room temperature in the dark for 1 hour 
with oestrogen alpha antibody and overnight with oestrogen beta antibody 
(table 2.5). Following, incubation with the primary antibody, slides were washed 
three-times in Tris-buffered saline (TBS). They were then immersed for five 
minutes, in in Peroxidase Block is (DAKO Real peroxidase blocking solution 
S2023, Dako, Cambridge, UK). The Block was applied to reduce endogenous 
peroxidase on cells and tissues that can cause non-specific background 
staining when HRP conjugate antibody is used. Block was washed off by 
immersion of slides in TBS for five minutes. 
Secondary antibody (DakoREAL Envision / HRP, Rabbit/Mouse, DAKO, 
Cambridge, UK) was then applied and the slides are incubated for 30 minutes 
in the dark. Secondary antibodies were used to amplify the antigen detected 
thus allowing for better visualization and greater signal detection. After 
incubation secondary antibody was washed off by immersion into TBS three 
times. DAB was added by applying 0.5ml of DAB (Dako REAL DAB) substrate 
for 10 minutes followed by washing in distilled water.  
Haematoxylin stain (Dako, Cambridge, UK) was now applied to provide visual 
contrast so that the DAB positive cells are easier to visualize. Slides were 
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further washed in water, dipped in Scott’s Tap Water Substitute (STWS) 
(enhances the blue colour form haematoxylin) and immersed in 2%w/v copper 
sulphate to enhance the DAB staining. The slides were finally washed in 
distilled water for 5 minutes and then dehydrated in varying concentrations of 
alcohol (50%, 70%, 90%, 100% Methanol each for 1 minute).  
Slides were then taken and immersed in histo-Clear which pushes out the 
alcohol and a generous amount of DPX (neutral plastic resin dissolved in 
xylene) is applied prior to carefully laying on the coverslip. The slides were 
allowed to dry overnight in a fume cupboard before visualization on the Nikon 
Eclipse 50i microscope. Images were taken on Nikon digital sight camera with 
the microscope. 
Indirect immunofluorescence method was used to stain for T, NK and T 
regulator cells as mentioned above. After incubation with the respective primary 
antibodies, the slides were washed three times, five minutes each in TBS and 
incubated for 1 hour with secondary antibodies (Table 11). After incubation the 
secondary antibody was washed off with TBS and Dako fluorescent mounting 
media S3023 (Dako, Cambridge, UK) was applied over the specimen. A cover 
slip was gently lowered onto the slide and the mounted slides were kept in the 
dark over night to dry before visualization on the Leica AF hardware version 
2013.1.1 (Leica microscope systems CMS, Germany). 
To quantitate the number of NK cells, T cells and T regulatory cells, 13 random 
images at x200 magnification were taken per slide and positive cells were 
counted. Results were shown as total numbers and mean in the results chapter 
5. 
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Function Primary Antibody all 
monoclonal anti-human 
Clone  Primary dilution in 
antibody diluent 
Antibody Diluent HIER – retrieval buffer 
 MCL cell identification 
CD20
+
, CyclinD1
+
 
Mouse CD20 L26 DAKO, Cambridge, UK 1:1000 DAKO S2022 Citrate pH 6 
Rabbit CyclinD1 SP4 Abcam, Cambridge, Uk 1:100 DAKO S2022 Citrate pH 6 
T cell identified 
CD3
+
 
Rabbit CD3 SP7 Abcam, Cambridge, UK 1:100 DAKO S2022 EDTA pH 8 
 NK cell identification 
 
CD56
+
, CD3
-
 
Mouse CD56 NCL-L 
CD56 
Novocastra Lieca microsystem, 
Milton Keynes, UK 
1:50 DAKO S2022 EDTA pH 8 
Rabbit CD3 SP7 Abcam, Cambridge, UK 1:100 DAKO S2022 EDTA pH 8 
T regulatory cell 
identification 
CD3
+
, FoxP3
+
 
Mouse FoxP3 236A/E7 Abcam, cambridge, UK 1:100 DAKO S2022 EDTA pH 8 
Rabbit CD3 SP7 Abcam, Cambridge, UK 1:100 DAKO S2022 EDTA pH 8 
Oestrogen Beta 
receptor identification 
Mouse oestrogen Beta 14C8 Abcam, Cambridge, UK 1:200 DAKO S2022 Citrate pH 6 
Oestrogen Alpha 
Receptor identification 
Rabbit oestrogen Alpha EP1 DAKO, Cambridge, UK 1:200:  
Secondary antibodies 
Immunoflourescence Alexa Fluor® 488 Goat Anti-Mouse IgG (H+L) Life Technologies, Paisley, UK 
Immunoflourescence Alexa Fluor® 546 Goat Anti-Rabbit IgG (H+L) Life Technologies, Paisley, UK 
Immunoflourescence 
Nuclear staining 
DAPI (4′,6-diamidino-2-phenylindole) Life Technologies, Paisley, UK 
For oestrogen IHC receptor antibodies DAKO REAL Envision HRP, anti-mouse/ anti - rabbit DAKO, Cambridge, UK 
 Table 11: Primary and secondary antibodies used in Immunohistochemistry and Immunofluorescence
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2.9 NK cells Isolation  
Principle  
Negative selection of NK cells was undertaken, resulting in untouched NK cells 
in the final solution. Non-target cells consisting of T cells, B cells, dendritic cells, 
monocytes, granulocytes and erythroid cells are indirectly magnetically labelled 
with a cocktail of biotin-conjugated antibodies against lineage specific antigens 
and a cocktail of MicroBeads. Isolation of the untouched NK cells is achieved by 
passing the solution through a column in a magnetic field thus depleting the 
magnetically labelled cells (non-NK cells) form the solution which passes 
through the column. 
Method 
Buffer solution was prepared by adding 0.5% CS-HI-FBS with 2mM EDTA to 
sterile PBS. After isolation of PBMCs, the total cell number was determined. 
PBMC cells were resuspended in 40µl of buffer per 107 total cells, followed by 
the addition of 10µl of NK cell Biotin-Antibody Cocktail per 107 total cells and 
incubated for 5 minutes at 40C. After incubation, 30µl of buffer per 107 total cells 
was added with 20µl of NK cell MicroBead Cocktail per 107 total cells. This was 
further incubated at 40C for ten minutes after which the volume was adjusted to 
a minimum of 500µl of buffer. Magnetic separation was done with miniMACSTM 
separator and MACS column (Miltenyi Biotec, Surrey, UK). The columns were 
primed with buffer in the magnetic field of the MACS separator and cells were 
applied gently to the top of the column. The effluent consisting of negatively 
selected NK cells were collected in a 5ml FACS tube. The cells were 
resuspended in CCM and counted. 
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2.9.1. NK cell mediated cytotoxicity  
Target Cells 
K562 cells were used here as they have been widely accepted as lacking in 
MHC-1 antigen making them sensitive to NK mediated cell death. Target cells 
were generated using the same technique described in section 2.7. 
Effector cells and cytotoxicity assay 
Isolated NK cells were counted and were planned to be incubated with target 
cells at a ratio of 1:25, target to effector cell, or lower ratios, depending on the 
final number of NK cells isolated.  Once the target and effector cells were plated 
in a 96 flat bottom well plate, they were incubated for 4 hours prior to analysis 
by flow cytometry using the same method as in section 2.7.  
Of note in reference to section 2.6.7, viability of NK cells after this isolation 
technique was poor <50%, and in addition the number of NK cells were 
insufficient to conduct any further viable cytotoxicity experiments. Due to the  
limited patient material the NK isolation and cytotoxicity assay was not 
performed. 
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Chapter 3 
  
Results 
 
 
 
Enumeration and characterisation of immune cell subsets; NK cells, T 
cells, T regulatory cells and NK activating receptors on NK cells in the 
peripheral blood of untreated male and female MCL patients 
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3.1. Background 
The gender differences in the incidence of cancer is well documented, with the 
overall incidence of all cancers in males being 1.4 times higher than in females 
(Cook et al, 2011). The incidence of MCL in males is up to three times higher 
than in females (McKay et al, 2012; Chandran et al, 2012). There are a number 
of factors, such as the influence of hormones, environment and genetics, that 
have been implicated to influence this difference (Pennell et al, 2012; Libert et 
al, 2010; Dorak & Karpuzoglu, 2012). One of these factors is the difference 
between the innate and adaptive immune systems of males and females (Dorak 
& Karpuzoglu, 2012; Oertelt-Prigione, 2012; Fairweather et al, 2008; Chang et 
al, 2014). Females mount a better immune response than males (Klein, 2000; 
Hewagama et al, 2009; Pal & Hurria, 2010) and survive sepsis at higher rates 
(Dorak & Karpuzoglu, 2012). The difference between the cancer incidence and 
infection rates in male and females may be accounted in part by the immune 
system and its role in infection / pathogen surveillance and elimination. This 
mechanism is similar to cancer immunosurveillance by the immune cells 
(Gajewski et al, 2013; Swann & Smyth, 2007).  
Cancer immunosurveillance is a process by which the immune system identifies 
cancerous and / or precancerous cells and eliminates them before they can 
cause any harm (Swann & Smyth, 2007). This forms a part of the 
immunoediting concept which provides a more complete explanation of the 
mechanism by which the immune system acts on tumours (Swann & Smyth, 
2007).  The concept of immunoediting is divided into three phases; elimination, 
equilibrium and escape as described in further details in chapter 1 section 1.1.7.  
The NK cells have been implicated in the process of immunosurveillance (Imai 
et al, 2000; Vitale et al, 2014) and one of the mechanisms by which NK cells 
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eliminate tumour or unhealthy cells is through the activation of  NK activating 
receptors (Koch et al, 2013). A group of NK activating receptors, NCRs, NKp46, 
NKp30 and NKp44 have been described to deliver potent signals through 
ITAMS to stimulate the NK cells directly to lyse cancerous cells (Hudspeth et al, 
2013) . This occurs after engagement with their ligands on tumour cells without 
the need for prior antigen activation thus allowing for rapid clearance of the 
cancerous cells (Hudspeth et al, 2013). Additionally, the activating receptor 
NKG2D on the surface NK cells, has also been described to be crucial for 
immunosurveillance of epithelial and lymphoid malignancies (Iannello & Raulet, 
2013; Vivier et al, 2012b) by inducing direct cytotoxic activity of NK cells. 
NKG2D activation by its ligands; the MHC class I chain related protein A (MICA) 
and B (MICB) family and the UL16- binding proteins (ULBPs) family (López-
Soto et al, 2014),  results in the phosphorylation of the signal adaptor protein 
DNAX-activating protein and recruitment of phosphatidylinositol-3-kinase 
(PI3K). Activated PI3K in turn activates mitogen activated protein kinase (MEK) 
for stimulation of extracellular signal-regulated kinase (ERK). This ultimately 
leads to actin polymerisation and the granules (perforin and granzymes) 
become polarised towards the target. Exocytosis occurs, which results in target 
cell apoptosis. Thus activation of this pathway enables NK cells to secrete 
cytokines (IFN-γ) and induces exocytosis of cytotoxic granules to facilitate killing 
of the target cells (López-Soto et al, 2014; Nandagopal et al, 2014; Anel et al, 
2012) (for further details on immunosurveillance and immunoediting please 
refer to chapter 1 section 1.1.7). 
The concept of immunosurveillance has been supported by the increased 
incidence of cancer in conditions where the immune system is suppressed 
(Yanik et al, 2013). Individuals with primary or acquired immunodeficiency, for 
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example, as in post-organ transplantation patients who are immunosuppressed 
by drugs, have been observed to have an increased incidence of secondary 
cancers such as lymphoma (Ponce et al, 2014). The risk of B cell lymphoma is 
the highest in the first year post transplantation. This has been attributed to the 
greater immunosuppression during this period, which causes either reduced 
numbers of immune cells and activating receptors or reduced function of the 
immune cells during this period to reduce graft rejection (Opelz & Döhler, 2004).  
Furthermore, studies in various subtypes of lymphoma have shown circulating 
numbers of T cells or NK cells to be lower and in turn act as surrogates for 
prognosis depending on the enumeration at diagnosis.  A study in follicular 
lymphoma has demonstrated a lower number of absolute NK cells (<150/µl) 
correlating to an inferior outcome, p=0.02 (Shafer et al, 2013).  Another study 
has demonstrated a lower absolute lymphocyte count (ALC) results in a poor 
outcome (ALC ≥ 1.0 x 109/L versus ALC ≤ 1.09/L, overall survival of 175 months 
vs 73 months, respectively, p<0.04) in patients with follicular lymphoma 
(Siddiqui et al, 2006). Variations in the immune cell subset counts have been 
demonstrated to influence the outcome in other subtypes of lymphomas like 
Diffuse Large B-cell Lymphoma (DLBCL) and lymphoproliferative disorders like 
chronic lymphocytic lymphoma (Palmer et al, 2008; Mittal et al, 2008). It has 
also been demonstrated that females exhibit a better response to lenalidomide, 
an immunomodulatory drug, which provides further support of the immune 
system’s role in immunosurveillance  (Eve et al, 2012). In other haematological 
malignancies such as chronic myeloid leukaemia, low number of NK activating 
receptors such as the NKG2D have also been reported (Boissel et al, 2006). 
There is a lack of data with regards to inhibitory NK receptors an MCL and 
further studies are needed.  
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To date, there has been no published data showing the difference in the 
immune cell subsets between males and females with MCL. On the basis of the 
above data and discussion, it was undertaken to enumerate the circulating 
immune cells (T cells, NK cells and T regulatory cells) and measure the NK 
activating receptor (NKp46, NKp30, NKp44 and NKG2D) expression on NK 
cells.  
The hypothesis proposed was that women with MCL have a higher number of 
circulating immune cells and higher expression of NK activating receptors on 
NK cells. 
The aims of this chapter were; 
1) To determine if there is a difference in the number of circulating NK cells, 
T cells and T regulatory cells in the peripheral blood between untreated 
male and female patients with MCL. 
2) To determine if there is a difference in the NK activating receptors 
(NKp46, NKp44, NKp30 and NKG2D) on NK cells in the peripheral blood 
of male and female with MCL. 
 
Enumeration of NK cells, T cells, T regulatory cells and the expression of NK 
activating receptors was performed by flow cytometry on BD FACSCanto flow 
cytometer and analysis performed using the BD FACSDiva software. For further 
details of the materials and methods please refer to chapter 2 section 2.2. 
3.2. Statistical testing 
The results are presented as the mean of each group (male and female patients 
and controls) and +/- standard error of the means (SEM). Statistical analysis 
was performed using Kruskal–Wallis test for non-parametric data when 
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comparing more than two groups a post-hoc Dunn’s multiple comparison test 
was applied to identify a significant difference between any of the 4 groups. The 
non-parametric Mann-Whitney U test was used to compare two groups, that is, 
between male and female patients. Statistically significant results were taken as 
a p value of less than 0.05. Confidence interval was at 95%. Statistical analysis 
was performed using GraphPad Prism Version 6.0 (GraphPad Software, San 
Diego, USA). 
3.3. Enumeration and characterisation of immune subsets; T / NK / T 
regulatory cells in the peripheral blood 
 
Enumeration of immune cell subsets was performed on peripheral venous blood 
from the participants. All patient samples were taken prior to the individual 
having had any form of therapy for MCL. 
3.3.1. Enumeration of total NK cell and NK cell subset numbers 
 
The total number of NK cells and NK subset cells were assessed in males and 
females from control and untreated MCL groups. The NK cell subsets included 
in the analysis were; CD3-CD56
bright
CD16
dim
 (involved with cytokine release in 
their cytolytic response) and CD3-CD56dimCD16bright (involved with direct 
cytotoxic response). 
There was no significant difference observed in the quantification of the total 
number of NK cells in the peripheral blood from male and female patients and 
healthy control (figure 17.0). However, there was a trend towards greater 
number of NK cells in male MCL patients compared to female MCL patients 
(figure 17.0). In addition, in only one male MCL patient out of 6 and one female 
MCL patient out of 6, the NK cell quantification was below the normal reference 
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range adopted by Derriford Hospital Combined Laboratories; NK cells 67-1134 
cell/µl. 
Further analysis of the subsets of NK cells did not exhibit a significant difference 
in the mean number of NK CD56dim CD16bright cells and NK CD56bright CD16dim 
cells between male and female patients nor was there any significant difference 
between healthy controls and MCL patients cells (Figure 15)(P=0.713 and 
P=0.588, CD56brightCD16dim and CD56dimCD16bright, respectively).  
However, there was a trend towards the NK CD56dim CD16bright cells in the male 
MCL patients demonstrating a higher mean count (34% higher) than mean of 
the female MCL patients (Figure 15 B).  
Conversely, the mean number of the NK CD56bright CD16dim cells was greater in 
the female patient group, but on examining the individual female results it was 
noted that one of the female patient subjects had an unexpectedly high number 
of these cells (Figure 15 C). 
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Figure 15: NK cells and NK cell subsets numbers in peripheral blood of healthy 
controls and MCL patients 
Panel A: total number of NK cells determined in the peripheral blood of MCL patients 
and healthy control subjects, no significant difference was observed between the male 
and female MCL patients (p=0.91). There was a trend toward higher number in the 
patient group compared to the healthy controls. 
Panel B: number of CD56dim and CD16bright positive NK subset cells, no significant 
difference was observed between the genders p=0.86, however there was trend 
towards male MCL patients exhibiting greater number of these cells compared to the 
females MCL patients, p=0.50.  
Panel C: number of CD56 bright and CD16dim positive NK cells.  No statistical difference 
was observed between the female and males in either group p=0.08, however one 
female patient exhibited an unexpectedly high number of these cells which account for 
this result.  
n= 5 healthy male controls, n=6 male MCL patients, n= 6 healthy female controls, n=5 
MCL females MCL patients. 
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Interestingly, there was a trend toward patients with clinically indolent MCL 
exhibiting higher number of NK cells compared to the clinically aggressive 
patients. Therefore, further analysis of the NK cell numbers in respect to 
clinically indolent and aggressive MCL patients was evaluated. Patients with 
clinically indolent MCL were defined as asymptomatic and not requiring 
treatment for up to a minimum of 1 year. Clinically aggressive patients were 
symptomatic and requiring immediate therapy. Patients with clinically indolent 
MCL exhibited a higher mean number of NK cells compared to the patients with 
clinically aggressive MCL (Table 12). Not all patients could be included as some 
did not meet the criteria that defined clinically indolent MCL or clinically 
aggressive. 
MCL patient 
gender 
Clinically Indolent Clinically 
aggressive 
MCL patient gender 
 Total NK cells (cells/µl) Total NK cells 
(cells/µl) 
 
Male 344 101 Male 
Male 412 94 Male 
Female 114 98 Female 
  176 Female 
MEAN   290 (+/- 90.2) 117 (+/- 19.6)  
Table 12: Indolent versus aggressive MCL in relation to NK cells 
Indolent MCL patients in general tended to exhibit higher number of NK cells in the 
peripheral blood compared to patients with clinically aggressive MCL, p=0.11. A direct 
comparison between male and female MCL patients in either the clinically indolent or 
aggressive group could not be assessed due to the limited number of subjects. 
 
Subsequently NK CD3-CD56dim CD16bright subset numbers were evaluated in 
patients with clinically indolent MCL and aggressive MCL. The results exhibited 
greater number of NK CD3-CD56dim CD16bright cells in the indolent patients 
compared to the clinically aggressive patients (p=0.06) (Table 13). The 
difference between males and females with clinically indolent and aggressive 
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MCL was not feasible to evaluate, due to the small numbers and unequal 
distribution of the clinical characteristics between the genders.  
MCL patient 
gender 
Clinically Indolent MCL patient 
gender 
Clinically aggressive 
 NK subset:  CD56dim 
CD16bright (cells/µl) 
 NK subset:  CD56dim 
CD16bright (cells/µl) 
Male 254 Male  37 
Male 213 Male 45 
Female 148 Female 84 
  Female 68 
MEAN 205 (+/- 10.7)  59 (+/- 30.9) 
Table 13: Clinically indolent versus aggressive MCL patients in relation to 
CD3+CD56dimCD16bright NK cell subset 
Enumeration of the CD3+CD56dimCD16bright NK cell subsets in relation to the clinical 
presentation of MCL in patients. The data presented here is groups according to the 
clinical presentation; aggressive vs indolent MCL. Direct comparison between male 
and female MCL patients in each clinical group could not be analysed due to the limited 
number of subjects. 
 
3.3.2. Enumeration of T cells; T cells CD3+, CD3+ CD4+ (T-helper cells) and 
CD3
+
 CD8
+
 (cytotoxic T cells) between male and female patients with MCL 
and age matched healthy controls. 
 
The enumeration of T helper and cytotoxic T cells was performed due to their 
central role in cancer immunosurveillance and to determine if there was any 
gender bias in the untreated MCL patients (Kallies, 2014; Swann & Smyth, 
2007; Gajewski et al, 2013).   
There was no significant difference found in the mean numbers of the total T 
helper or cytotoxic T cells between male and female MCL patients (Figure 16) 
and additionally, no statistical difference was observed when all 4 groups were 
compared (P>0.5).  
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The male patients exhibited a trend towards greater number of both the T 
helper and cytotoxic T cells in the peripheral circulation compared to the male 
controls and female patients. Therefore, all the T cells (CD3+) were enumerated 
in all the groups to determine if there was a gender bias. The male patient 
group exhibited significantly greater number of T cells in the peripheral blood 
compared to both the male control group and the female patient group (Figure 
16).   
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Figure 16: Enumeration of T cells (CD3+), T helper cells (CD3+CD4+) and Cytotoxic 
T cells (CD3+CD8+) 
T cell and T cell subset numbers in peripheral blood of age matched healthy controls 
and MCL patients 
Panel A: total number of T helper cells (CD3+CD4+) in MCL patients and age matched 
healthy control subjects, no statistical difference was observed between the genders in 
either MCL patients or healthy controls patients (P=0.240). There was a trend towards 
male MCL patients (1229 cells/µl) exhibiting greater number of T helper cells compared 
to the female MCL patients (738 cells/µl). 
Panel B: Number of Cytotoxic T cells (CD3+CD8+) in MCL patients and age matched 
healthy controls, no significant difference was observed between the genders of either 
MCL patients or healthy control (P=0.082) , however as with T helper cells the male 
MCL patients (789 cell/µl) exhibited a greater number of cytotoxic T cells compared to 
the female MCL patients (375 cell/µl). 
Panel C: Total number of T cells CD3+, male patients demonstrate a significantly 
greater number of circulating T cells compared to age matched male controls, *p=0.006 
and female patients, **p=0.03.   
n= 5 healthy male controls, n=6 male MCL patients, n= 6 healthy female controls, n=5 
MCL females MCL patients. 
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As with the NK cells additional evaluation was performed on the T cells (CD3+) 
numbers in clinically aggressive male (n=3) and female MCL (n=3) patients to 
determine whether the clinical characteristics of MCL would influence the 
immune cell numbers. There was no significant difference between the genders 
(p=0.10) (Table 14). However, there was a trend towards the male MCL 
patients exhibiting greater number of T cells in the peripheral circulation 
compared to the female MCL in this cohort of subjects which are age matched 
and all have stage IV disease. The number of T cells in clinically indolent MCL 
had similar results as those of clinically aggressive MCL however direct 
comparison was not feasible due to limited numbers (n=2 males and n=1 
females). This could perhaps be reflective to the difference seen in the tumour 
microenvironment between the male and female MCL patients. It is possible 
that female patients could exhibit higher number of T cells within the tumour 
microenvironment thus resulting in fewer T cells in the peripheral blood as the T 
cells egress towards the affected nodes. It is not possible to comment on the 
activation of the T cells between the genders with these results as they primarily 
reflect the numbers of T cells in the peripheral circulation. 
 
T cells (CD3+) (cells/µl) 
 
Male clinically aggressive MCL Female clinically aggressive MCL 
1473 1456 
2224 1355 
2537 1268 
Mean                  2078 (+/- 316)                                          1360 (+/- 54.3) 
Table 14: T cells numbers in the peripheral blood of 3 male and 3 female MCL 
age matched 
(median age for the MCL patients; males 70 years and females 68 years) patients 
presenting with clinically aggressive MCL. All the subjects in both male and female 
MCL groups presented here has stage IV disease (p=0.10).  
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3.3.3. Enumeration of T regulatory cells; CD4+CD25+CD127dim in male and 
female patients and age matched healthy controls 
Enumeration of T regulatory cells was performed due to their vital role in cancer 
immunosurveillance as discussed above. T regulatory cells are primarily 
function to suppress the immune response. They are involved in the 
suppression of T cells which in turn indirectly inhibits the T cells (T helper cells) 
activity against cancerous cells as described in chapter 1 section 1.1.4. 
No significant difference was found in the mean numbers of T regulatory cells 
between male and female patients or when all 4 groups were compared 
(p=0.476)(Figure 17). 
In both the male and female MCL patient groups there was a trend exhibiting 
greater number of T regulatory cells when compared to their respective controls 
groups (Figure 17).  
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Figure 17: Enumeration of T regulatory cell (CD4+CD25+CD127dim) in peripheral 
blood of all 4 groups. Age matched subjects; n=5 healthy males, n=6 MCL males, n= 
6 healthy females, n=5 MCL females measured by FACS analysis (p=0.59).  
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Additional analysis was performed to determine if there was a gender difference 
in relation to the numbers of T regulatory cells between clinically indolent and 
aggressive MCL patients.  There was no significant difference between the 
male and female MCL patients when comparing the clinically aggressive MCL. 
However there was overall trend toward higher numbers of T regs in female 
MCL patients (Table 15). Due to the limited number of clinically indolent MCL 
patients direct comparison was not possible. 
One female patients had a lower T regulatory cell count compared to the rest of 
the female MCL subjects shown here (Table 15). This difference was could not 
fully be accounted for by the clinical features of the patient as this was 
consistent with the rest of the group. It is thought to reflect individual variation in 
T regulatory cell numbers. It is not possible to conclude further on this ‘outlier’ 
result with the one female aggressive MCL, however greater number of subjects 
would be warranted to fully describe this result. 
 
T regulatory cells (cells/µl) 
 
Male clinically aggressive MCL 
patients 
Female clinically aggressive MCL 
patients 
54 143 
99 48 
64 102 
Mean 
72 (+/- 10.7) 97 (+/- 27.5) 
Table 15: Quantification of T regulatory cells in the peripheral blood of clinically 
aggressive MCL male and female MCL patients 
All subjects had stage IV disease at diagnosis. Both male and female MCL subjects 
presented here were age matched (median age 70 years male MCL and 68 years 
female MCL patients) (p=0.40).  
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The results demonstrating the enumeration of the T regulatory cells in the 
peripheral blood of  age matched male and female MCL patients exhibit no 
significant difference between the genders. However there is a trend towards 
female MCL patients in this cohort exhibiting a greater number of T regulatory 
cells. When compared to age matched controls the patient groups exhibit a 
trend towards greater number of T regulatory cells in the peripheral circulation, 
however this did not achieve statistical significance. 
3.4. Examining the expression of the NK cell activating receptors; NKp46, 
NKp30, NKp44 and NKG2D in male and female patients and age matched 
controls 
 
NK activating receptors; NKp46, NKp30, NKp44 or NKG2D on the two subsets 
CD3-CD56bright and CD3-CD56dim where examined to determine whether there 
was any evidence of gender difference. NK activating receptors have an 
important role in NK-mediated elimination of cancerous cells (Koch et al, 2013; 
López-Soto et al, 2014).  
3.4.1. Evaluating the expression of the NK activating receptor; NKp46, 
NKp30, NKp44 and NKG2D on CD3-CD56bright NK cells  
 
The CD3-CD56bright NK cells (cytokine subset of NK cells) exhibited high levels 
of NKp46, NKp30 and NKG2D and a moderate level of NKp44 activating 
receptor in both the control and patient groups when compared to the isotype 
controls for each activating receptor (Figure 18). 
None of the NK activating receptors; NKp46 (p=0.75), NKp30 (p=0.69), NKp44 
(p=0.34) or NKG2D (p=0.50) on the CD3-CD56bright NK cells exhibited a 
statistically significant difference between the males and females in the control 
and patient groups. Furthermore, there was no significant difference between 
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the male control group and the male patient group or the female control group 
and the female patient group (p=0.50) (Figure 18).  
Although there were small variations amongst the groups of the expression of 
the NK activating receptors, there were no notable trends in the groups. 
Therefore, in conclusion there was no significant difference in the expression on 
the NK activating receptors between the male and female MCL patients on the 
CD3-CD56bright NK cells (cytokine subset of NK cells). 
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Figure 18: Expression of NK cell activation receptors on NK cytokine subset CD3
-
CD56
bright 
cells in the peripheral blood of 5 
male and 6 female age matched healthy controls and 6 male and female MCL patients (p >0.05, Kruskal-Wallis). All NK activating 
receptors had greater expression than isotype controls.  1. NKp46 expression ; 2. NKp30 expression; 3. NKp44 expression;  4. NKG2D expression on 
NK cytokine subset CD3
-
CD56
bright 
cells.   
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3.4.2. Comparison of the expression of NK activating receptors on NK 
cells; CD3-CD56dim between male and female MCL patients and controls 
 
3.4.2.1 Evaluating expression of NK activating receptor NKp46, 
NKp30, Nkp44 and NKG2D on CD3-CD56dim NK cells 
 
The CD3-CD56dim NK cells (cytotoxic NK cells) exhibited high levels of NKp46, 
NKp30 and NKG2D and a moderate level of NKp44 activating receptor in both 
the control and patient groups when compared to the isotype controls for each 
of activating receptor. There were no significance difference in the expression of 
all the four NK activating receptors when compared between all the groups 
(NKp46 p=0.68; NKp30 p=0.40; NKp44 p=0.66; NKG2D p=0.34; Kruskal-Wallis 
test)(figure 21.0) and specifically there was no significant difference exhibited 
between male and female MCL patients (Figure 19). However, there was a 
trend towards a greater expression of NK activating receptor NKG2D in the 
male and female controls when compared to the respective patient groups 
(Figure 19). 
In conclusion there was no significant difference between the male and female 
MCL patients with respect to the activating receptors on the cytotoxic NK cells 
CD3-CD56dim.  
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Figure 19: Expression of NK cell activation receptors on cytotoxic NK cells CD3-CD56dim cells in the peripheral blood of 5 
male and 6 female healthy age matched controls; and 6 male and female MCL patients(p>0.05, Kruskal-Wallis). Expression 
of the NK activating receptors were analysed by flow cytometry. All receptors had greater expression than isotype controls.  1. 
NKp46 activating receptor; 2. NKp30 activating receptor; 3. NKp44 activating receptor; 4. NKG2D activating receptor expression on cytotoxic 
NK cells. 
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3.5.2. T cells CD3+, CD3+CD4+ (T- helper cells) and CD3+C8+ (Cytotoxic T 
cells) 
There was a significant increase in the number of circulating T cells (CD3+) in 
male MCL patients when compared to female MCL patients, p=0.04. 
There was no significant difference exhibited when comparing the male and 
females MCL patients with regards to the T cell subsets; T helper and cytotoxic 
cells. However, in both these subsets, there was a trend towards greater 
numbers in male MCL patients compared to the female MCL patients. 
3.5.3. T regulatory cells 
The T regulatory cells did not exhibit a significance difference between male 
and female MCL patients or healthy controls. 
However there was a trend toward female MCL patients exhibiting greater 
number of T regulatory cells compared to the male MCL patients. It is important 
to note that the enumeration of the T regulatory cells is in the peripheral blood. 
Therefore, as T regulatory cells have been implicated in regulation and 
suppression of the T cells (Josefowicz et al, 2012), it is probable that the 
number of T regulatory cell in the tumour microenvironment of female MCL 
patients could be significantly lower than compared to the male MCL patients, 
thus enabling females to mount a greater immune response to the MCL cells. 
3.5.4. Expression of NK activating receptors on NK cell subset CD3-
CD56brightCD16dim 
There was no significant difference observed between the expression of the NK 
activating receptors between the male MCL patients and female MCL patients. 
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3.5.5. Expression of NK activating receptors on NK cell subset: CD3-
CD56dimCD16bright 
There was no significant difference between the expression of the NK activating 
receptors between the male MCL patients and female MCL patients. 
There was a trend exhibiting greater expression of the NKG2D receptor on 
control groups compared to the patient groups. 
As previously described in chapter 1, NCRs receptors (NKp30, NKp44 and 
NKp46) belong to the immunoglobulin superfamily. These receptors comprise of 
an extracellular ligand-binding domain, transmembrane domain and a short 
cytosolic domain. They involve the ITAM-dependent signalling molecules to 
activate several intercellular pathways and in addition it has been described that 
they can activate each other through phosphorylation of the adapter molecules 
thus increasing their efficiency (Koch et al, 2013). Individually they are activated 
by ligands which attach onto the extracellular domains. NKp30 receptor has 
been shown to be activated by the tumour antigen B7-H6 which are tumour 
specific as this ligand is not found on healthy cells (Brandt et al, 2009; Koch et 
al, 2013). Interestingly the expression of NKp44 is increased only after 
activation and also correlates to the efficiency of the NK cell activity and killing 
(Fauriat et al, 2007). However the activating ligand for NKp44 is yet to be 
described as with the NKp46 receptor’s ligand which again remains unknown. 
Nonetheless the activating NCRs can crosstalk between each other and is 
thought to enhance their efficiency to stimulate the NK cells to either release 
cytokines or activate cytotoxicity (Augugliaro et al, 2003; Koch et al, 2013). 
These NCRs are found on both subsets of NK cells and although they can 
potentially be stimulated individually they also complement each other for 
activation. It has been described that lower expression of NCRs lead to reduced 
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activity (Fauriat et al, 2007) and the results do not show any significant 
difference between the expression of the NCRs between the genders 
suggesting that these activating receptors may not play a significant role in the 
immune response mounted by either the male or female MCL patients.   
 NKG2D is a c- type lectin like receptor and it is not able to respond if stimulated 
alone but needs another ‘co-activation’ signal from other activating receptors 
such as NKp46. It has two MICA and MICB ligands that activate the receptor. It 
is interesting that the expression of NKG2D has a higher trend in the control 
group compared to the MCL patient. This could relate to lower activation of the 
NK cells in MCL patients possibly due to inhibitory ligands expressed by MCL 
cells. There is no difference between the genders which may negate the role of 
the NK cells in between the genders in terms of the activating receptors 
investigated here. 
3.6.0 Discussion  
Despite the results showing very few statistically significant differences between 
the male and female immune cell subsets and NK activating receptors, some 
interesting trends emerged that are further discussed below: 
3.6.1. NK cells and NK cell subsets 
NK cells, cytokine NK cells CD3-CD56bright CD16dim and cytotoxic NK cells 
CD3-CD56dim CD16bright 
In summary, the quantification of NK cells and the subsets demonstrated no 
significant difference between male and female MCL patients. There was a 
trend towards greater mean number of total NK cells in MCL patients compared 
to healthy controls. In addition there was a trend towards greater number of NK 
cells as a whole in male MCL patients compared to the female MCL patients. 
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To date there is no published data that has examined whether there is a 
difference in NK cell numbers between male and female patients with MCL or B 
cell lymphoproliferative disorders. 
The trend exhibited by the total number of NK cells described above may be 
explained by the differing distribution of clinically indolent MCL in male and 
female patients. In this cohort of patients there were 50% of male patients and 
15% of the female patients with clinically indolent MCL patients (table 6.0, 
chapter 2). Patients with a clinically indolent subtype of MCL (asymptomatic and 
not requiring therapy for > 1 year) tend to present a more favourable outcome 
compared to the more aggressive subtype (symptomatic and needing therapy 
immediately) (Hsi & Martin, 2014; Shah & Rule, 2014). The results also showed 
that clinically indolent patients exhibited a higher mean of NK cells (290 cells/µl 
+/- 90.2) compared to patients with clinically aggressive MCL (117 cells/µl +/- 
19.6)(table 11.0). Patients with clinically indolent MCL have better OS 
compared to clinically aggressive MCL as discussed in chapter 1 (Hsi & Martin, 
2014). The NK cell numbers observed between clinically indolent and 
aggressive disease correlate in part to other studies which demonstrated an 
association between patients exhibiting a greater number of NK cells and 
improved overall survival (Palmer et al, 2008; Shafer et al, 2013; Siddiqui et al, 
2006; Sanchez et al, 2011). Another study reported by Shafer, et al, 
demonstrated a low number of peripheral NK cells was associated with an 
inferior outcome in patients with follicular lymphoma (5% versus 2% had died 
p=0.02, low NK numbers versus high NK numbers respectively) (Shafer et al, 
2013). This has also been demonstrated in patients with high grade diffuse 
large B cell lymphoma with low NK cells numbers in peripheral circulation 
resulted in an inferior survival (p=0.02) (Plonquet et al, 2007).  
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In addition there was a trend towards greater mean number of NK cells in the 
peripheral circulation of MCL patients compared to the healthy controls. This 
possibly reflects the response of the immune system against the cancerous 
cells. The trend observed here correlates to a study which demonstrated higher 
number of circulating NK cells in CLL patient compared to controls (p<0.05) 
(Costello et al, 2012). They accounted for the increase in absolute NK cell 
numbers to greater numbers of CD3-CD56dim NK cells subset which are 
involved in direct cytotoxicity, suggesting the increase in NK cells was due to 
the immune system’s response to eliminate CLL cells (Costello et al, 2012). 
Majority of the subjects (91%) described in the study by Costello et al, exhibited 
Binet stage A disease (low stage, indolent) disease, the results here with 
clinically indolent MCL patients (table 12.0) also correlate to their findings 
(Costello et al, 2012) suggesting that a similar mechanism may exist with NK 
cells and MCL. 
NK Cell subsets:  Cytokine NK cells CD3-CD56brightCD16dim  
The numbers of the NK cell subset; CD3-CD56brightCD16dim was found to be 
higher in female patients compared to male patients. This was accounted for by 
one female patient exhibiting an unexpectedly high number of this NK subset 
which notably skewed the result (Chapter 2.0; Table 6.0; patient FP004). 
Interestingly, the cytokine NK cell subset CD3-CD56brightCD16dim makes up 
about 10% of the NK cells in the circulation and 95% of the NK cells in lymphoid 
tissue (Caligiuri, 2008; Campbell & Hasegawa, 2013; Ferlazzo et al, 2004). 
Cytokine NK cell subset CD3-CD56brightCD16dim bridge the innate and adaptive 
immune system by producing cytokines to induce T cells (Caligiuri, 2008). IFN-γ 
is considered to be the prototypic NK-cell cytokine produced by NK cell subset 
CD3-CD56brightCD16dim. This NK subset needs two signals to produce IFN-γ. 
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One always includes IL-12 and the second can be either IL-1, IL-2, IL-15, or IL-
18, or engagement of an NK-activating receptor (Cooper et al, 2001). The 
release of cytokines IFN-γ, TNF-α and MIP-1α occurs rapidly and the release of 
IFN-γ by the NK cells can activate the APCs to upregulate MHC class 1 and 
increase APC cytokine secretion which help to bridge and activate the adaptive 
immune system (Fehniger et al, 2003). In addition the Cytokine NK cell subset 
CD3-CD56brightCD16dim expresses the high-affinity IL-2 receptor complex (HA IL-
2αRβγ and IA IL-2Rβγ) and competes for picomolar concentrations of IL-2 that 
are released by the T cells in the lymph nodes. This co-stimulation with IL-2 
derived from T cells and IL-12 derived monocytes or DC cells results in large 
amounts of IFN-γ production. Thus, consolidating the process by which the NK 
cells link the innate and adaptive immune system. 
 The cytokine NK cell subset CD3-CD56brightCD16dim expresses high levels of L-
selectin and CCR7, both of which are involved in trafficking of immune cells to 
the lymph nodes. Therefore it is probable that these NK cells could traffic to the 
site of developing adaptive immune responses and have dynamic interactions 
with the T cells and APCs. This could also explain the excess number of NK cell 
subset CD3-CD56brightCD16dim present in the peripheral blood of this one female 
patient, where these cells may be migrating to the affected lymph nodes. A 
possible method to determine whether these cells are migratory is to analyse 
the expression of the CCR7. CCR7 is expressed on the NK cell subset CD3-
CD56brightCD16dim and not usually present on the NK cell subset CD3-
CD56dimCD16bright .High expression of CCR7 is related to NK cells homing to 
affected nodes. The expression of CCR7 could be used as a surrogate marker 
to compare their expression to control NK cells to determine if these cells are 
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migratory (Somanchi et al, 2012). Discounting this result from the data set no 
overall difference was observed between male and female MCL patients.   
NK subset: Cytotoxic NK cells CD3-CD56dimCD16bright 
Interestingly, Cytotoxic NK cell subset; CD3-CD56dimCD16bright which is involved 
in direct killing of tumour cells was found to exhibit a trend towards lower 
numbers in female MCL patients compared to male MCL patients. This subset 
is deemed to be the more mature of the NK cell subset and represents 90% of 
the circulating NK cell population (Sanchez et al, 2011; Caligiuri, 2008). It could 
be that these cells remain and continue to mature in the affected lymph nodes 
in order to kill the MCL cells. This may explain the lower numbers present in the 
circulation.  
Further analysis of the NK cell subset CD3-CD56dimCD16bright between clinically 
aggressive and indolent MCL patients found that the patients with a clinically 
aggressive MCL had lower numbers than patients with clinically indolent MCL 
(table 3.0b). The lower numbers of NK cell subset CD3-CD56dimCD16bright in 
female patients could be accounted for by the higher numbers of female 
patients with aggressive disease in this cohort.  
It is probable that lower number of NK cells observed in the peripheral 
circulation may reflect higher numbers in the affected lymph node or that 
aggressive MCL could be inhibiting the bone marrow and lymph nodes’ capacity 
to produce these cells. A study with mouse models has demonstrated increased 
number of NK cells in lymph nodes affected with lymphoma in λ-myc transgenic 
mice which are prone to develop spontaneous lymphomas compared to wild 
type mice, thus supporting the possibility of NK cells migrating to affected nodes 
(Brenner et al, 2010).  
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One of the limitations of the enumeration of NK cells and NK cell subsets has 
been the exclusion of CD3-CD56+CD16- cells. Although the overall result may 
be unaltered it would be interesting to explore this. Currently, there are no pan-
antibody markers for NK cells and some studies have used NKp46 as a marker 
for all NK cells types (Caligiuri, 2008; Tomasello et al, 2012) but this has also 
been shown to be expressed on T cells, thus limiting its specificity for NK 
cells .It would have been interesting to explore this by flow cytometry where the 
CD3 negative, CD4 negative cells, CD56 positive and NKp46 positive cells are 
identified and evaluated to determine whether this encompasses all NK cells. 
Although there was no significant difference observed with the number of NK 
cells and the subsets between male and female MCL patients it would be 
interesting to determine whether there is a difference in the base line activation 
of the NK cells between the genders in MCL. One possible method is to 
measure the surface expression of the lysosomal-associated membrane 
protein–1 (CD107a) by flow cytometry. As the expression of CD107a correlates 
to NK cell activation (Penack et al, 2005) this would potentially provide a rapid 
quantification of activated cytotoxic NK cells between the genders.  
3.6.2. T cells CD3+, CD3+CD4+ (T Helper cells) and CD3+CD8+ (cytotoxic T 
cells) 
The results exhibited a significantly greater numbers of CD3+ T cells in male 
MCL patients compared to female MCL patients. Although the numbers of the T 
cell subsets CD3+ CD4+ and CD3+ CD8+ showed no statistical difference 
between the genders there was a trend towards male MCL patients exhibiting 
higher numbers in the peripheral blood.  
The findings above may be explained by the migration of T cells to the tumour 
microenvironment. It is possible that the female patients may have higher 
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number of T cells surrounding the MCL cells within the affected lymph nodes 
and therefore lower numbers in the peripheral circulation. As mentioned 
previously the burden of MCL in the lymph nodes in clinically aggressive MCL 
may inhibit the proliferation or migration of the T cells resulting in fewer T cells 
in the circulation. As this cohort of patients had more females with clinically 
aggressive MCL patients this may be another possible explanation for male 
patients exhibiting a higher mean number of T cells in the peripheral circulation 
compared to female patients. It would be interesting to analyse the chemokine 
receptors on T cells that are involved with the migration of T cells. For example 
CCR7 chemokine receptor is associated with migration of T cells into lymph 
nodes (Von Andrian & Mackay, 2000). Analysing the expression of this receptor 
by flow cytometry on T cells of female and male MCL patients may aid to 
explain the difference in in the number of T cells in the peripheral blood (Von 
Andrian & Mackay, 2000; Pham et al, 2008).  
The analysis of the enumeration of T cells in 6 clinically aggressive male (n=3) 
and female (n=3) patients with MCL found no statistically significant difference 
(p=0.1). However there was a trend towards the male MCL patients exhibiting 
greater number of T cells.  
Another T cell subset that would be of further interest to explore is the Natural 
Killer like T cells (NKT cells). These cells are T cells with a T cell receptor, but 
unlike conventional T cells that detect peptide antigens presented by the 
conventional MHC molecules, NKT cells recognize lipid antigens presented by 
CD1d, a non-classical MHC molecule (Rossjohn et al, 2012; Vivier et al, 
2012b).  They bridge the innate and adaptive immune system by producing 
large and rapid quantities of cytokines that can stimulate T cells and NK cells 
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(Terabe & Berzofsky, 2008). NKT cells are represented by two subsets; type I 
NKT cells (also known as invariant NKT or iNKT cells) expressing the invariant 
Vα24Jα18 TCR and Type II NKT cells expressing the more diverse set of α 
chains in their TCR, however both are CD1d restricted (Godfrey et al, 2004). 
NKT cells are primary class of T cells that can provide the immune system with 
a mechanism of specific recognition of lipid antigens as CD1d is found to be 
present in lipids or glycolipids rather than peptides (Godfrey et al, 2010). 
Type I NKT cells are activated by α-GalCer or endogenous lipids (may be 
tumour derived) presented by CD1d on immature dendritic cells. They produce 
interferon-γ which induces maturation of the dendritic cells which promotes the 
dendritic cells to produce IL-12, which augments the IL-2 and IFN-γ production 
by type I NKT cells. Production of IL-2, IL-12 and IFN-γ activates NK cells, CD8+ 
T cells and macrophages (Terabe & Berzofsky, 2008). Additionally activation of 
NK cells (CD56bright subset) would potentially lead to increase in IFN-γ 
production resulting in a positive feedback loop to enhance the T cells and NK 
cells activity.  
Type II NKT cells tend to suppress tumour immunity. These cells are activated 
by tumour derived glycolipids presented by CD1d to produce IL-13. Together 
with TNF-α induces expression of TGF-β which suppresses activation of 
cytotoxic CD8+ T cells. In some setting the IL-13 may induce M2 macrophages 
that also suppress CD8+ T cells (Terabe & Berzofsky, 2008; Rossjohn et al, 
2012).  
Interestingly it has been reported that NKT cell have anti-tumour effect on MCL 
cells by the production of IFN-γ. This has been demonstrated in vitro by human 
NKT cells producing higher levels of IFN-γ when exposed to B cells derived 
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from MCL patients compared to healthy donors which suggest mechanisms by 
which NKT cells recognize and respond to malignancy (Li et al, 2014). It would 
therefore be interesting to enumerate these cells in MCL patients to identify if 
there is any difference between the genders. As reduced numbers of iNKT cells 
could potentially related to poorer immunity against MCL. 
3.6.3. T regulatory cells 
T regulatory cells are an immunosuppressive T cell subset that functions to 
prevent autoimmunity and regulate immune response. These cells are important 
in the immunosurveillance process and data has suggested that their role is 
context-dependent. In some solid tumours such as ovarian, breast and prostate 
cancers higher number of infiltrating T regulatory cells is associated with a poor 
outcome (Ebelt et al, 2009; Cureil et al, 2004). However, in lymphoid 
malignancies a number of studies have shown a better outcome with higher 
number of T regulatory cells, especially in follicular lymphoma and diffuse large 
B cell lymphoma (Głowala-Kosińska et al, 2013; Kelley & Parker, 2010). These 
studies have proposed that the better outcome could be due to the possible 
direct cytotoxic effect of T regulatory cells on the lymphoma cells or by 
interfering with T-cell help. One of the mechanisms proposed in suppressing 
malignant B cells is related to the suppressive effects of the T regulatory cells 
on T cells. T regulatory cells release IL-10, TGF-β and IL-35 which are largely 
inhibitory cytokines. IL-10 induces anergy in both CD4+ and CD8+ T cells and 
downs regulates the expression of co-stimulatory molecules, adhesion 
molecules and MHC-class II on antigen presenting cells (Steinbrink et al, 2002). 
TGF-β inhibits IL-2 production and in turn can inhibits T cell proliferation. IL-35 
can also inhibit T cell proliferation and conversely stimulate T regulatory cell 
proliferation. Malignant B cells require the microenvironment to develop and this 
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relates to close contact with T helper cells. It is likely that T regulatory cells 
which inhibit T helpers cells can disrupt the microenvironment of the malignant 
B cells to inhibit its proliferation by indirectly inhibiting the T helper cells 
(Lindqvist & Loskog, 2012).   A recent study has demonstrated direct interaction 
of T regulatory cells with malignant B cells. When T regulatory cells from 
healthy controls and from patients with CLL were exposed to autologous 
malignant B cells (CLL) they exhibited lysis of the malignant B cells and killing 
was confirmed by granzyme ELISAs (Lindqvist et al, 2011). This study 
suggested that the T regulatory cell’s natural function as a suppressor of 
autoimmunity is related to direct cytotoxicity of the malignant B cells. It has been 
proposed that CLL is driven by autoantigens and CLL cells were shown to 
produce autoantibodies. In addition CLL has been connected to several 
different autoimmune conditions (Ansell et al, 2011).  T regulatory cells 
controlling B cells express the B cells in an antigen specific manner (T cell 
receptor – MHC II- restricted) because malignant B cells express MHC-II and 
killing via death receptor ligands or granzyme release is commonly regulated 
via T cell antigen recognition (Lindqvist et al, 2011; Lindqvist & Loskog, 2012).  
However there are studies as mentioned previously that correlate high number 
of T regulatory cells to poor outcomes. These discrepancies may be due to the 
methods used to detect T regulatory cells, an example being the use of 
PCH101 antibody can mistakenly also stain activated T cells. Thus what are 
thought to be T regulatory cells could represent activated T cells. Currently, The 
role of T regulatory cell in mantle cell lymphoma has not been fully investigated 
and require further studies. 
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There was no significant difference found between male and female MCL 
patients or controls with the quantification of T regulatory cells. Interestingly, the 
patient group tended to have a higher mean compared to the controls. This may 
suggest that the patients possess a more activated immune system in order to 
deal with the cancerous cells or alternatively due to the lymph node infiltration 
with MCL there is an egress of T regulatory cells into the peripheral blood. This 
trend also conforms to T regulatory findings in other studies with lymphoma, 
where the numbers have been higher in patients compared to controls (Mittal et 
al, 2008; Kelley & Parker, 2010). One such study reported by Mittal S, et al, 
demonstrated T regulatory cells increased in patients with B cell non-Hodgkin’s 
disease compared to healthy controls ( 20.4% versus 3.2% patients vs. controls 
respectively, p=0.001)(Mittal et al, 2008). Furthermore, the results show a trend 
of higher T regulatory cell numbers in female patients. This concurs with the 
finding reported by Eve et al (Eve et al, 2012).   
Therefore, the trend towards female MCL patients in this study having a higher 
number of T regulatory cells compared to male MCL patients could provide a 
reason for the gender difference observed in MCL. However this trend observed 
with T regulatory cells needs to be further correlated in studies with larger 
number of MCL participants. As mentioned above, the exact role of T regulatory 
cells in MCL needs to be understood. 
3.6.4. NK activating receptors; NKp46, NKp30, NKp44 and NKG2D on CD3-
CD56bright NK cell subset and CD3-CD56dim NK cell subset 
The high expression of NKp46 activating receptor has been shown to correlate 
with higher NK cell cytotoxicity activity and is also associated with improved 
outcomes in haematological malignancies such as acute myeloid leukaemia 
(Fauriat et al, 2007; Epling-Burnette et al, 2007; Sivori et al, 1999). Interestingly 
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majority of the evidence in relation to NK cells role in tumour clearance in 
leukemia has come from killer cell inhibitory receptor (KIR) mismatch in 
allogenic stem cell transplantation in the treatment of acute myeloid leukemia 
(Moretta et al, 2014). Study by Fauriat et al, demonstrated reduction in NCR 
expression in patients with AML. The expression of the NCRs improved after 
therapy when patients achieved a complete remission. AML patients with low 
expression of NCRs on the NK cells played a role in the patients’ outcome 
suggesting a possible surveillance role of the NK cells against leukemia cells 
(Fauriat et al, 2007).  
However, there was no significant difference observed in the expression of 
NKp46 activating receptor on either of the NK cell subsets between male and 
female MCL patients or when compared to the control groups. NKp46 is 
constitutively expressed on NK cells as is NKp30 (Hudspeth et al, 2013), which 
also demonstrated no significant difference between the male and female 
patients or the controls. It is possible that circulating NK cells are not activated 
or stimulated and thus the expression of the NKp46 and NKp30 is not altered 
significantly between the genders or controls. It is also possible that these 
circulating NK cells remain dormant until they reach the tumour site where they 
are stimulated by the antigen on the tumour itself, dendritic cells or T cells and 
their production of cytokines within the microenvironment (Moretta, 2002). Both 
the NK 56dim and NK 56bright cells expression cytokine receptors which influence 
their functions. The following cytokine receptors are expression on both subsets 
of NK cells; IL-12R (IL-12Rb1 and IL-12Rb2), IL-15R (IL-15Rα and IL-
2/15Rβγc), IL-18R (IL-18Rα/R1 and IL18Rβ/RAP), IL-21R (IL-21Rγc) and IL-2R 
(IL-2Rαβγ; CD56bright and IL-2Rβγ; CD56bright and CD56dim) (Romee et al, 2014). 
Cytokines produced by dendritic cells, T cells and macrophages in the 
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microenvironment activate the NK cells and encourage further cytokine 
production, proliferation, survival and cytotoxicity of the NK cells (Romee et al, 
2014).  
IL-2 and IL-15 have been the most studied cytokine activators of NK cells. The 
signalling through the IL-2/IL15 receptor induces proliferation, and enhances 
cytotoxic effects. IL-2 and IL-15 share the IL-2/IL-15Rβ and γc as the primary 
signalling subunits. Both CD56bright and CD56dim cells have high affinity IL-2 
receptors that respond to picomolar concentrations of IL-2 (Nandagopal et al, 
2014). IL-15 is produced by APCs and can activate the IL-2/IL-15 receptor. It 
has been suggested that picomolar concentrations of IL-2 only activates the IL-
2Rαβγ receptor and high concentrations are needed to activate both the IL-2/IL-
15Rβγc and therefore IL-15 could be a more useful cytokine to activate NK cells 
as it will act through both the IL-2 and IL-15 receptor (Vitale et al, 2014). 
Interestingly, IL-2 also activates T regulatory cells which can limit the function of 
the NK cells thus inducing an inhibitory effect (Romee et al, 2014).  
In resting NK cells the NKp44 expression is induced by the presence of IL-2 
(Moretta et al, 2001) . The examination of the NKp44 activating receptor 
demonstrated a moderate expression on both subsets of NK cells compared to 
the isotype control. It is possible that the NK cells in the peripheral circulation of 
the male and female MCL patients are unstimulated and it may be this that 
results in the lack of significant expression of the NKp44 receptor. It would be 
interesting to examine the expression of the NKp44 on NK cells from affected 
lymph nodes to correlate if there is a higher expression due to the activated 
microenvironment of the tumour. This could be achieved by analysing cells 
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obtained by fine needle aspiration from the affected lymph node and using flow 
cytometry to measure the expression of the NKp44 activating receptor. 
The expression of NKG2D activating receptor exhibited no significant difference 
between male and female MCL patients. There was a trend which 
demonstrated lower expression of the NKG2D receptor on the patient NK cells 
subset CD3-CD56dim compared to the control group. This suggests that the NK 
cells subset CD3-CD56dim is less activated in MCL patients. It is possible that 
MCL itself could inhibit the NK cells by producing inhibitory ligands thus 
resulting in lower expression of this receptor compared to the healthy controls 
(Sanchez et al, 2011; López-Soto et al, 2014). Evaluation of certain activating 
ligand such as B7-H6, MICA or MICB in the primary MCL patients may shed 
further light on certain aspects of the NK cell activating receptor expression. 
Currently inhibitory ligands to NK cells in mantle cell lymphoma have not been 
identified. However the inhibitory ligand B7-H1 has been shown to be 
expressed by mantle cell lymphoma cells which inhibit T cells function, which 
was recently reported by Wang et al (Wang et al, 2013a).  
Larger studies are required to confirm the observed trend and further research 
is needed to determine if MCL exhibits any inhibitory ligands to NK receptors. 
In this study only four activating receptors that have been implicated in 
haematological malignancies were evaluated (Costello et al, 2012; Epling-
Burnette et al, 2007; Sanchez et al, 2011). However, one of the future plans is 
to evaluate the NK inhibitory receptors such as KIR and CD92 to determine 
whether the expression of these inhibitory receptors is different between the 
genders. 
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One of the major limitations of this study was the low number of participants. 
Given that MCL is a rare disease recruitment of patients that were either newly 
diagnosed or untreated was challenging. Therefore, in order to research these 
trends and results further, a larger cohort of patients is required. This would also 
allow for more robust statistical testing as individual variations could be better 
accounted for. 
3.7. Conclusion 
The major finding in this chapter was that the male MCL patients exhibited a 
significantly higher number of T cells in the peripheral circulation compared to 
the female MCL patients. Additionally, there was a trend towards greater 
number of T regulatory cells in the female MCL patients compared to the male 
MCL patients. These results suggest that there is possibly an egress of the 
immune cells from the lymph node. It is possible that higher number of T cells 
would be present in the affected lymph nodes of female patients compared the 
males thus inversely correlating to the number of T cell in the circulation. As 
discussed earlier T regulatory cells have an inhibitory effect on T cells and thus 
if this observation remains consistent then fewer T regulatory cells in the 
microenvironment could reduce their inhibitory effects in female patients. Hence 
an assumption could be made that, female patients with MCL are potentially 
able to mount a stronger immune response within the microenvironment of the 
MCL. The exact role of T regulatory cells and the other immune cells in the 
context of MCL needs additional studies and importantly these results illustrate 
the cell numbers in the peripheral blood of the patients, which could be 
significantly different to the numbers and function in the microenvironment of 
MCL. Nonetheless, larger studies are warranted to explore further these results 
and trends observed. 
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Results 
 
 
 
 
The cytotoxic analysis of peripheral blood immune cells in male and 
female MCL patients and healthy controls. Analysis of the effects of 
oestrone and IL-2 on immune cell numbers and cytotoxic action.  
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4.0. Background 
Immunosurveillance and immunoediting is a process by which the innate and 
adaptive immune system eliminates cancerous cells (Swann & Smyth, 2007; 
Ponce et al, 2014; Plonquet et al, 2007). The evidence for this process 
occurring in humans is provided in part by the increased cancer incidence in 
immunosuppressed transplant patients compared to age matched healthy 
controls (Opelz & Döhler, 2004). In addition, patients with human 
immunodeficiency virus (HIV) have an increased incidence of lymphoma rates 
especially when the CD4 counts are low (Yanik et al, 2013). T cell have been 
implicated in immunosurveillance and a recent study has demonstrated their 
importance in B cell lymphoma proliferation, where by removal of T cells 
accelerates the progression of lymphoma (Afshar-sterle et al, 2014; Kallies, 
2014).  NK cell are well recognised to play a pivotal role in the first defence 
against cancerous cells by inducing direct cell mediated death on defective cells 
(Vivier et al, 2011). Furthermore, quantification of T and NK cells in B cell 
malignancies have been associated with prognostication implying their 
importance in immunosurveillance (Głowala-Kosińska et al, 2013; Shafer et al, 
2013; Plonquet et al, 2007). A recent study has demonstrated that the presence 
of T cells within the tumour environment can be a positive prognostic indicator 
in MCL (Nygren et al. 2014). Therefore, cell mediated cytotoxicity by immune 
cells is an important first line defence and whether females mount a better 
response in MCL is warranted for further study. 
The role of IL-2 
Functional enhancement of T, T regulatory and NK cells has been 
demonstrated by IL-2 (Boyman & Sprent, 2012; Bordignon et al, 1999; Liao et 
al, 2013). IL-2 stimulates the production of lymphokine activated killer cells 
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(LAK) which are stimulated NK and cytotoxic T cells. LAK cells have been 
proven to be more effective in killing tumour cells (Bordignon et al, 1999; Grimm 
et al, 1982). Furthermore, by utilising and enhancing the hosts immune cells 
with IL-2, it has been demonstrated that certain malignancies such as 
melanoma and renal cell carcinoma have been treated with some success  
(Rosenberg, 2014). In addition IL-2 has been recognized to have beneficial 
effects in the treatment of acute myeloid leukaemia (AML) by stimulating the 
host’s immune system to eliminate any remaining leukemic cells following initial 
induction chemotherapy (Romero et al, 2009). Therefore, stimulation of PBMCs 
by IL-2 increases the immune cell cytotoxic function and it would be interesting 
to determine whether female patients with MCL have a superior response to   
IL-2. There is no data on the effects of oestrone on IL-2 receptors or its effect in 
the context of B cell lymphomas and this may warrant further studies. 
Oestrone 
As mentioned in chapter 1, the incidence of MCL has a male to female 
prevalence of approximately 3:1 and a study has demonstrated that females 
with MCL respond better to immunomodulatory therapy such as lenalidomide 
(Eve et al, 2012). Although the exact mechanism of this gender difference is not 
fully understood, there appear to be several factors that may influence it. These 
include the ability of the female immune system to mount a greater immune 
response, better response to activating cytokines such as IL-2 and possibly the 
influence of oestrogens (Klein, 2012).  
The median age of the female patients participating in this study was 62 years 
and oestrone is the most abundant female hormone in postmenopausal women 
of the three female hormones; oestriol, oestrodiol and oestrone (Gruber et al, 
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2002). Studies have also demonstrated oestrogen receptor α and β presence 
on immune cells; T cells and NK cells (Phiel et al, 2005; Henderson et al, 2003; 
Yakimchuk et al, 2013) and in turn oestrone has an affinity to both receptors 
(Gruber et al, 2002) with a capability of activating them both. Furthermore, 
oestrogen receptors have been identified on B lymphocytes and some B cell 
lymphomas (Römer & Pfreundschuh, 2014)(chapter 1 section 1.3). Therefore 
investigating the effects of oestrone on the immune cell mediated cytotoxicity on 
target cell would be interesting to determine and determine whether addition of 
oestrone would enhance the cell mediated cytotoxicity. 
Lenalidomide 
A recent study has demonstrated better response rates with lenalidomide in 
female patients with relapsed / refractory MCL thus suggesting a possible 
influence due the gender (Eve et al, 2012). Due to the small size of the study 
the researchers could not fully address this observation. However, it could be 
possible that the female immune cells or hormones may have influenced this 
result. Lenalidomide, a derivative of thalidomide, is an immunomodulatory drug 
which has been shown to enhance T cell and NK cell cytotoxic activity against 
lymphoma cells (McDaniel et al, 2012; Richardson et al, 2010)(chapter 1 
section 1.2.2d). Therefore the cytotoxic function of these cells was evaluated 
following incubation with lenalidomide to determine if there was a difference 
between the male and female immune cells in patients with mantle cell 
lymphoma. 
On the basis of the above data the aim of this chapter was to; 
1) Determine whether effector cells (PBMCs) from female MCL patients have a 
greater cell mediated cytotoxicity compared to males. 
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2) Determine whether incubation with IL-2, oestrone and lenalidomide exerts an 
effect which is different between the cell mediated cytotoxicity of female MCL 
patients’ effector cells compared to male MCL patients’ effector cells. 
3) Determine whether incubation with IL-2, oestrone and lenalidomide 
influences the quantity of immune cells compared to untreated control cells.  
4) Determine the effects of IL-2, oestrone and lenalidomide on the NK activating 
receptors; NKp46, NKp44, NKp30 and NKG2D. 
It must be taken into consideration that due to the problems with isolation of NK 
cells on viability, effector cells were cultured for 24 hours in media containing 
various treatments (chapter 2, section 2.7). Unless otherwise stated, all the 
effector cells utilised in this chapter were non-adherent cells which were either 
untreated (control) or treated with IL-2, oestrone, lenalidomide, lenalidomide 
combined with oestrone and lenalidomide combined with oestrone and IL-2. 
The effector cells contained T cells, NK cells, NK-T cells and neutrophils. In all 
the experiments presented in this chapter  the effector cells were from clinically 
unselected male and female MCL patients consisting of 3 male patients; 2 
clinically aggressive and 1 clinically indolent and 3 female patients; 1 clinically 
aggressive and 2 clinically indolent were used. Effector cells from 5 healthy age 
matched male and female controls were used. 
‘Clinically unselected’ is defined; that there was no pre-selection of patient in 
relation to their clinical characteristics but due to the limited number of material 
and patients available, any suitable patient sample was utilised as described 
above throughout this chapter (chapter 2). 
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4.1. Direct cytotoxicity effect of oestrone and lenalidomide on Granta 519 
(G519) mantle cell lymphoma cells and K562 cells 
The direct effect of oestrone and lenalidomide was evaluated on both cell lines 
to determine whether there was an effect on the target cells (G519 and K562), 
prior to investigating the cell mediated cytotoxicity of PBMCs (effector cells) on 
target cells when incubated with these compounds. There was no significant 
direct cytotoxic effect of oestrone or lenalidomide on G519 cells at various 
concentrations when incubated for up to 48 hours (Figure 20). Similarly, there 
was no significant direct cytotoxicity exhibited on K562 cells when incubated 
with oestrone and lenalidomide at similar concentrations (data not shown). 
 
Figure 20: Direct effects of oestrone and lenalidomide on G519 target cells 
A. G519 cells were incubated with varying concentrations of oestrone as shown over a 
period of 48 hours incubation to assess direct cytotoxic effect of oestrone on G519 
cells.  
B. Similarly G519 cells were incubated with lenalidomide at 1µM and 2µM 
concentration over a period of 48 hours incubation.  
(similar results were observed when oestrone and lenalidomide were used in 
combination  as well as oestrone, lenalidomide and IL-2 (100IU) at the above stated 
concentrations, data not shown). 
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4.2. Cell mediated cytotoxicity of control (untreated) effector cells from 
male and female healthy controls and MCL patients on K562 target cells.  
The K562 cells lack the MHC-class 1 complex and thus exhibit good sensitivity 
to NK cytotoxicity. The activating receptors on NK cells sense the absence of 
MHC-class 1 and target these cells for destruction. Therefore, K562 cells are a 
good model in which to assess the cytotoxic ability of PBMC population due to 
their extreme sensitivity to NK cytotoxicity. The cell mediated cytotoxicity of 
K562 target cells by effectors cells were analysed by flow cytometry as 
described in the methods chapter 2, section 2.7. 
The control effector cells which were incubated with vehicle control DMSO 
(1µl/ml, <0.001%) will be referred to as untreated throughout this chapter. There 
was no difference observed between effector cells with or without DMSO (data 
not presented). 
K562 target cells were exposed to untreated effector cells from male and female 
healthy controls and unselected MCL patients (consisting patients exhibiting 
both clinically indolent and aggressive disease) (Figure 21). There was a 
significant increase in cell mediated cytotoxicity on the K562 cells by effector 
cells from female controls compared to male controls, p=0.04 at E:T ratio of 
50:1 (Figure 21 B). No significant difference was observed in the cell mediated 
cytotoxicity of effector cells from male and female MCL patients, p=0.9 (Figure 
21 C). Interestingly the base line activity of MCL patients was similar to the male 
controls. 
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Figure 21: Cell mediated cytotoxicity of effector from both MCL patients and 
healthy control groups on K562 target cells 
Effector cells from unselected male and female MCL patients consisting of 3 male 
patients; 2 clinically aggressive and 1 clinically indolent and 3 female patients; 1 
clinically aggressive and 2 clinically indolent were used. Effector cells from 5 healthy 
age matched male and female controls were used. Plots above demonstrate cell 
mediated cytotoxicity by mean (+/- SE) percentage cell death of target (K562) cells. 
 
Plot A exhibits cell mediated cytotoxicity of effector cells from male and female healthy 
controls and unselected male and female MCL patients. 
Plot B exhibits cell mediated cytotoxicity of effector cells from male and female 
controls. 
Plot C exhibits cell mediated cytotoxicity of effector cells from female MCL patients and 
female controls. 
Plot D exhibits cell mediated cytotoxicity of effector cells form unselected male and 
female MCL patients. 
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4.3. Cell mediated cytotoxicity of control effector cells (untreated) from 
male and female healthy controls and MCL patients on Granta 519 target 
cells 
The baseline cell mediated cytotoxicity of control (untreated) effector cells from 
male and female controls and MCL patients on Granta 519 target cells was 
analysed. The cell mediated cytotoxicity was analysed by the flow cytometry as 
described in the methods chapter 2, section 2.7. 
The Granta 519 target cells were exposed to the untreated effector cells from 
the male and female healthy controls and unselected MCL patients. There was 
no significant difference in cell mediated cytotoxicity between the female and 
male control group, p=0.9 (Figure 22 A & B) and there was no significant 
difference observed in the cell mediated cytotoxicity between the male and 
female MCL patients, p=0.8 (Figure 22 C). 
The healthy control groups demonstrated an overall greater cell mediated 
cytotoxicity compared to the MCL patients (Figure 22). However, this only 
reached significance in the female MCL patients versus female healthy controls, 
p=0.03 at E:T ratio 50:1 (Figure 22 D). 
The cell mediated cytotoxicity exhibited when using G519 target cells differed 
compared to K562 target cells (figure 24.0) largely due to the K562 cells being 
more sensitive to NK cell mediated cell death. G519 cells have expression of 
MHC- class 1 and therefore are not killed as effectively as K562 cells by NK 
cells as mentioned in section 2.4.2.  
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Figure 22: Cell mediated cytotoxic activity of male and female untreated effector 
cells from unselected MCL patients and healthy control groups on Granta 519 
target cells 
Cell mediated cytotoxicity is presented by mean percentage (+/- SE)  of target cell 
(G519) death. Effector cells from unselected male and female MCL patients consisting 
of 3 male patients; 2 clinically aggressive and 1 clinically indolent and 3 female 
patients; 1 clinically aggressive and 2 clinically indolent were used. Effector cells from 5 
healthy age matched male and female controls were used. 
 
Plot A exhibits the cell mediated cytotoxicity of the effector cells from healthy male and 
female controls compared to the unselected male and female MCL patients. 
Plot B exhibits cell mediated cytotoxicity of the effector cells from healthy female and 
male controls. 
Plot C exhibits cell mediated cytotoxicity of effector cells from the unselected male and 
female MCL patients. 
Plot D exhibits cell mediated cytotoxicity of effector cells from female controls 
compared to female MCL patients. 
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4.4. Cell mediated cytotoxicity function of IL-2 treated effector cells from 
male and female healthy controls and MCL patients on K562 and Granta 
519 target cells 
 
PBMCs (effector cells) from the subjects were incubated with IL-2 100IU for 24 
hours as described in the methods chapter 2, section 2.7. Incubation with IL-2 
produces LAKs as described earlier.  
K562 target cells 
K562 target cells were exposed to LAK cells from both healthy controls and 
MCL patients. Incubation with IL-2 resulted in an overall increase in cell 
mediated cytotoxicity in all groups when compared to untreated effector cells 
(Ϯ+ϮϮp=0.02, Figure 23, Table 16). The LAK cells from the female controls 
exhibited a significant increase in cell mediated cytotoxicity when compared to 
the untreated effector cells from the same group (*p=0.04, **p=0.003 and 
***p=0.04, Figure 23, Table 16).  
The LAKs cells from the female controls demonstrated a greater increase in cell 
mediated cytotoxicity compared to the male controls (Figure 23, Table 16) and 
they also exhibited the greatest overall cytotoxicity activity (Figure 23). 
Interestingly, the cell death observed with LAKs cells from clinically unselected 
MCL patients was similar to male controls. LAKs cells from the female controls 
exhibited a significantly greater cell death compared to the male controls, 
*p=0.009, at ratio 25:1 E:T cells (Figure 23B). Additionally, LAK cells from 
female controls exhibited a significantly greater cytotoxicity compared to the 
clinically unselected female MCL patients, *p=0.02 (Figure 23 D).  
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Figure 23: Cell mediated cytotoxic activity of effector cells treated with IL-2 on 
K562 target cells 
Cell mediated cytotoxicity is presented by mean percentage (+/- SE) of target cell 
(K562 cells) death. Effector cells from unselected male and female MCL patients 
consisting of 3 male patients; 2 clinically aggressive and 1 clinically indolent and 3 
female patients; 1 clinically aggressive and 2 clinically indolent were used. Effector 
cells from 5 healthy age matched male and female controls were used. 
 
Plot A compares cell mediated cytotoxicity activity of LAK cells on K562 target cells in 
all 4 groups.  
Plot B demonstrates cell mediated cytotoxicity of LAK cells from female controls and 
male controls. 
Plot C demonstrates cell mediated cytotoxicity of LAK cells from clinically unselected 
male and female MCL patients. 
Plot D demonstrates cell mediated cytotoxicity of LAK cells from female controls and 
MCL female patients.  
Table 16: Percentage increase in cell mediated cytotoxicity of LAK cells on 
K562 target cells when compared with untreated effector cells. 
 
 
 
 
Table 16 
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Granta 519 Target Cells 
Granta 519 target cells were exposed to effector cells treated with IL-2 (to from 
LAK cells) from all four groups. The LAK cells exhibited an overall greater 
increase of cell mediated cytotoxicity activity when compared to the cell 
mediated cytotoxicity of the untreated effector cells (Table 17, *p=0.03, 
**p=0.005 and ***p=0.03). As with the K562’s target cells, the control groups 
exhibited greater overall increase when compared to the patient groups. 
Interestingly, the female MCL patients did not exhibit an increase in the cell 
mediated cytotoxicity after the effector cells were incubated with IL-2 (Table 17).  
When comparing the cytotoxic activity between the groups of the LAK effector 
cells on Granta 519 target cells there was a trend towards male controls 
exhibiting greater cell mediated cytotoxicity compared to the rest of the groups 
and interestingly when compared to the female control group (Figure 24 A & B). 
However this did not reach statistical significance, p=0.9 (Figure 24). 
Additionally the male MCL patient group exhibit a significantly greater cell 
mediated cytotoxicity compared to the female MCL group (E:T – 50:1, *p=0.04, 
figure 28 C). The female and male control group demonstrated a greater cell 
mediated activity compared to the respective patient groups (E:T ratio 25:1 and 
50:1, *p=0.03 and **p=0.002 respectively, Figure 24 D). 
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Figure 24: Cell mediated cytotoxicity of effector cells treated with IL-2 (LAKS) on 
Granta 519 target cells 
Cell mediated cytotoxicity by mean percentage (+/- SE) of target cell (G519) death. 
Effector cells from unselected male and female MCL patients consisting of 3 male 
patients; 2 clinically aggressive and 1 clinically indolent and 3 female patients; 1 
clinically aggressive and 2 clinically indolent were used. Effector cells from 5 healthy 
age matched male and female controls were used. 
 
Plot A compares cell mediated cytotoxicity of LAK cells from male and female controls 
and MCL patients. 
Plot B; cell mediated cytotoxicity of LAK cells from female and male control groups. 
Plot C; cell mediated cytotoxicity of LAK cells from male and female patient groups.  
Plot D; cell mediated cytotoxicity of effector cells compared between female patients 
and female controls. 
Table 17: Percentage increase in cell mediated cytotoxicity of effector cells on 
G519 cells from the subjects incubated with IL-2 compared to untreated effector 
cells. 
 
 
* 
Table 17 
171 
 
4.5. Cell mediated cytotoxicity of effector cells incubated with oestrone 
from male and female healthy controls and MCL patients on K562 and 
Granta 519 target cells  
 
The median age at which MCL presents is 65 years (McKay et al, 2012). The 
male and female patients in this study had a median age of 64 and 62 years 
respectively. All the healthy control subjects were over the age of 50 years 
(median age 54 years). The physiological level of oestrone in post-menopausal 
women is 40pg/ml, which was used throughout the experiments to determine 
the effects of oestrone on the cytotoxic activity of effector cells (Gruber et al, 
2002). The effector cells were incubated with oestrone for 24 hours and 
subsequently used to analyse the cell mediated cytotoxicity on the target cells 
by flow cytometry. Oestrone was included in the media in which the cell 
mediated cytotoxicity was carried out. 
K562 and Granta 519 target cells were exposed to effectors cells incubated with 
oestrone from both healthy controls and MCL patients. No significant change 
was observed in the cell mediated cytotoxicity when compared to the cell 
mediated cytotoxicity activity of the untreated effector cell (Table 18 and 19). 
There was a trend towards a marginally greater cell mediated cytotoxicity 
activity in the male MCL patients compared to the female MCL patients. This is 
probably due to the marginally greater number of NK cells and T cells in the 
male MCL patients compared to the female MCL patients rather than an effect 
of oestrone (Figure 25 and 26)  
K562 and Granta 519 target cells were exposed to effector cells incubated with 
oestrone from male and female healthy controls and MCL patients. There was 
no significant difference observed between the male and female healthy 
controls and MCL patients.  
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The cell mediated cytotoxicity on K562 target cells exhibited a trend towards 
greater activity in female controls compared to male controls and MCL patients, 
p=0.9 (Figure 26, B & D). There was no significant difference exhibited of the 
cell mediated cytotoxicity on K562 target cells between the male and female 
MCL patients, p=0.5 (Figure 26 C). 
There was no significant difference in the cell mediated cytotoxicity between 
male and female healthy controls on G519 target cells, p=0.9 (Figure 26 A & B). 
Similarly there was no significant difference was exhibited in the cell mediated 
cytotoxicity between male and female MCL patients, p=0.7 (Figure 26 C). 
However at the E:T ratio of 50:1 there was a trend towards greater activity in the 
male MCL patients compared to female patients, p=0.3 (Figure 26 A & C). This 
result is possibly a reflection of the variation in numbers of effector cells 
between the two groups (Figure 25 & 26). Notably, the percentage of target cell 
death was less in the G519 cells compared to the K562 cells. This is probably 
accounted for by K562 cells being more sensitive to NK cell mediated death due 
to the lack of MHC-class 1. The G519 cells exhibit reduced MHC-class 1 
expression and are therefore less sensitive to NK cell mediated cell death.  
 In relation to both the K562 and Granta 519 target cells the results observed 
are comparable to the cell mediated cytotoxicity exhibited by the untreated 
effector cells (Figure 25 & 26).  
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Figure 25:  Cell mediated cytotoxicity of effector cells incubated with oestrone on 
K562 target cells 
Cell mediated cytotoxicity presented by mean percentage (+/- SE) of target cell 
(K562 cells) death. Effector cells from unselected male and female MCL 
patients consisting of 3 male patients; 2 clinically aggressive and 1 clinically 
indolent and 3 female patients; 1 clinically aggressive and 2 clinically indolent 
were used. Effector cells from 5 healthy age matched male and female controls 
were used. 
 
Graph A: Cell mediated cytotoxicity activity comparing all 4 groups. 
Graph B: Cell mediated cytotoxicity activity of male and female healthy controls. 
Graph C: Cell mediated cytotoxicity activity of male and female MCL patient 
groups. 
Graph D:  Cell mediated cytotoxicity of healthy female controls and female MCL 
patients 
Table 18: Percentage increase in cell mediated cytotoxicity on K562 target cells 
after effector cells from the subjects were incubated with oestrone.  
Table 18 
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Figure 26: Cell mediated cytotoxicity of effector cells incubated with oestrone on 
Granta 519 target cells 
Cell mediated cytotoxicity presented by mean percentage (+/- SE) of target cell 
(G519 cells) death. Effector cells from unselected male and female MCL 
patients consisting of 3 male patients; 2 clinically aggressive and 1 clinically 
indolent and 3 female patients; 1 clinically aggressive and 2 clinically indolent 
were used. Effector cells from 5 healthy age matched male and female controls 
were used. 
 
Graph A: Cell mediated cytotoxicity of effectors cells from male and female 
controls and patients.  
Graph B: Cell mediated cytotoxicity of effector cells from female and male 
control groups. 
Graph C: Cell mediated cytotoxicity of effector cells from male and female 
patient group. 
Graph D: Cell mediated cytotoxicity of effector cells from female controls and 
female MCL patients   
Table 19: The percentage increase in cell mediated cytotoxicity of effector cells 
incubated with oestrone compared to untreated (control) effector cells.  
 
Table 19 
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4.6. Cell mediated cytotoxicity of effector cells incubated with 
lenalidomide and a combination of lenalidomide and oestrone from male 
and female healthy controls and MCL patients on Granta 519 target cells 
 
Lenalidomide has been described to modulate the immune cells and female 
patients with MCL have demonstrated greater response rates (Eve et al, 2012). 
Therefore, in addition to lenalidomide, a combination of lenalidomide and 
oestrone was also used to determine whether simulating a postmenopausal 
‘female’ environment with oestrone would demonstrate greater cell mediated 
cytotoxicity by effector cells. The cell mediated cytotoxicity on Granta 519 cells 
of effector cells from healthy controls and MCL patients that had been incubated 
with lenalidomide 2µM and a combination of lenalidomide 2µM and oestrone for 
24 hours was analysed. The cell mediated cytotoxicity was analysed by flow 
cytometry as described in chapter 2, section 2.7. Due to the limitation on the 
quantity of effector cells available for each subject, the cell mediated cytotoxicity 
was only evaluated on G519 cells and not on K562 cells. This was done 
primarily to evaluate the effects on MCL cells. 
Granta 519 target cells exposed to effector cells incubated with lenalidomide 
and a combination of lenalidomide and oestrone from healthy controls and MCL 
patients demonstrated no significant increase in cell mediated cytotoxicity when 
compared to untreated effector cells from the same groups (Table 20 and 21).  
Effector cells incubated with only lenalidomide demonstrated no significant 
difference in the cell mediated cytotoxicity between the male and female healthy 
control groups, p=0.5 (Figure 27 A). However, the healthy male and female 
control groups exhibited greater cell mediated cytotoxicity on G519 target cells 
compared to the MCL male and female patient groups (p=0.04*; E:T 50:1 
Figure 31 D; male healthy controls compared to male MCL patients). There was 
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no significant difference in the cell mediated cytotoxicity between the genders in 
either the healthy controls, p=0.5 or MCL patient, p=0.4 (Figure 27 B & C). 
Effector cells incubated with lenalidomide and oestrone in combination exhibited 
similar results to effector cells incubated with only lenalidomide as described 
above. There was no significant difference observed between the genders from 
healthy controls or MCL patients, p=0.45 (Figure 28 A & B). However, there was 
a significantly greater cell mediated activity in the healthy controls compared to 
the MCL patients (p=0.02* and p=0.04*; Figure 28 C & D, respectively).   
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Figure 27: Cell mediated cytotoxicity of effector cells incubated with 
lenalidomide on Granta 519 target cells 
Cell mediated cytotoxicity presented by mean percentage (+/- SE) of target cell 
(G519 cells) death. Effector cells from male and female MCL patients consisting 
of 3 male patients; 2 clinically aggressive and 1 clinically indolent and 3 female 
patients; 1 clinically aggressive and 2 clinically indolent were used. Effector 
cells from 5 healthy age matched male and female controls were used. 
 
Graph A: Cell mediated cytotoxicity of effectors cells from male and female 
controls and MCL patients. 
Graph B: Cell mediated cytotoxicity of effector cells from female and male 
healthy control. 
Graph C: Cell mediated cytotoxicity of effector cells from male and female MCL 
patient. 
Graph D: Cell mediated cytotoxicity of effector cells from male patients and 
male healthy controls.  
Table 20: Percentage increase of cell mediated cytotoxicity of effector 
cells incubated with lenalidomide compared with untreated (control) 
effector cells on Granta 519 target cells. 
Table 20 
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Figure 28: Cell mediated cytotoxicity of effector cells incubated with 
lenalidomide and oestrone in combination 
Cell mediated cytotoxicity presented by mean percentage (+/- SE) of target cell 
(G519 cells) death. Effector cells from male and female MCL patients consisting 
of 3 male patients; 2 clinically aggressive and 1 clinically indolent and 3 female 
patients; 1 clinically aggressive and 2 clinically indolent were used. Effector 
cells from 5 healthy age matched male and female controls were used. 
 
Graph A: Cell mediated cytotoxicity of effectors cells from male and female 
controls and MCL patients. 
Graph B: Cell mediated cytotoxicity of effector cells from female and male 
patient groups. 
Graph C: Cell mediated cytotoxicity of effector cells from male healthy control. 
Graph D: Cell mediated cytotoxicity of effector cells from female healthy 
controls and female MCL patients. 
Table 21: Percentage increase in cell mediated cytotoxicity of effector cell 
incubated with a combination of lenalidomide and oestrone compared with 
untreated (control) effector cells on Granta 519 target cells.  
Table 21 
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4.7. Cell mediated cytotoxicity of effector cells from male and female 
patients and healthy controls incubated with a combination of 
lenalidomide, IL-2 and oestrone on Granta 519 target cells 
 
The effector cells were treated with a combination of lenalidomide 2µM, IL-2 
100IU and oestrone 40pg/ml for 24 hours. This was to determine if LAKs 
mounted a greater response in the presence of lenalidomide and oestrone. The 
combination of IL-2, oestrone and lenalidomide was used to ascertain whether 
there was an enhanced response to IL-2 in the presence of oestrone and 
lenalidomide and in turn if the ‘female environment’ enhanced the cell mediated 
cytotoxicity.  The cell mediated cytotoxicity was performed in media containing 
lenalidomide, IL-2 and oestrone. The analysis was performed by flow cytometry 
as described in chapter 2 section 2.7. Cell mediated cyctotoxicity on K562 
target cell was not analysed to limitations in the availability of adequate number 
of effector cells from the subjects. 
Granta 519 target cells exposed to effector cells incubated with a combination 
of IL-2, oestrone and lenalidomide from male and female healthy controls and 
MCL patients exhibited a percentage increase in the cell mediated cytotoxicity 
when compared to untreated effector cells (Figure 29, Table 22). There was a 
significant increase in the cell death observed in healthy male and female 
controls at the T:E ratios of 1:50, *p=0.001, ***p=0.001 (Table 22). There was 
no statistically significant increase observed in the female MCL patients, 
however a trend toward greater increase in cell mediated cytotoxicity was 
observed in male MCL patients compared to the female MCL patients (Table 
23).  
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There was no significant difference in the cell mediated cytotoxicity of the 
effector cells from male and female controls, p=0.8 (Figure 29 A & B). However 
there was a trend towards male controls exhibiting greater cell mediated 
cytotoxicity compared to the female controls. Additionally the control groups 
exhibited a trend towards greater cell mediated cytotoxicity compared to the 
MCL patients. Female controls exhibited a significantly greater cell mediated 
cytotoxicity compared to the female MCL patients (*p=0.02, **p=0.001, Figure 
29D). Interestingly, the male MCL patients exhibited significantly greater cell 
mediated cytotoxicity when compared to the female patients (*p=0.01, Figure 29 
C). This observed result is largely related to the greater number of T and NK 
cells in male MCL patients compared to female MCL patients (Figure 29) 
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Figure 29: Cell mediated cytotoxicity of effector cells incubated with a 
combination of lenalidomide, IL-2 and oestrone 
Cell mediated cytotoxicity presented by mean percentage (+/- SE) of target cell 
(G519 cells) death. Effector cells from male and female MCL patients consisting 
of 3 male patients; 2 clinically aggressive and 1 clinically indolent and 3 female 
patients; 1 clinically aggressive and 2 clinically indolent were used. Effector 
cells from 5 healthy age matched male and female controls were used. 
 
Graph A: Cell mediated cytotoxicity of effectors cells from male and female controls 
and patients.  
Graph B: Cell mediated cytotoxicity of effector cells from female and male control 
groups.  
Graph C: Cell mediated cytotoxicity of effector cells from male and female patient 
group.  
Graph D: Cell mediated cytotoxicity of female healthy controls and female MCL 
patients.  
Table 22:  Percentage increase in cell mediated cytotoxicity after effector 
cells incubated with combination of IL-2, oestrone and lenalidomide 
compared with untreated effector cells on Granta 519 target cells.  
 
Table 22 
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4.8. The increase in cell mediated cytotoxicity was due to an IL-2 effect 
 
Following the results of the cell mediated cytotoxicity analysis, the most notable 
increase was observed in effector cells incubated with IL-2 or IL-2 in 
combination with lenalidomide and oestrone. Further cell mediated cytotoxicity 
experiments were carried out with effector cells from 3 male and female healthy 
controls incubated with oestrone 40 pg/ml,  IL-2 100IU, lenalidomide 1µM, IL-2 
100IU and oestrone 40pg/ml, IL-2 100IU and lenalidomide 2µM, IL-2 100IU, 
lenalidomide 2µM  and oestrone 40pg/ml. These combinations were utilised to 
evaluate whether the increased cell mediated cytotoxicity was largely due to IL-
2 or whether the other treatments also has an influence. 
 
The results demonstrated a notable increase in cell mediated cytotoxicity with 
effector cells incubated with IL-2 or with IL-2 combined with lenalidomide and or 
oestrone. This increase in cell mediated cytotoxicity was concluded to be a 
result of the effects of IL-2 rather than lenalidomide or oestrone (Figure 30). 
Notably, in both male and female groups, there was no significant difference in 
the cell mediated cytotoxicity between IL-2 incubated effector cells compared to 
effector cells incubated with IL-2 and lenalidomide or IL-2, lenalidomide and 
oestrone or IL-2 and oestrone, p>0.05 (Figure 30). 
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Figure 30: Cell mediated cytotoxicity of effector cells treated with IL-2 with and 
without lenalidomide, oestrone and combination of the three on G519 target cells 
Actvity of cell mediated cytotoxicity was measured as percentage of dead target cells (+/- SE). 
Effector cells from 3 healthy age matched male and female controls were used in these 
analysis.  
Graph A: Cell mediated cytotoxicity of effector cells from male control subjects  
Graph B: Cell mediated cytotoxicity of effector cells from female control subjects. 
VC-vehicle control DMSO; IL2- interleukin-2; IL2 +est - IL-2 with oestrone; il2+len- IL-2 with 
lenalidomide; il2/est/len- IL-2 + oestrone + lenalidomide. 
 
 
 
4.9. Incubation with either lenalidomide, oestrone or IL-2 had no 
quantitative effects on NK cells, T cells or T regulatory cells 
Quantification of the NK cells, T cells and T regulatory cells was performed on 
the PBMCs from the male (n=4) and female (n=4) controls and male (n=3) and 
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female (n=3) patient groups after 24 hours incubation with control media 
(DMSO), IL-2 (100iu), oestrone (40pg/ml), lenalidomide (2µM) and a 
combination of lenalidomide (1µM) and oestrone (40pg/ml) plus a further 
combination of IL-2, oestrone and lenalidomide. These PBMCs were taken from 
the same solution used in the cell mediated cytotoxicity experiments described 
earlier (Chapter 2 and chapter 4). Due to the limited available numbers of 
PBMCs, only the treatments mentioned above were analysed. There were no 
additional PBMCs available for this analysis with other combination of 
treatments. Analysis was performed to determine whether there was 
proliferation of the immune cells after incubation with the above agents 
compared to untreated effector cells (Figures 31, 32, 33 & 34).   Quantification 
of the cells was performed by flow cytometry as described in the methods 
chapter 2.  
There was no significant change in the numbers of NK cells (CD3-
CD56brightCD16dim and CD3-CD56dimCD16bright), T cells; CD3+CD4+ (T helper 
cells), CD3+CD8+(cytotoxic T cells) and T regulatory cells 
(CD4
+
CD25
+
CD127
dim
) after incubation compared to the untreated effector cells 
(Figures 31 & 32).  
Notably the overall mean number of NK cells in the female MCL patients was 
lower than the male MCL patients in the PBMCs, although this difference was 
not significant, p=0.6 (Figures 31). The numbers in the NK cell subset CD56bright 
CD16dim were small and did not shown significant differences, p>0.05. 
The T cells: T cell subsets (CD3+CD4+ and CD3+CD8+) numbers overall were 
observed to be greater in the female controls compared to the male controls 
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and in the male patients compared to the female patients, however the 
difference was no significant (p>0.05)  (Figure 32 and 34).  
The mean number of T regulatory cells were similar in all groups with marginally 
greater numbers observed in the female groups compared to the male groups 
(p>0.05) (Figure 36). Interestingly, there was a trend towards an increase in 
numbers of the T regulatory cells when incubated with IL-2 or IL-2 in 
combibation with lenalidomide and oestrone in the female controls and male 
and female MCL patients. The male control group did not exhibit a notable 
trend, which could be related to the lower number of T regulatory cells resulting 
in no demonstrable change in numbers (Figure 32).  In additional there was a 
trend toward greater increase in numbers of T regulatory cells demonstrated in 
the female controls after treatment with IL-2 only compared to IL-2 combined 
with lenalidomide and oestrone. No firm conclusions could be drawn from this 
due to the limited numbers and there was no significant difference in the PBMC 
numbers between the two treatments, p>0.05 (Figure 32). Nonetheless, it would 
have been expected that there would be a greater increase in T regulatory 
numbers after incubation with IL-2 in combination with lenalidomide and 
oestrone as both lenalidomide and oestrone enhances the production of IL-2 
from T cells thus in turn simulating the increase in T regulatory cell numbers 
directly and indirectly (Ku et al, 2009; Kotla et al, 2009).   
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Figure 31: Healthy controls: CD3-CD56+ NK cells, CD3-CD56brightCD16dim and CD3-
CD56dimCD16brightNK cell subsets numbers in PBMCs.  
 
PBMCs from 4 male (grey bars - A, C & E) and female (pink bars – B, D & F) healthy 
controls post 24 hours incubation with various treatments as shown. Mean number of 
cells/microliter (+/- SE) are presented.  
(Len – lenalidomide; len + est - lenalidomide and oestrone; len + est + IL2 – 
combination of lenalidomide, oestrone and IL-2). 
 
 
 
Male Controls Female Controls 
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Figure 32: Healthy controls: T cells subsets and T regulatory cells quantification 
in PBMCs. 
PBMCs from 4 male (grey bars - A, C & E) and female (pink bars – B, D & F) healthy 
controls post 24 hour incubation with various treatments used in the cell mediated 
cytotoxicity experiments. Mean number of cells/microliter (+/- SE) are presented.  
 
(Len – lenalidomide: len + est = lenalidomide and oestrone; len + est + IL2 – 
combination of lenalidomide, oestrone and IL-2). 
 
 
Male Controls Female Controls 
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Figure 33:  NK and NK cell subsets quantification in PBMCs of MCL patients after 
incubation.  
 
PBMCs from 3 male (grey patterned bars - A, C & E) and female (pink patterned bars – 
B, D & F) MCL patients post 24 hour incubation with various treatments as shown. 
Mean number of cells/microliter (+/- SE) are presented.  
  
(Len – lenalidomide: len + est = lenalidomide and oestrone; len + est + IL2 – 
combination of lenalidomide, oestrone and IL-2) 
 
Male MCL Patients Female MCL Patients 
189 
 
 
 
Figure 34 : T cell subsets and T regulatory cell quantification in PBMCs from 
MCL patients post incubation 
PBMCs from 3 male (grey patterned bars - A, C & E) and female (pink patterned bars – 
B, D & F) MCL patients post 24hour incubation with various treatments. Mean number 
of cells/microliter (+/- SE) are presented.  
 
(Len – lenalidomide; len + est = lenalidomide and oestrone; len + est + IL2 – 
combination of lenalidomide, oestrone and IL-2). 
Male MCL Patients Female MCL Patients 
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4.10. Effects of IL-2, oestrone and lenalidomide on NK activating 
receptors; NKp46, NKp30, NKp44 and NKG2D on NK cells subsets; CD3-
CD56bright and CD3-CD56dim subsets. 
 
The effector cells from male (n=4) and female (n=4) healthy controls and male 
(n=3) and female (n=3) MCL patients were analysed by flow cytometry to 
assess the expression of NK activating receptors on the NK cell subsets; CD3-
CD56bright cells and CD3-CD56dim cells after incubation for 24 hours with either 
DMSO (control), IL-2 100IU, oestrone 40pg/ml, lenalidomide 2µM, oestrone 
40pg/ml and lenalidomide 2µM and IL-2 100IU, oestrone 40pg/ml and 
lenalidomide 2µM. The expression of the NK activating receptors on the 
cytokine CD3-CD56bright cells and cytotoxic CD3-CD56dim cells was compared to 
the untreated effector cells. 
Overall there was a high baseline expression of the NKp46, NKp30 and NKG2D 
and moderate to low expression of NKp44 compared to the isotype controls on 
both subsets of NK cells.  
No significant difference was found in the expression of all the NK activating 
receptors on the cytokine CD3-CD56bright cells and cytotoxic CD3-CD56dim cells 
between the untreated effector cells and effector cells treated with oestrone, 
lenalidomide or combination of oestrone and lenalidomide (p>0.05) (Figure 39 
to 42). There was no significant difference in the expression of NK activating 
receptors between the genders in either the healthy controls or MCL patients 
(P>0.05). Interestingly, there was a trend towards lower expression of NKp30 
on the cytotoxic NK subset CD3-CD56dim and cytokine NK subset CD3-
CD56bright in female controls, p>0.05 (Figure 35 D and 36 D). This trend was 
also observed in the female MCL patients, but was not as marked (Figure 37D 
and 37D). It is possible that female MCL have greater activation of these 
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receptors as there base line due to the presence of the MCL. Therefore these 
differences are observed between female controls and female MCL patients 
with regards to NKp30 receptor. There is no data on the NK cell receptors 
activation in patients with MCL who have been treated with lenalidomide, but 
other studies in myeloma patients have shown a reduction on NKp30 
expression when the NK cells are exposed to lenalidomide and also in 
combination with dexamethasone (Carter & Wood, 2011). Therefore as 
oestrogens have steroid like properties it is possible that similar effects are seen 
as those in myeloma patients. 
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 Figure 35: The expression of NK activating receptors NKp46, NKp30, NKp44 and 
NKG2D on NK cell subset: cytotoxic CD3-CD56dim from healthy controls 
PBMCs from 4 male (grey graphs A,C,E &G) and female (pink graphs B,D,F & H) 
healthy controls following incubation with either oestrone or lenalidomide or a 
combination of oestrone and lenalidomide (len + est). The results are presented as 
mean MFI +/- SE.  
(len - lenalidomide; len+est - lenalidomide and oestrone) 
Male Controls Female Controls 
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Figure 36: The expression of NK activating receptors NKp46, NKp30, NKp44 and 
NKG2D on NK cell subset: cytokine CD3-CD56bright of healthy controls 
 
PBMCs from 4 male (grey graphs A, C, E &G) and female (pink graphs B, D, F & H) 
healthy controls following incubation with either oestrone or lenalidomide or a 
combination of oestrone and lenalidomide (len + est).  
Expression of NK activating receptors are presented as the mean MFI +/-SE.  
 
(len- lenalidomide; len+est – lenalidomide and oestrone) 
Male Controls Female Controls 
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Figure 37: MCL patients: The expression of NK activating receptors NKp46, 
NKp30, NKp44 and NKG2D on NK cell subset: cytotoxic CD3-CD56dim  
 
Effector cells from 3 male (grey graphs A,C,E &G) and female (pink graphs B,D,F & H) 
MCL patients following incubation with either oestrone or lenalidomide or a combination 
of oestrone and lenalidomide (len + est).  
The expression of the NK cell activating receptors are presented as mean MFI +/- SE.  
(Len – lenalidomide; len+est – lenalidomide and oestrone) 
 
Male MCL Patients Female MCL Patients 
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Figure 38: Expression of NK activating receptors NKp46, NKp30, NKp44 and 
NKG2D on cytokine NK cell subset CD3-CD56bright in MCL patients 
 
Effector cells from 3 male (grey graphs A, C, E &G) and female (pink graphs B, D, F & 
H) MCL patients following incubation with either oestrone or lenalidomide or a 
combination of oestrone and lenalidomide (len + est). 
The expression of the NK cell activating receptors is presented as mean MFI +/- SE.  
(Len – lenalidomide; len+est – lenalidomide and oestrone) 
 
 
Male MCL Patients Female MCL Patients 
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IL-2 effect on NK activating receptors on NK cell subsets:  cytokine CD3-
CD56bright cells. 
 
The expression of NKp46 activating receptor exhibited no significant difference 
when compared to controls, p>0.05 in any of the groups. There was no 
significant difference observed between the genders or in the base line 
expression between healthy controls and MCL patients (Figure 39). 
 
However, the NKp30 activating receptor expression exhibited a significantly 
greater overall expression after incubation with IL-2 in all groups, p=0.04. A 
significant difference was seen in the female patients when comparing 
untreated with IL-2 treated effector cells, *p=0.01. There was a trend towards 
greater base line expression in healthy controls compared to MCL patients 
(Figure 39). 
 
In addition, the NKp44 activating receptor expression exhibited a significantly 
greater overall expression after incubation with IL-2, p=0.002, with the most 
significant difference in the male patients when comparing untreated with IL-2 
treated PBMCs, *p=0.01. There was no significant difference observed in the 
base line expression of NKp44 between healthy controls and MCL patients. No 
significant difference was observed between the genders (Figure 39). 
 
The NKG2D activating receptor expression in male patients exhibited a 
significant increase after IL-2 incubation, *p=0.02. PBMCs treated with IL-2 from 
male healthy controls and female MCL patients did not exhibit a notable 
increase in their NKG2D expression when compared to the control (untreated) 
effector cells. Similarly to the other receptors there was no significant difference 
observed in the base line expression between healthy controls and MCL 
patients (Figure 39). 
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Figure 39: Expression of NK activating receptors NKp46, NKp44, NKp30 and NKG2D 
on cytokine CD3
-
CD56
bright
 NK cell subset compared with control and after 
incubation with IL-2 
 
The expression of NK activating receptors shown above is presented as MFI +/- SE. 
 
(MC-male control group (n=4); MC IL-2- male control group incubated with IL-2 (n=4); FC- 
female control group (n=4) ; FC IL-2- female control group incubated with IL-2 (n=4); MP- 
male patient group (n=3); MP-IL2 male patient group incubated with IL2 (n=3); FP- female 
patient group (n=3); FP-IL2- female patient group incubated with IL2(n=3)). 
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IL-2 effect on NK activating receptors on NK cell subsets:  cytotoxic CD3-
CD56dim cells. 
 
The expression of NKp46 activating receptor exhibited no significant increase 
after IL-2 when compared to controls (P>0.05). No difference was observed 
between the genders in either of the groups.  Nor was there a difference 
exhibited in the base line expression between the healthy controls and MCL 
patients (Figure 40). 
 
Interestingly the NKp30 activating expression exhibited no significant increase 
after IL-2 incubation. However there was a trend towards the patient group 
exhibiting a more notable rise in the expression of the NKp30 after incubation 
with IL-2. There was no significant difference with the expression of NKp30 after 
incubation with IL-2 between male and female healthy controls or MCL patients, 
P>0.05.There was a trend towards greater base line expression of NKp30 
receptor in healthy controls compared to MCL patients (Figure 40). 
  
The expression of NKp44 activating receptor exhibited an overall significantly 
greater expression after incubation with IL-2 compared to the control arm, 
*p=0.01. There was a trend towards the male and female healthy controls 
exhibiting greater expression of NKp44 receptors compared to the male and 
female MCL patients respectively. There was no significant difference with the 
expression of NKp44 after incubation with IL-2 between male and female 
healthy controls or MCL patients, P>0.05). Similarly, there was a trend toward 
greater expression of NKp44 expression in healthy controls compared to MCL 
patients (Figure 40). 
 
Additionally the NKG2D activating receptor expression exhibited a significant 
overall increase in expression after incubation with IL-2 in all four groups, 
p=0.04 and the most significant increase was observed in the male patient 
group, *p=0.04. Again, there was a trend toward greater expression of NKG2D 
expression in healthy controls compared to MCL patients (Figure 40).
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Figure 40: Expression of NK activating receptors NKp46, NKp44, NKp30 and NKG2D on 
cytotoxic CD3
-
CD56
dim
 NK cell subset compared with control and after incubation with IL-
2 
 
The expression of NK activating receptors is  presented as MFI +/- SE. 
(MC-male control group (n=4); MC IL-2- male control group incubated with IL-2 (n=4); FC- 
female control group (n=4) ; FC IL-2- female control group incubated with IL-2 (n=4); MP- male 
patient group (n=3); MP-IL-2 male patient group incubated with IL-2 (n=3); FP- female patient 
group (n=3); FP-IL-2- female patient group incubated with IL2(n=3)) 
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Summary of results 
 
1. Both the male and female healthy controls exhibited a higher mean cytotoxic 
function compared to the respective patient subjects. 
2. The natural cytotoxicity of female health controls was greater than male 
healthy controls as demonstrated on K562 target cells. However on Granta 519 
target cells the cell mediated cytotoxicity was comparable between male and 
female healthy controls. 
3. Incubation with lenalidomide or in combination with oestrone did not result in 
any significant difference in the cytotoxic function or enhancement of 
cytotoxicity in any of the groups.  
4. Oestrone did not significantly affect the cell mediated cytotoxicity of any of 
the groups. However there was a small response seen in male MCL patients 
compared to female and healthy controls. 
4. IL-2 enhanced the cytotoxic function of the effector cells from all subjects, 
except for the effector cells from the female patients with Granta 519 target 
cells.  
5. IL-2 produced a significant increase in the NK activating receptors on both 
subsets of NK cells. NKp46 was unaffected by IL-2 incubation. Lenalidomide, 
and oestrone did not affect the expression of the activating receptors 
7. Incubation of PBMCs with oestrone, lenalidomide or IL-2 and their 
combinations did not increase the quantity of the immune cells.  
8. There were lower number of NK and T cells in the PBMCs of female MCL 
patients compared to male MCL patients. 
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4.11. Discussion 
The function of PBMCs (effector cells) from male and female MCL patients and 
male and female healthy controls was evaluated by measuring their cell 
mediated cytotoxic activity through flow cytometry. The percentage of dead 
target cells was determined and taken as the measure of cell mediated 
cytotoxic activity of the effector cells. Comparisons were then made between 
healthy controls and MCL patients, between female and male MCL patients and 
female and male controls to determine whether there was a significant 
difference in their function.  
4.11.1. Cell mediated cytotoxicity of effector cells from controls was 
superior to MCL patients 
The results demonstrated an overall greater cell mediated cytotoxicity of 
effector cells from healthy controls compared to MCL patients. This trend was 
especially evident with Granta 519 target cells compared to K562 target cells.. 
This is observation could be attributed to K562 cells’ high sensitivity to NK 
mediated cytotoxicity compared to G519 cells which have some expression of 
MHC-class 1 making it less sensitive to NK cell mediated cytotoxicity as 
described previously. These results correlate to other studies as discussed 
below 
Cancer patients exhibiting an inferior immune response has been observed in 
other studies (Kim et al, 2013; Imai et al, 2000; Guven et al, 2003). For 
example, a study reported by Dhodapkar et al, observed reduced cytotoxicity 
activity and reduced IFN-γ production in isolated T cells from blood and bone 
marrow from myeloma patients against autologous myeloma cells. The T cells 
from the myeloma patients were capable of producing adequate IFN-γ in 
response to influenza virus peptide suggesting the lack of response was due to 
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the tumour and its microenvironment. In this study the T cells were stimulated 
with autologous dendritic cells with or without anti-syndecan-1 antibody 
(Syndecans are heparan sulfate proteoglycans (HSPGs) that are involved in cell 
adhesion, tissue morphogenesis, differentiation, and act as low affinity co-
receptors of soluble growth factors) to enhance presentation of MHC class I 
products. In contrast to freshly isolated T cells, these stimulated T cells 
exhibited increase in secretion of IFN-γ in response to autologous tumour 
(Dhodapkar et al, 2002). IFN-γ is secreted by NK cells, NKT cells, CD4+ and 
CD8+ T cells, antigen presenting cells and B cells (Frucht et al, 2001; Lighvani 
et al, 2001). IFN-γ activated macrophages and induces the expression of MHC-
class I, class II and co-stimulatory molecules on APCs (Frucht et al, 2001). 
Therefore they indirectly enhance the killing effects of cytotoxic T cells and 
macrophages against tumour cells. Macrophages are stimulated by IFN-γ and 
result in classically activated macrophage M1 which are perceived as pro-
inflammatory, anti-microbial and anti-tumour (Foey, 2014). Patients with 
follicular lymphoma have also been shown to exhibit reduced immune response 
to cancerous cells. A study reported by Ramsay et al, demonstrated a 
significant reduction of T cell mediated cell cytotoxicity due to T cell dysfunction 
at forming F-actin synapses with cancer cells when compared to cells from 
healthy controls (p<0.01). This observation was thought to be due to the direct 
influence of the tumour cells as it was demonstrated that the T cells from 
healthy subjects exhibited a reduction of T cells synapses after a period of 
incubation with follicular lymphoma cells (Ramsay et al, 2009). There is a 
paucity of data to show the precise cytokines produced by Granta 519 cells. 
However, one of the futures additions to this study is to measure the amount of 
cytokines like IFN-γ and IL-2 secreted by the cells and also examine is Granta 
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519 cells secrete any inhibitory cytokines such as IL-4 (which enhances B cell 
proliferation), IL-13 and chemokines such as CXCL12 and 13 (adhesion 
molecules) by luminex technique which is a technology based on a 4 member 
solid phase sandwich immunoassay. Up to 100 different polystyrene beads, 
each of which possesses unique spectral properties and is coated with analyte-
specific capture antibodies. 
NK cells from healthy controls have been observed to demonstrate better 
function compared to those from patients with acute myeloid leukaemia. A study 
reported by Costella et al, demonstrated a reduction of at least 20-25% in in-
vitro cell mediated cytotoxicity of NK cells from patients with leukaemia 
compared to NK cells from healthy controls. They summarised the observation 
was secondary to lower NK activation receptor expression on the NK cells from 
AML patients (Costello et al, 2011).  
Another recent study has demonstrated patients with Hodgkin’s disease exhibit 
a significantly lower cell mediated cytotoxicity compared to healthy controls due 
to the elevated levels of inhibitory soluble ligands in their serum (MICA/ BAG6) 
(p=0.0001)(Reiners et al, 2013).  
The studies above show that tumours can have significant influence over the 
host’s immune response through differing mechanisms of immune evasion such 
as presence of inhibitory ligands, modification of the tumour microenvironment 
and possibly other more complex mechanisms yet to be fully understood. 
As mentioned above, one of the future directions of this study could be to 
investigate further the role of the MCL microenvironment. In-vivo method to 
grow MCL cells on fibroblast cells to simulate the microenvironment has been 
tried by our research group. This could be used to assess the presence of 
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various cytokines mentioned above and in chapter 1. Additionally, addition of 
various agents such as lenalidomide and osetrogens could be analysed to show 
their effects on the microenvironment. Interestingly IL-15 is which is trans-
presented by macrophages, together with CD40 interactions with TFH cells , may 
contribute to the proliferation of lymphoma cells by activating the STAT5 which 
could be investigated (Scott & Gascoyne, 2014; D Foey, 2015). 
4.11.2. Female healthy controls display greater cell mediated cytotoxicity 
compared to male healthy controls on K562 target cells 
Interestingly the female healthy controls demonstrated an overall greater cell 
mediated cytotoxicity compared to male healthy controls on K562 target cells. 
This observation could be due to lower numbers of cytotoxic T cells and NK 
cells in the PBMCs from male healthy controls when compared to the female 
healthy controls rather than the individual immune cell functionality. However, 
the difference in the cell numbers did not achieve statistical difference (figure 
4.14 & 4.15). Additionally the expression of the activating receptors on the NK 
cells were similar between the male and female healthy controls thus supporting 
the notion that the difference in numbers probably accounted for the results 
observed. 
When Granta 519 were the target cells the trend observed with the K562 target 
cells was not as evident. One of the possible reasons for this is that Granta 519 
cells exhibit some expression of MHC class-1 and are therefore are less 
susceptible to NK cell mediated cytotoxicity (Wang et al, 2013) and although the 
numbers of both T cells and NK cells were higher in female healthy controls 
than male healthy controls the difference in the numbers of T cells was not as 
marked as that of NK cells.  
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One of the limitations presented here was the variation in numbers of NK and T 
cells numbers between the groups. Although the total number of effector cells 
was consistent between the experiments, the number of individual immune cell 
groups which make up the PBMCs could not be verified. Isolation of ‘untouched’ 
NK cells was attempted in this study using Miltenyi MACS separator as per 
manufacturer instructions. However the viability (less than 50%) and quantity of 
the NK cells isolated was poor and could not be utilised in any of the planned 
experiments. This is an area that was planned for further investigation following 
optimisation of the techniques used. In addition to isolation of NK cells, isolation 
of T cells to analyse their function would be interesting. The advantage of 
isolating immune cells is that it would enable the investigation of individual 
immune cell groups. It would also allow more consistent cell numbers to be 
used between the subjects thus enabling better comparison.  
4.11.3. The cell mediated cytotoxicity function of effector cells incubated 
with oestrone, lenalidomide or combination of oestrone and lenalidomide 
demonstrated no significant effect or difference between the genders 
 
As discussed previously a recent study demonstrated female MCL patients had 
a better response to lenalidomide compared to male MCL patients (Eve et al, 
2012). In order to further investigate this observation, cell mediated cytotoxicity 
was evaluated in the presence of lenalidomide and oestrone. The overall trend 
observed with the cell mediated cytotoxicity of effector cells incubated with 
oestrone or lenalidomide or a combination of both, from healthy controls and 
MCL patients was comparable to the results exhibited by the untreated effector 
cells from the respective groups. This suggests that the addition of oestrone or 
lenalidomide did not have any significant effect on the cell mediated cytotoxicity 
of effector cells towards either of the target cells. Furthermore there was no 
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significant difference observed in the cell mediated cytotoxicity when male and 
female MCL patients were compared. A limitation to the assessment of 
oestrone was that the bioactivity of oestrone was not specifically measured. 
This could have been investigated by whethere addition of oestrone lead to 
increased activity of NK cells or T cells. For example measuring degranulation 
of NK cells by analysis of CD107a could indicate its activity on these cells. 
Interestingly, the effector cells incubated with oestrone from the male MCL 
patients demonstrated a trend towards greater cell mediated cytotoxicity 
compared to the female MCL patients at E:T ratio of 50:1 (Figure 4.9), but this 
did not achieve statistical significance. On further analysis of this trend it was 
found that one of the male patients that presented with clinically indolent and 
limited stage disease exhibited a much greater cell mediated cytotoxicity 
compared to the rest of the male patients. This therefore affected the mean 
result due to individual variation. Discounting this result there was no notable 
difference between the male and female MCL patients of effector cells 
incubated with oestrone. Therefore it is not possible to conclude if incubation 
with oestrone influences cell mediated cytotoxicity. Furthermore, oestrone did 
not have any significant influence on the expression of NK activating receptor or 
proliferation of the immune cell subsets after a 24 hour incubation (figure 4.18 to 
4.21). It is possible that the dose used in these experiments was suboptimal as 
oestrone can have a dose dependent effect (Straub, 2007). It is difficult to 
ascertain the exact concentration of oestrogens in the tumour microenvironment 
as there have been no studies published to date to demonstrate concentrations 
within this environment. Additionally the lack of significant effect of oestrone on 
the effector cells could be a result of the relative short incubation time of 24hrs. 
The activity of oestrone on G519 cells could be assessed by Ki67 a marker of 
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proliferation. This can be done by immunofluorescence technique. Studies by 
Yakimchuk et al, have reported reduction in Ki67 on MCL cell lines when 
treated with oestrogen Beta agonist. Additionally they also demonstrated by real 
time PCR decreased B cell activating factor (BAFF), which is a proliferation 
protein in B cell lymphoma (Herman et al, 2011; Scott & Gascoyne, 2014). 
Therefore when compared to control (unstimulated) G519 cells the activity of 
oestrone on G519 cells could be assessed (Yakimchuk et al, 2014, 2011a). 
Lenalidomide is able to modulate the immune system, enhancing anti–tumour 
immune responses via activation and proliferation of NK cells (chapter 1). It 
does not activate the NK cells directly but instead acts by providing potent co-
stimulatory signals to T cells, increasing IL-2 and IFN-γ production (Anderson, 
2005). The results presented here are in contrast to other studies which have 
demonstrated an increase in immune cell activity against cancerous cells after 
treatment with lenalidomide (Richardson et al, 2010; McDaniel et al, 2012; 
Ramsay et al, 2009). A study reported by Richardson et al, demonstrated up to 
a 15-20% increase in cell mediated cytotoxicity of effector cells incubated with 
lenalidomide compared to untreated effector cells (p<0.05). This significantly 
enhanced cell mediated cytotoxicity was thought to be in part secondary to a 
significant increase in NK cells numbers after incubation with lenalidomide 
(Richardson et al, 2010). Another study has demonstrated repair of the 
dysfunctional synapse of T cells from patients with follicular lymphoma after 
incubation of T cells with lenalidomide resulting in restoration of the cell 
mediated cytotoxicity (Ramsay et al, 2009). A further study reported by Davies, 
et al, also demonstrated enhanced activation of T cells and NK cells when 
treated with lenalidomide. This again was not a direct effect on the immune cells 
but secondary to an increase in IL-2 and IFN-γ resulting in the improved 
208 
 
function of NK cells and T cells (Davies et al, 2001). They suggested that in 
patients who responded to lenalidomide had increased levels of IL-2 and IFN-γ 
in the serum resulting in increased number of NK cells and enhancement of 
their activity. It was also suggested that the increase in the IL-2 and IFN-γ was 
due to the direct effect of lenalidomide and thalidomide on T cells (Davies et al, 
2001). To date there is no precise data on lenalidomide’s effect on other cells 
such as macrophages and NK T cells. However it effect on the 
microenvironment as discussed in chapter 1 would lead to the assumption that 
other cells such as the macrophages could also be implicated in its actions. 
Lenalidomide has an inhibitory effect on pro-inflammatory cytokines and it is 
therefore no unreasonable to assume that M1 macrophages which are pro-
inflammatory could have a protective function on MCL and thus may be 
augmented by lenalidomide. This is an area that would need further research 
and as mentioned before MCL cells grown in-vitro on fibroblast to stimulate the 
microenvironment could be a good platform to do these initial studies. One of 
the limitations of this study was that IL-2 and IFN-γ was not done at the time. 
This was in the planning for the next phase of the experiments but due to 
limitations of patient material it was difficult to do it in this context. Furthermore 
a better plateform to perform this assay would be in the MCL simulation of the 
microenvironment by growing MCL on fibroblast beds or stromal cell beds.  
The results presented here are in contrast to other studies probably due to the 
shorter time effector cells were incubated with lenalidomide and differences in 
the dose used (Hayashi et al, 2005b; Richardson et al, 2010; Chanan-Khan & 
Cheson, 2008). The results also demonstrated no significant increase in the 
number of immune cell subsets after incubation with lenalidomide or its 
combination with oestrone. This again was in contrast to other studies which 
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have reported increase in the immune cells numbers after incubation with 
lenalidomide (Richardson et al, 2010; Chanan-Khan et al, 2006). Again this 
could be a reflection of the dose and incubation times used in these other 
studies. Hence, these results suggest a lack of immunomodulation effect by 
lenalidomide on its own or when combined with oestrone within the time frame 
of the incubation period. It should be noted that we selected this dose based on 
the likely physiological dose achieved in vivo. 
To date there have been no other studies to evaluate the better response rate 
of female MCL patients to lenalidomide compared to male MCL patients. In 
order to fully investigate this observation these experiments would need to be 
repeated with longer incubation times of at least 72 hours and possibly higher 
concentrations (possibly doubling the concentrations) of lenalidomide and 
oestrone. The rationale for this period is based on the clinical observation where 
the effects or benefits of the treatments are not seen for at least 5 days on 
treatment with lenalidomide. This could be a cumulative effect and periodic 
experiments may aid to describe this observation. 
4.11.4. IL-2 enhanced cell mediated cytotoxicity 
 
IL-2 plays a pivotal role in the immune response. It mediates T cell growth and 
proliferation, promotes cytotoxic T cells and NK cell (LAK cells) cytolytic activity 
which is essential for activation-induced cell death. It modulates naïve CD4+ T 
cell differentiation to T helper 1 and 2 cells. It also influences the development 
and maintenance of T regulatory cells (Liao et al, 2013). Therefore as expected, 
incubation with IL-2 demonstrated increased cell mediated cytotoxicity function 
in both control and patient groups. These results correlate to other studies in 
which IL-2 demonstrated an increased activation and function of the immune 
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cells against cancerous cells (Higuchi et al, 1989; Grimm et al, 1982; Gottlieb et 
al, 1990). Incubation of effector cells with IL-2 resulted in NK cells exhibiting an 
increase in the expression of the NK activating receptors which in turn may 
imply that the NK cells were better primed to carry out the cell mediated 
cytotoxicity (section 4.10) (Hudspeth et al, 2013). Interestingly, there was no 
significant increase in the number of immune cell subsets after incubation with 
IL-2 when compared to the untreated effector cells (figure 4.14 to 4.17). This is 
probably accounted for by the relative short incubation time as discussed 
above. 
The positive effects of IL-2 on immune cell function have been demonstrated in 
other malignancies such as renal cancers, melanoma and lymphomas 
(Coventry & Ashdown, 2012; Rosenberg, 2014; Liao et al, 2013; Hombach et al, 
2005; Foa et al, 1991).  A study reported by Foa et al, demonstrated a 
functional increase of immune cells from a basal level of 12% to 42% (p<0.005) 
after incubation with IL-2 (Foa et al, 1991). Another study in with B cell 
lymphomas including mantle cell lymphoma, demonstrated a significant rise in 
NK cell activity (up to 60% increase in cell mediated cytotoxicity) following IL-2 
administration. This study reported the rise in activity correlated in part to the 
expansion of the NK cells  numbers after IL-2 treatment (Gluck et al, 2004). 
Although there was an increase in cell mediated cytotoxicity of IL-2 incubated 
effector cells from MCL patients, their cell mediated cytotoxicity activity was still 
lower than the healthy controls. This observation suggests impaired function of 
the immune cells from patients with MCL which may be due to the MCL. A study 
reported by Wang et al, similarly demonstrates reduced function of the effector 
cells from MCL patients. They demonstrated that cytotoxic T cells in MCL was 
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significantly inhibited by the inhibitory effects of the lymphoma related ligand 
B7-H1 (Wang et al, 2013a). This suggests that cancerous cells can evade the 
immune system by inhibiting the activation of the immune cells despite the 
presence of indigenous IL-2.  
Another possible reason for the lower cytotoxicity function of effector cells from 
MCL patients could be that these effector cells possess a lower base line 
activity. Therefore despite exhibiting an increase in the cytotoxicity function from 
their base line function they are unable to mount a similar response to that of 
healthy effector cells. This could be a result of ineffective release of cytolytic 
granules as demonstrated in a study reported by Danielou-Lazareth et al 
(Danielou-Lazareth et al, 2013), where although they demonstrated an increase 
of the cytotoxicity after IL-2 therapy, the extent of increase was approximately 
15-20% less than that of healthy controls, similar to the results presented here.  
Interestingly the effector cells from female MCL patients did not exhibit a 
significant increase in the cell mediated cytotoxicity after incubation with IL-2 as 
seen with the effector cells from male MCL patients (section 4.4). Further 
evaluation of this result suggested that this trend could be accounted for by the 
greater number of NK cells and T cells quantified in the effector cells of the 
male patients compared to the female patients (figure 4.14 to 4.17). 
Interestingly the NK cells from male MCL patients exhibited a greater and more 
significant rise in the expression of the activating NK cell receptor NKG2D after 
incubation with IL-2 (figure 4.18 and 4.19). This could also support the greater 
cell mediated cytotoxicity observed in male MCL patients compared to the 
female MCL patients. As discussed previously, further analysis of the results 
revealed unexpectedly greater cytotoxicity function in one of the male MCL 
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patients compared to the rest. This male patient exhibited a clinically indolent 
MCL compared to the rest of the male MCL patients which may also account for 
this discrepancy. It is also possible that the cohort of female MCL patients 
investigated here presented with clinically aggressive MCL. This could have 
resulted in them possessing functionally impaired immune cells as previously 
discussed (Danielou-Lazareth et al, 2013).  However, this trend observed in the 
female MCL patients needs to be further investigated to determine if it is 
consistent when greater numbers of MCL patients are investigated. 
One of the main limitations of this study is the small number of participants. As 
mentioned above individual variations in cell function and numbers can 
significantly impact on the overall mean result. More participants would be 
valuable to evaluate some of the trends that have been observed. This will allow 
for individual variations and for more robust statistical analysis.  
It would be interesting to measure the cytokine levels of IL-2 and TNF-α in the 
supernatant of the culture media by enzyme linked immunosorbent assay 
(Davies et al, 2001). This could provide further information to determine if 
effector cells from female MCL patients produce greater quantities of these 
cytokines compared to male MCL patients.     
In addition identification of ligands in the serum of patients would be interesting 
to investigate. This may be possible using methods which involve flow 
cytometry. The level of ligands such as B7-H1, MICA and MICB would perhaps 
enable us to identify inhibitory effects of ligands from MCL cells on the function 
of the T and NK cells.  
Although oestrone is the most abundant female hormone in postmenopausal 
women, there is still presence of other oestrogens. These oestrogens may have 
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different immunomodulatory effects on the tumour microenvironment which may 
help to explain the gender difference in the incidence of MCL. The cell mediated 
cytotoxicity experiments could be evaluated with other female hormones such 
as oestradiol or oestriol to determine if they have a significant effect. In addition 
the research group were in the process of obtaining patient serum for analysis 
of various cytokines and hormones and this was about to get ethical approval 
which would have been a good additional anaylsis to supplement these work. 
The function of immune cells in the peripheral blood could be different to that of 
the cells present in the tumour microenvironment such as in an affected lymph 
node. Evaluation of immune cells after fine needle aspiration of affected lymph 
nodes would be interesting to analyse. Firstly to examine their cell mediated 
cytotoxicity compared to the immune cells from the peripheral blood and 
secondly to ascertain if there is a gender difference. 
Clinically indolent MCL in now an increasingly recognised subgroup of MCL (Hsi 
& Martin, 2014). The patients included in this thesis exhibited both clinically 
aggressive and indolent MCL. In chapter 3 we presented data which exhibited 
greater number of immune cells in the circulation of patients with clinically 
indolent MCL. Unfortunately due to the limited numbers we could not compare 
the gender difference between the two clinical subtypes. Furthermore patients 
with clinically indolent MCL can be monitored for an extended period of time 
without the need to commence treatment and these patients do not exhibit any 
evidence of disease progression during this monitoring phase. This suggests 
that the immune system holds in ‘check’ the cancer according to the 
immunoediting principle (Gross et al, 2013). This is an area that would be 
interesting to study further and investigate whether there is a difference in 
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function of the immune cells between the two subtypes of MCL and at the same 
time between the genders in each of the subtypes of MCL. A national 
observational study in MCL that is going to collect clinical data and obtain blood 
and tissue samples for a research Biobank is due to be launched by the 
haematology research group here in Plymouth. This would provide a vital 
source of participants and material to enable further studies as described 
above.   
4.12. Conclusion 
 
Healthy controls exhibited greater cell mediated cytotoxicity compared to the 
MCL patients. 
Incubation with IL-2 enhanced the cell mediated cytotoxicity of the effector cells 
in both healthy controls and male MCL patients. It also enhanced the 
expression of NK cell activating receptors; NKp44, NKp30 and NKG2D in all 
groups. 
There was no significant effect of lenalidomide, oestrone and their combination 
on the cell mediated cytotoxicity of effector cells to result in a meaningful 
difference between the genders or when compared to untreated effector cells. 
In addition there was no increase in immune cell numbers or expression of the 
NK activating receptors when PBMCs were incubated with lenalidomide, 
oestrone or the combination of lenalidomide and oestrone.  
These results do not exhibit a significant difference in the cell mediated 
cytotoxicity of effector cells from male and female MCL patients. 
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Chapter 5 
 
 
 
Results 
 
 
 
 
 
Enumeration of NK, T and T regulatory cells in the lymph node biopsies of 
patients with Mantle Cell Lymphoma and identification of oestrogen 
receptors α and β on MCL cells in the lymph node biopsies of patients and 
in Granta 519 cell line 
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5.0. Background  
Lymph nodes are vital to the immune system. They comprise of most subtypes 
of immune cells which have greater presence in certain areas of the lymph 
nodes. The B cells are mainly located in the cortex and are arranged into 
follicles in the lymph nodes. The T and NK cells are located in the paracortex 
area and around the parafollicular and inter follicular areas (Willard-Mack, 
2006)(Figure 41 and 42).  
 
Figure 41: Diagrammatic representation of a normal lymph node 
The cortex is mainly composed of B cells arranged in follicles which develop a central 
germinal centre when B cells are activated. The Paracortex mainly consists of T cells 
and other immune cells such as the NK cells and macrophages. The medulla contains 
medullary sinuses, plasma cells, memory B-cells, some T-cells, and histiocytes. 
Adapted from pathpedia.com 
NK cells location 
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Figure 42 A & B: Lymph node structure from normal healthy control 
Figure A; Haematoxylin and eoisin (H&E) stain of lymph node from a healthy control 
(magnification x 100).  Demonstrating follicles in the cortex of the node and to the left of 
these is the paracortex which is rich in T cells. 
Figure  B exhibiting the follicles largely composed of B cells (white arrows), surrounded 
by para follicular T cells with CD3+ (red) cytoplasmic staining by immunofluorescence 
(magnification x 100). Right of the follicles exhibit the paracortex area which have no 
follicles in that area. 
A 
B 
Paracortex 
Paracortex 
cortex 
cortex 
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Lymph nodes harbour approximately 40% of all the lymphocytes and there are 
a greater number of T and NK cells within the lymph nodes compared to the 
peripheral blood. These lymphocytes ‘home’ to the lymph nodes and 
subsequently migrate to their selected compartments within the lymph node. 
Movement of the immune cells into the lymph nodes is mediated by series of 
chemokine gradients, which facilitate the specific recruitment of select immune 
cells based on their chemokine receptor expression. B cells ‘home’ to the lymph 
node by the coordinated expression of integrins (leukocyte function-associated 
molecule – LFA) and adhesion molecules such as the vascular cell adhesion 
molecule (VCAM-1), as well as chemokines (CCL19 and CCL21) on the 
endothelial cells of the high endothelial venules (HEVs) (Von Andrian & 
Mempel, 2003).   The expression of cell adhesion molecules such as P-selectin 
and E-selectin also assist in the movement of immune cells into the lymph 
node. Movement of the B cells between zones of the lymph nodes is achieved 
via the expression of CXC chemokine receptor 4 (CXCR4) or CXCR5 on the B 
cells and the increase of their respective ligands CXCL12 and CXCL13(Von 
Andrian & Mempel, 2003; Mueller & Germain, 2009) .  The migration of other 
immune cells such as T cells, NK cells and macrophages into the lymph node is 
via a similar mechanisms of that described in the B cells above. These cells 
have homing receptors and in the T cells these are VCAM-1 integrin receptors, 
the NK cells express intercellular adhesion molecule (ICAM – 1,2) and VCAM-1, 
and macrophages have similar expression to that of NK cells (Delves et al, 
2011). In addition naïve lymphocytes and dendritic cells, express the CCR7 
chemokine receptor and are therefore also directed into the peripheral lymph 
nodes due to the HEVs expressing chemokines CCL19 and CCL21 on their 
luminal surface (Von Andrian & Mempel, 2003).  Large number of dendritic cells 
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are also transported to the affected lymph node which in turn encourages 
immune cells to migrate into the lymph node as they release the chemokines to 
facilitate this (Girard et al, 2012). 
The B cells proliferate within the follicles of the lymph node when activated by 
antigens presented to them. The T cells and T regulatory cells proliferate after 
they encounter their antigens presented by the dendritic cells. Upon stimulation 
the T cells secrete IL-2 which in turn stimulates the NK cells that are amongst 
the T cells in the lymph nodes. This interaction bridges the innate and adaptive 
immune systems and switches on the cytolytic activity of the NK cells and T 
cells to eliminate the diseased or cancerous cell (Ferlazzo et al, 2004; Fehniger 
et al, 2003; Willard-Mack, 2006).  As discussed in the previous chapter 3, the 
results have demonstrated that females have lower number of T cells and NK 
subset CD3-CD56dim cells in the peripheral blood and we hypothesised that 
females with MCL could possess a higher number of immune cells within the 
lymph node compared to the male patient with MCL. This may in part explain 
why prognosis is better in females as they may have more cytotoxic cells at the 
site of lymphoma and within the tumour microenvironment. This may enable the 
female MCL patients to mount a greater immune response due to the increased 
numbers to eliminate tumour cells. 
5.0.a. Oestrogen can influence prevalence of cancer 
An epidemiological study reported by Nelson et al, has demonstrated that in 
women who have used oral contraceptives had a significantly lower risk of 
intermediate or high grade lymphoma when compared to women who had never 
used these compounds. The increased oestrogen levels was thought to be the 
reason for this observation. Additionally, this study also demonstrated that 
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postmenopausal women were at a greater risk than premenopausal women of 
developing NHL (Nelson et al, 2001). Further epidemiological studies have 
corroborated these findings in lymphoma where a significant risk reduction in 
women treated with hormone replacement therapy or oral contraceptives was 
observed (Lee et al, 2008a). 
These epidemiological studies have also been supported by observations 
reported by Yakimchuk et al, who demonstrated that T cell lymphomas grew 
faster in male versus female mice. The female protection was abolished by 
ovariectomy, implying that female hormones are involved in the protection. This 
was further confirmed when proliferation of these tumours was markedly 
reduced when mice were treated with an oestrogen receptor agonist 
(Yakimchuk et al, 2011a).  
As previously discussed in chapter 1, section 1.3, the effects of oestrogen is via 
the two oestrogen receptors ERα and β. They have opposite effects with the 
ERα eliciting a proliferative and the ERβ exerting an apoptotic and anti-
proliferative effect on certain cells when stimulated (Gruber et al, 2002).  
Recently the expression of ERs in immune cells have been described 
(Yakimchuk et al, 2013). CD4+ T cells have been shown to exhibit a much 
higher level of ERα compared to CD8+ T cells which exhibit both ERα and ERβ 
equally but at much lower expression levels (Phiel et al, 2005). However, there 
is limited data on the expression of ER on T regulatory cells. The  ERβ is 
primarily expressed on the B cells lymphocytes (Shim et al, 2006). The 
expression of ERs, have been described on other immune cells. Monocytes and 
NK cells express more ERβ (Komi & Lassila, 2000) and macrophages tend to 
express more ERα (Mor et al, 2003).  The effects of oestrogens on these cells 
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vary according to the more abundant ER on the cell type. Oestrogens have 
been known to affect the immune cells response (Straub, 2007). Oestrogens 
also affect the lymphopoiesis and also exert suppressive effects on T and B 
cells (Yakimchuk et al, 2013). Oestrogens have been shown to cause thymic 
involution negatively affecting both the CD4/CD8 populations (Straub, 2007). 
Furthermore the effects of oestrogen on the innate immune cells such as 
neutrophils, NK cells have been shown to increase their activity which probably 
relates to the difference found in the innate immune reactivity between males 
and females  (Pennell et al, 2012). Other studies have demonstrated ERβ 
expression in Burkitt cell lines and PBMCs from CLL patients. These studies 
have observed activation of the ERβ receptor by an agonist, DPN had an 
inhibitory effect on the tumour survival (Yakimchuk et al, 2012a, 2011a). The 
expression of ERβ on lymphoid malignancies is not surprising as it has been 
demonstrated that there is high expression of ERβ on normal B cells  and in 
particular, in the B cells in the mantle zone of the lymph node follicle (Phiel et al, 
2005). Therefore the expression of ERβ on MCL was investigated. 
 
 
The aims of this chapter were to: 
1. Determine if the numbers and/ or distribution of the NK, T and T regulatory 
cells in the lymph node biopsies differ between male and female patients with 
MCL. 
 
2. Investigate the expression of oestrogen receptor α and β on Granta 519 MCL 
line and MCL in lymph node biopsies from male and female patients. 
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Statistical analysis 
The results of the enumeration of the NK cells (CD3-CD56+), T cells (CD3+) and 
T regulatory cells (CD3+ FoxP3+) were analysed on GraphPad Prism version 
6.0. The results were presented at the mean with +/- standard error of the mean 
(SEM). Non-parametric analysis was performed using Mann-Whitney U testing 
when comparing two groups, i.e. female MCL patients versus male MCL 
patients. 
5.1. Distribution of MCL depicted by CD20 and Cyclin D1 in the lymph 
node 
 
Using immunofluorescence microscopy six lymph node biopsies from 3 male 
and 3 female patients with MCL (patient characteristics shown in chapter 2) and 
one control were examined for the presence of MCL cells (defined as CD20+ 
with nuclear cyclinD1+); NK cells (defined as CD3- CD56+); T cells (defined as 
CD3+) and T regulatory cells (defined as CD3+ with nuclear Foxp3+).The results 
demonstrated a diffuse infiltration of mantle cell lymphoma cells (CD20+ cyclin 
D1+) in all of the 6 biopsies from the MCL patients. There was no normal lymph 
node architecture present in any of the biopsies examined (Figure 43). 
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 Lymph node from healthy control  Lymph node from patient with MCL 
 
Figure 43: Panel A and B illustrating the distribution of B cells and MCL cells 
A. Immunofluorescence demonstrating distribution of B cells in a normal lymph node 
from a healthy control. Arrow shows the CD20 (green) B-cells mainly distributed within 
the lymph node follicle. There was no nuclear staining present in this particular biopsy 
to exhibit cyclin D1 presence (magnification x200). 
B. Immunofluorescence with CD20 (green) and cyclin D1 (red) on a lymph node biopsy 
section of a male patient with MCL. CD20 is represented by surface staining of the 
CD20 (green) and Cyclin D1 (red) is represented by nuclear staining. The majority of 
the cells were CD20+ and Cyclin D1+ (MCL cells) demonstrating the loss of normal 
architecture of the lymph node by diffuse infiltration of the MCL cells. This figure is 
representative of all 6 biopsies from MCL patients (magnification x200). 
 
 
 
5.2. Distribution of NK, T and T regulatory cells in the lymph node biopsy 
of male and female patients with MCL 
 
In the normal lymph node the distribution of NK, T and T regulatory cells was 
found to be largely around the follicle. There were a few T cells and T regulatory 
cells scattered within the B cell follicle as illustrated by Figure 44 below.  
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Figure 44: Distribution of NK cells, T cells and T regulatory cells within the lymph node 
from a healthy control (Magnification x200 unless otherwise stated)  
Cells of interest are shown with the white arrow. Panel A & B: Representative images from 
sections stained with CD3 (red) and CD56 (green). Panel C & D: Representative images from 
sections stained with CD3 (red) and Foxp3 (nuclear green). Panel E is H&E stain depicting 
CD20 B cells distribution (brown)(magnification x100). 
T cells (CD3
+
) are shown by the red surface staining and are largely distributed around the 
follicle with some scattered cells within the follicle as shown in panel A, B and D. 
NK cells (CD3
-
CD56
+
) are shown by the green surface staining amongst the T cells and 
scattered around the follicle as shown by panel A and B (arrows). 
T regulatory cells (CD3
+
Foxp3
+
) are demonstrated by the red surface and green nuclear 
immunofluorescence staining for CD3
+
 and Foxp3
+
 respectively (arrows). These cells are 
amongst the T cells parafollicular regions and occasionally within the follicle as shown in panel 
C and D. Panel D is an enlargement (magnification x400) of a section of Panel C demonstrating 
the surface staining of CD3
+
(red) and nuclear staining of Foxp3
+
 (green) as highlighted by the 
arrows. 
Follicle
e 
Follicle 
Follicle 
E 
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All 6 lymph nodes from MCL patients examined demonstrated a complete loss 
of normal lymph node architecture due to the diffuse infiltration by MCL cells as 
shown in the below figure 49. This resulted in the NK, T and T regulatory cells 
scattered through the lymph node with loss of their normal pattern of distribution 
(Figure 44)  
 
Figure 45: Distribution of the NK, T and T regulatory cells within the lymph node from a 
patient with MCL (magnification x200) 
Cells of interest are shown with the white arrow. Panel A & B: Representative images from 
sections stained with CD3 (red) and CD56 (green). Panel C & D: Representative images from 
sections stained with CD3 (red) and Foxp3 (nuclear green). 
T Cells (CD3
+
) are demonstrated in red and are seen scattered throughout the lymph node 
specimen in panel A (arrows). 
NK cells (CD3
-
CD56
+
) are shown in green amongst the T cells (red) and scattered throughout 
the lymph node panel B (arrows). 
T regulatory cells (CD3
+
Foxp3
+
) are demonstrated by the red surface and green nuclear for 
CD3
+
 and Foxp3
+
 respectively. These cells are amongst the T cells (CD3
+
 Foxp3
-
) as shown in 
panel C and D (arrows). Panel C and D are lymph nodes biopsy from male and female MCL 
patient respectively. Due to the limited lymph node tissue available dual staining with CD20 was 
not done. However majority of the unstained cells were CD20 B cells surrounding the NK, T or T 
regulatory cells shown above and as demonstrated in figure 43 B. 
All six biopsies had a similar presentation as represented here. 
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5.3. The enumeration of NK, T and T regulatory cells within the lymph 
node of male and female patients with MCL 
 
To determine if there was a difference in the numbers of immune cells in the 
lymph nodes of male and female MCL patients the quantification of the NK, T 
and T regulatory cells in male (n=3) and female patients (n=3) with MCL was 
performed on images taken from 13 randomly chosen sites from within each 
biopsy section at x200 magnification. Quantification was performed using the 
Leica LAS AF software. 
The total number of NK and T cells were lower in both the male and female 
patient samples, when compared to the control lymph node (n=1; figure 50). 
However, there was a trend towards higher numbers of T cells in the female 
patients when compared to the male patients, although this did not reach 
statistical significance (Figure 46 A & D). The total number of T cells (CD3+) 
from all 3 lymph node samples in female patients was 5032 cells compared with 
3322 cells in the male patients in 13 random fields of view per specimen at a 
magnification of x100. One male patient was observed to have a greater 
number of T cells in the lymph node compared to the rest of the male patients 
(Figure 50 D). On further analysis this patient at diagnosis presented with a 
clinically aggressive behaving MCL. However, his history was suggestive of a 
more indolent course where by the patient noticed an enlarged lymph node in 
his axilla for greater than 12 months preceding his presentation at diagnosis. 
This may explain his higher T cell count as the history is suggestive of an 
indolent initial course. 
Male patients exhibited a reduced number of T regulatory cells when compared 
to the control. Although the difference between males and females did not differ 
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significantly, the female patients had comparable numbers of T regulatory cells 
to the control subject (Figure 46C). 
Overall, the results appeared to suggest that within this cohort of patients, there 
are a greater number of immune cells in the lymph nodes of female patients 
when compared to the male patients.  
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Figure 46: Comparison of the immune cells subsets numbers in the lymph nodes 
 
A. Represents the mean number of T cells in the lymph node of male (1107 cells +/- 
505) and female (1677 cells +/- 209) MCL patients and control subject (5548 
cells).Female exhibit a higher number of T cells in the lymph nodes compared to the 
male MCL patients (p=0.70). 
B. Represents the mean number of NK cells in the lymph node of male (14 cells +/-
4.06) and female (16 cells +/- 4.93) MCL patients and control subject (100 cells) 
(p=0.80). 
C. Represents the mean number of T regulatory cells in the lymph node of male (88 
cells +/- 34.9) and female (141 cells +/- 25.1) and control subject (136 cells). Females 
tend to exhibit higher numbers of T regulatory cells compared to the male MCL patients 
(p=0.40). 
D. Table to present the individual total mean number of immune cells per lymph node 
between male and female MCL patients. Female patients exhibit a consistently higher 
T cells and T regulatory cell count compared to the male MCL patients. 
(male (n=3), and female (n=3) MCL patients and a control (n=1)). 
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5.4. The presence of oestrogen receptor β on mantle cell lymphoma and 
Granta 519 cell line 
 
Identification of ERα and ERβ was undertaken by immunohistochemistry 
method as described in chapter 2. The lymph node biopsies from 3 female and 
3 male MCL patients undergoing routine diagnostic biopsies were utilised for 
analysis. The expression in the MCL cell line, Granta 519 target cells used 
through this study were also assessed. One male nodal biopsy was excluded 
due to a technical error during the staining process. Due to the limited lymph 
node material avialable additional slides could not be made.  
A neuronal tissue from neuroblastoma was the positive control that was utilised 
to confirm that the ERα antibody was working under these IHC conditions (Cao 
et al, 2015)(Figure 47 A). Using the same conditions it was demonstrated that 
the ERα was absent from both the Granta 519 cells and mantle cell lymphoma 
cells in all the lymph node biopsies examined here (Figure 47 B & C 
respectively).   
A histological section of an ovarian cancer biopsy was utilised to confirm that 
the ERβ antibody was working under these IHC conditions (Figure 48 A and B). 
In contrast to the ERα receptor expression, ERβ was expressed on both the 
Granta 519 (Figure 48 C &D) and on MCL cells (Figure 48 E, F) of all the lymph 
nodes examined. There was marginally less ERβ staining on the lymph node 
biopsy compared to the Granta 519 cells probably due to the other immune 
cells amongst the MCL cells not taking up the antibody.  
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Figure 47: ERα in Granta 519 cells and MCL cells in lymph node biopsy 
A. Neuronal tissue used as a positive control to demonstrate the ERα presence. ERα 
was demonstrated by the brown nuclear staining pattern on the control tissue (panel A) 
(x 200 magnification). 
B. No positive staining with ERα antibody was present on Granta 519 cells. This 
represents the lack of ERα expression on Granta G519 cells (panel B) (x 200 
magnification). 
C. No positive staining with ERα was present on the MCL cells in the lymph node 
biopsies of 5 MCL patients (males n=2 and female n=3). This represents the lack of 
ERα receptor on the MCL cells present in these biopsies. (Panel C is representative of 
all five lymph node biopsies)(panel C) (x 200 magnification). 
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Figure 48: ERβ expression on Granta G519 cells and MCL cells 
A. Negative control achieved by having no ERβ antibody present for staining on 
ovarian cancer biopsy (magnification x 200). 
B. Positive control achieved by ERβ antibody on ovarian cancer biopsy depicted by the 
brown nuclear staining (magnification x 200). 
C & D. Brown nuclear staining of the Granta 519 cells representing positive expression 
of nuclear ERβ expression on these cells (red arrows) (magnification x 200). 
E & F. Lymph node sample from male and female patient with diffuse infiltration of 
MCL exhibiting positive staining for ERβ by exhibiting brown nuclear staining (E. 
magnification x 100 and F. magnification x 200), 5 MCL nodes (3 female and 2 males) 
all stained positive for ERβ with no significant difference in the distribution of ERβ. 
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Summary of results 
 
1. There was a trend towards female MCL patients exhibiting greater number of 
immune cells compared to male MCL patient.  
 
2. Oestrogen receptor β was predominately expressed on MCL cells in both 
male and female patient samples and Granta 519 cells. 
 
5.5. Discussion 
 
Lymph nodes of patients with MCL were examined to establish whether B-cell 
and T-cell populations within the lymph nodes differed in males and females. 
The patients evaluated were from a homogeneous group all presenting with 
clinically aggressive MCL (defined as patients presenting with B-symptoms and 
requiring immediate treatment without any period of observation). It was found 
that all the lymph node biopsies exhibited a diffuse pattern of infiltration by MCL 
characterised by a loss of the normal lymph node architecture. The normal 
architecture whereby the follicle of the lymph node typically consists of mainly B 
cells and the parafollicular and interfollicular areas consist of mainly T cells and 
NK cells was lost in the lymph nodes from these MCL patients. This loss of 
architecture correlates to the typical loss of normal architecture described in the 
histology of lymphomas (Feller & Diebold, 2004). Therefore it is not surprising 
that due to the diffuse infiltration of MCL within the lymph nodes that were 
examined, lower numbers of all the immune cells were present compared to the 
control lymph nodes The immune cells were ‘scattered’ amongst the MCL cells 
without any formal structure. In addition there is no specific description of 
immunoglobulin production by MCL. In other B cell malignancies like CLL, it has 
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been described reduced production of immunoglobulins, but in mantle cell 
lymphoma there has been no precise description of this however it has been 
described that although there is production of immunoglobulins in some cases 
their function is impaired (Kuppers, 2005; Gribben, 2010) 
Interestingly the general trend was for the female MCL patients to exhibit a 
greater number of NK, T and T regulatory cells in the lymph nodes when 
compared to the male MCL patients. However, this did not achieve statistical 
significance which may be accounted for in part by the limited number of 
samples and patients examined.  
 
T cells  
The results presented in chapter 3 demonstrated that the female patients had 
significantly lower numbers of T cells in the peripheral circulation compared to 
the male patients. It was speculated that this observation could be due to higher 
number of T cells infiltrating the lymph node to kill MCL cells in females, who 
typically have better overall survival and response to therapy. Greater numbers 
of T cells were indeed observed in the lymph nodes of female patients when 
compared to male patients, although this did not reach significance. These 
trends observed here suggest that in context of the tumour microenvironment 
female MCL patients may elicit a greater immune response compared to male 
MCL patients due to the greater number of relevant potentially tumour targeting 
immune cells present within their lymph nodes (Gajewski et al, 2013). Other 
studies support this suggestion. For example, a recent study by Nygren et al, 
demonstrated higher numbers of CD4+ & CD8+ T cells in the lymph node of 
patients with MCL was associated with a more favourable outcome and patients 
with an indolent behaving MCL were observed to have a greater number of T 
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cells in their lymph nodes. Notably, the results presented here agree with their 
observation that female patients exhibited significantly greater number of T cells 
(CD3+) in the lymph nodes compared to the male patients (p=0.009)(Nygren et 
al, 2014). As has already been discussed this disease is more prevalent in men 
when compared to women and those women who do get MCL, frequently have 
a more indolent form of the disease. An alternative explanation for the higher 
number of immune cells within the lymph node could be that the female patients 
have a reduced tumour burden compared to male patients and so preserve 
more of the normal architecture of the lymph node. In turn, this may be related 
to the females when compared to males being able to mount a better immune 
response and eliminate more cancerous cells within the immediate vicinity of 
the immune cells stopping MCL spread. However, the lymph nodes examined 
here from 3 male and female MCL patients did not have a distinct difference in 
the pattern of infiltration of MCL cells on any of the nodes form either gender. 
They all exhibited a diffuse infiltration of MCL cells with a complete loss of 
architecture. It would require a larger number of patients and lymph node biopsy 
to achieve any formal conclusions. Additionally, it could also be secondary to 
females being able to eliminate MCL cells more effectively in the periphery 
again preventing the spread of MCL. Additionally, the effects of oestrogen in the 
female environment may further inhibit the cancerous cells directly via the ER or 
indirectly through stimulating the immune cells. The exact mechanism by which 
females may be able to eliminate cancerous cells more effectively is not yet 
identified but one of the methods to investigate whether females have more 
effective immune cells in the lymph nodes or peripheral blood is to isolate the 
immune cells from each compartment by B cell depletion to leave predominately 
T and NK cells and then compare the difference in cell mediated cytotoxicity of 
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the immune cells from the lymph nodes and peripheral blood and from male and 
female MCL patients. Extraction of cells from the lymph nodes can be achieved 
by either fine needle aspiration of cells or excision of the whole node followed 
by extraction of cells by needle aspiration (Lotze & Thomson, 2005). Once the 
cells have been extracted similar techniques as described above can be utilized 
to assess the activity of these immune cells. The control lymph nodes studied in 
Nygren et al, also demonstrated higher number of T cells compared to the 
patient lymph nodes. This and the trend observed in the results may explain the 
reason why female MCL patients tend to have a more favourable outcome.  
It would be interesting to further analyse the T cell subsets; CD3+CD4+ T helper 
cells and CD3+CD8+ cytotoxic T cells in the nodal biopsies to correlate the 
results reported in the above mentioned study.  
 
T Regulatory cells 
The overall trend demonstrated female patients exhibiting a greater number of T 
regulatory cells in the lymph nodes compared to the male patients, although this 
did not achieve significance. This was also observed in the quantification of T 
regulatory cells in the peripheral blood of the female MCL patients compared to 
the male patients as discussed in chapter 3. Although there have been no 
specific studies to date examining the gender difference with T regulatory cells 
in MCL, other studies have demonstrated that greater number of T regulatory 
cells, such as in diffuse large B cell lymphoma correlate to a better overall 
survival. In follicular lymphoma higher tumour infiltrating T regulatory cells have 
shown to be associated with better survival (Lee et al, 2008b; Carreras et al, 
2006). This has also been observed in classical Hodgkin’s lymphoma 
(p=0.004)(Tzankov et al, 2008). Generally, T regs suppress the immune 
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response as discussed in chapter 1. However they are able to directly suppress 
B cells by reducing the expression on AID (activation induced cytidine 
deaminase) and inhibiting their Ig class switch recombination and 
immunoglobulin production (Lim et al, 2005a). Additionally T regulatory cells 
may suppress MCL cell proliferation via the up-regulation of perforin and 
granzymes to induce B cell cytotoxicity and cell death (Zhao et al, 2006). It is 
possible that the gender difference observed in MCL is due to the female MCL 
patients exhibiting greater number of T regulatory cells which may have a direct 
inhibitory effect on the MCL cells. However further larger studies are needed 
with clinical correlation to establish the significance and function of T regulatory 
cells in MCL as it is generally accepted that T regulatory cells appear to have an  
inhibitory effect on T cells (Josefowicz et al, 2012).  
 
NK cells  
The number of NK cells in the lymph nodes examined, were comparable 
between the male and female MCL patients. The quantity of NK cells in the 
patients was lower when compared to the control subject. This could be 
accounted for by a reduced migration of the NK cells into the affected lymph 
node. Migration of NK cells into lymph nodes is facilitated by endogenous IFN-γ 
and dendritic cells expressing chemokine ligands CXCR3 (Wendel et al, 2008; 
Watt et al, 2008). As shown above the normal lymph node architecture in 
patients with MCL examined here is completely distorted and largely comprises 
of MCL cells. Therefore there are fewer endogenous NK cells and possibly 
dendritic cells, resulting in less IFN-γ and chemokine expression within the 
lymph nodes to facilitate migration of NK cells into the affected lymph nodes.   
Immunomodulatory drugs such as lenalidomide have been shown to increase 
238 
 
NK cell migration into the tumour microenvironment by modifying dendritic cell 
responses and altering their chemokine expression profile, supporting the 
above hypothesis that reduced migration of NK cells may be due to the 
presence of MCL (Reddy et al, 2008).  
It was not feasible to analyse by immunohistochemistry the subsets of NK cells; 
CD56bright and CD56dim due to the lack of suitable antibodies and the inability to 
reliably quantify expression levels. In order to determine whether the affected 
nodes from males and females exhibit greater numbers of CD56dim NK cells 
(direct cytotoxicity activity) compared to the CD56bright NK cell (cytokine 
mediated cytotoxicity) a fine needle aspiration from the affected lymph nodes 
would be required. The cells could then be analysed by flow cytometry to 
examine the specific subsets.  
5.6. Oestrogen Receptor β present on MCL 
 
As discussed earlier, studies have suggested that there is probable influence of 
oestrogen on the prevalence of NHL in males and females (Nelson et al, 2001). 
To understand whether there is a direct effect of the female hormones on the 
lymphoma cells, the two ER α and β were examined to establish their 
expression on the MCL cells in the lymph node biopsies of male and female 
MCL patients. Normal B cells express the ERβ and a study by Shim et al, has 
demonstrated that B cells in the mantle zone of the follicles in the lymph nodes 
express primarily ERβ (Shim et al, 2006). As this is the site from which MCL 
cells are derived it is conceivable that they may also express the ERβ and 
therefore possible that female oestrogens could have a greater direct influence 
on the cell characteristics through these receptors. 
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The results confirmed the presence of ERβ on Granta 519 cells and mantle cell 
lymphoma cells in the biopsies from both the male and female MCL patients. 
The expression of ERβ on the MCL cells from both the male and female 
patients had similar pattern of distribution and expression with no significant 
difference.  This is consistent with other studies of MCL and B cell 
lymphoproliferative disorders (Yakimchuk et al, 2014, 2012b). A study as 
demonstrated that activation of ERβ with the oestrogen receptor agonist 
diarylpropionitrile (DPN) and KB9520 significantly inhibit the proliferation of 
engrafted Burkitt lymphoma cells by at least 50% (p<0.001) in NOD SCID mice 
(Yakimchuk et al, 2011a). Other Studies involving mouse models have also 
demonstrated tumour regression in grafted T cell lymphoma with DPN, an ERβ 
agonist (Yakimchuk et al, 2011b). However, it was not clear whether the 
hormone sensitivity reflected in the tumours was due to a direct effect on the 
MCL cells or an effect on the tumour microenvironment. An attempt has been 
made to determine whether the tumour microenvironment comprising of 
immune, endothelial and stromal cells which provide regulatory signals to 
lymphoma cells are influenced by the ERβ receptor they possess or whether the 
ERβ on the lymphoma cells have a direct effect. ERβ-/- mice, treated with ERβ 
agonist DPN, when compared with wild type mice grafted with ERβ positive 
murine EG7 T cell lymphoma cells showed a significant reduction of the EG7 T 
cell lymphoma in both groups of mice but there was no significant difference in 
the response of the lymphoma growth between the two groups suggesting that 
the ERβ agonists did not have much of an effect on the tumour 
microenvironment, but more on the tumour itself. However, further 
investigations are needed to determine whether ERβ expression in cells of the 
microenvironment have a role in lymphomas other than murine EG7 T cell 
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lymphoma tumours, as immunocompromised mice deficient in ERβ expression 
are not widely available (Shim et al, 2003; Yakimchuk et al, 2014). Once this is 
established the subsequent investigations that could be considered include 
investigation into the molecular pathways affected and the plethora of cellular 
genes involved in cell proliferation / inhibition after activation of ERβ. 
Additionally, the ERβ has two splice variants; denoted as receptor β1 and β2  
(Yakimchuk et al, 2013, 2012a; Shaaban et al, 2008).The oestrogen receptor β2 
splice variant is capable of antagonising the proliferative effect of ERα and it 
can heterodimerize with oestrogen receptor β1 and enhance the anti-
proliferative activity (Pettersson & Gustafsson, 2001). It has also been 
described to inhibit ERα thus altering the cellular signalling and survival of the 
cells (Zhao et al, 2007). Therefore, it would be interesting to further identify the 
oestrogen receptor subtype variants present on the MCL cells and determine 
whether expression of particular splice variants would impact on the direct 
action of the oestrogen receptor on MCL, or if males and females differentially 
express the splice variants. 
The results presented certainly provide a good platform from which to further 
investigate the role of oestrogens on MCL. It would however be important to 
confirm these findings in other biopsies from a larger cohort of MCL patients. A 
further confirmation of the expression of ERs with flow cytometry and either 
western blot or PCR may be warranted. Testing other MCL cell lines such as 
REC1 and JVM2 cell lines for the oestrogen receptors would be valuable to 
confirm whether there is any uniformity on the receptor expression in different 
cell lines. Pursuing experiments with oestrogen receptor β agonists and 
antagonists would be interesting to determine if ERβ could be a therapeutic 
target in the treatment of MCL.  
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The presence of ERβ on MCL cells provides some insight into the gender 
difference observed in prevalence and response to treatment in MCL. Further 
studies are needed to understand the role of ER in MCL. These findings 
correlate to others studies and provide an area to investigate further. 
5.7. Conclusion 
There was a trend towards greater number of immune cells in affected lymph 
nodes of the female MCL patients compared to male MCL patients in this 
cohort. This could result in female exerting a greater immune response within 
the tumour microenvironment therefore being able to exhibit better responses to 
therapy. In relation to the immunoediting concept females may be able to keep 
the MCL in check more effectively than males. One of the limitations of this 
study was that it didn’t assess the distribution of the other immune cells that 
form the microenvironment milieu such as the macrophages, dendritic cells, NK-
T cells, NK subsets. Further studies with a greater inclusion of other immune 
cells would be needed to fully appreciate any gender bias which is related to the 
immune cells of the MCL microenvironment. 
Additionally, MCL and Granta 519 cells both express nuclear ERβ. The ERα 
was not expressed on either of the Granta 519 cells or the MCL cells in the 
lymph node biopsies examined. Although it is not clear whether ER have a 
definite role in MCL, however it provides another potential area to investigate. 
As described in chapter 4, exposure of G519 cells to oestrone did not result in 
any direct cell death and there was no increase in cell mediated cytotoxicity 
when PBMCs where exposed to oestrone as well. As mentioned earlier, there is 
no data on the exact concentration or action of oestrogens in the 
microenvironment of MCL and it may be that the doses used in the experiments 
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were inappropriate or that other oestrogens such as oestradiol could have more 
of an influence.    
These observations may aid to explain the gender difference observed in MCL. 
However, larger and broader studies are needed to further investigate these 
findings. 
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Chapter 6 
 
 
Final Discussion 
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The aim of this project was to examine the gender difference displayed in MCL. 
MCL is predominant in males with a 3:1 ratio (males: females). A recent study 
has demonstrated female MCL patients have a better response rate to 
lenalidomide, an immunomodulatory drug, than male MCL patients (Eve et al, 
2012). In addition, epidemiological studies have shown women exhibit a lower 
incidence of B and T cell lymphomas and have a better prognosis (Nelson et al, 
2001; Römer & Pfreundschuh, 2014; Cook et al, 2011).  Lymphomas are not 
generally perceived to be hormone controlled but a study reported by Nelson et 
al suggested oestrogen may have a protective effect against lymphoma (Nelson 
et al, 2001). It is generally recognised that women mount a stronger immune 
response compared to men and the concept of immunosurveillance and 
immunoediting is a well described mechanism by which the immune system 
plays a vital role in eliminating cancer  (Swann & Smyth, 2007).  
6.0. Higher number of T cells in male MCL patients compared to female 
MCL patients 
 
A major finding in chapter 3 was the significantly greater number of T cells 
(CD3+) in the peripheral blood of male MCL patients compared to female MCL 
patients. The T cells subsets; T helper (CD3+CD4+) and cytotoxic T cells 
(CD3+CD8+) also exhibited a trend towards greater numbers in the peripheral 
blood of male MCL patients compared to female MCL patients. 
This finding was contrary to the hypothesis that female patients with MCL would 
exhibit greater numbers of T cells in the peripheral circulation so as to mount a 
greater immune response against cancerous cells compared to the male 
patients. A possible reason could be that greater number of T cells remain 
within or move into affected lymph nodes. In order to examine this concept 
enumeration of T cells (and NK and T regulatory cells) in the lymph nodes of six 
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MCL patients (3 male and 3 female) all presenting with clinically aggressive 
disease was undertaken (chapter 5). The results exhibited a notable trend 
towards greater number of T cells in lymph nodes of female MCL patients 
compared to the male MCL patients. This observation of T cells numbers in the 
nodal biopsy of MCL patients agreed with a recent study reported by Nygren et 
al who demonstrated significantly higher number of T cells in nodal biopsies of 
female MCL patients when compared to male MCL patients (P=0.0009). This 
study also demonstrated that patients with greater number of T cells in the 
nodal biopsy exhibited a better OS (p=0.043) (Nygren et al, 2014).  Together 
these studies suggest that female MCL patients may have a better clinical 
outcome due to a higher number of T cells observed in their lymph node 
biopsies. 
It is possible that the total function of the T cells present in the tumour 
microenvironment may also differ between the genders. This could be either 
due to the difference in the number of T cells and / or their inherent function 
within the tumour microenvironment. There have been no studies to date in 
MCL to evaluate the gender difference with regards to the T cell function within 
the tumour microenvironment. However a study examining the function of the T 
cells in follicular lymphoma demonstrated reduced overall functionality of T cells 
infiltrating the lymphoma. These T cells were found to have a much lower 
signalling response to IL-4, IL-10 and lL-21 cytokine stimulation indicated by low 
phosphorylation of STAT5 and STAT6 measured by phospho-flow cytometry 
(mean fold change of phosphorylation of STAT6 of 0.79 in T cells of FL patients 
compared to 2.18 in healthy controls). They also evaluated T cells from MCL 
patients and although these T cells infiltrating the MCL tumour were found not 
to have as significantly reduced function as those in follicular lymphoma, there 
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was a trend towards lower function compared to the normal T cells from healthy 
controls (Myklebust et al, 2013). Therefore it would be interesting to evaluate in 
additional larger studies the functional difference of T cells from the MCL 
microenvironment between the genders. The T cells could be isolated from 
fresh excised lymph nodes or by fine needle aspiration of the affected nodes. 
Their functional activity could then be compared with the T cells from the 
peripheral blood and between the genders.   
6.1. NK cells  
 
As with T cell numbers, there was a trend towards the male MCL patients 
exhibiting higher number of NK cells (chapter 3) in the peripheral blood 
compared to the female patients and the NK cell (CD3-CD56+) numbers were 
greater in the nodal biopsy of female MCL patients compared to the male MCL 
patients (chapter 5).  The migration of NK cells between the affected lymph 
node and peripheral blood is similar to the T cells. It is possible that there is 
greater migration of NK cells into the affected lymph node in response to the 
cancerous cells resulting in a lower number of NK cells in the peripheral blood 
of female MCL patients. A study reported by Eve, et al, exhibited an initial 
reduction of NK cell numbers in the peripheral circulation of patients with MCL 
when treated with lenalidomide with restoration of these numbers after a period 
of time. They suggested that this observation could be a result of NK cells 
migrating into the affected lymph node which may have been facilitated by 
lenalidomide’s immunomodulatory effect on the tumour microenvironment (Eve 
et al, 2012).  
A further notable finding was the trend towards greater numbers of the NK cell 
subset: CD3-CD56dim in the peripheral blood of male MCL patients compared to 
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the female MCL patients (chapter 3). This trend could be due to more clinically 
indolent MCL patients in the male cohort compared to the female cohort. It was 
not possible to compare the clinically indolent MCL patients between the 
genders due to the limited numbers, however the difference between immune 
cell numbers between male and female MCL patients with clinically indolent and 
aggressive disease would be an interesting area to further evaluate.  A national 
study coordinated by University of Plymouth, Clinical Trials Unit and Derriford 
Hospital is currently in place to collect clinical data and biological material 
including PBMCs and nodal biopsies on clinically indolent MCL patient. This 
would be a valuable potential source to enable this further study. 
The NK subset CD3-CD56dim has been described to have direct cell cytolysis 
without the need for prior activation (Vivier et al, 2012a). Evaluation of their NK 
activating receptors (NKp44, NKp46, NKp30 and NKG2D) demonstrated no 
significant difference between the male and female MCL patients or the healthy 
controls (chapter 3). It has been recognised that the expression of these 
activating receptors correlates to the activation of NK cells (Sivori et al, 
1999).Therefore these results suggest that these NK cells did not exhibit a 
difference in their activation status between the male and female MCL patients 
in the peripheral blood. However, this does not rule out differences of activation 
status between the genders within the tumour microenvironment and this 
warrants further investigation.   A further limitation of this study is that the 
inhibitory receptors of NK cells were not evaluated. It is possible that higher 
expression of inhibitory receptors may be present in MCL patients. Evaluation of 
the inhibitory receptors by flow cytometry on NK cells would be interesting to 
examine both in the blood and in biopsies. 
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Within the affected lymph nodes representing the tumour microenvironment, it 
was not possible to evaluate and quantify the subsets of NK cells; CD3-CD56dim 
and CD3-CD56bright due to the lack of suitable antibody that could identify them 
accurately with IHC technique. One of the methods suggested earlier was to 
obtain cells via a fine needle aspirate of the affected node and using flow 
cytometry identify and quantify the NK cell subsets. It would be interesting to 
examine whether the female MCL patients would exhibit greater number of NK 
subsets; CD3-CD56dim and CD3-CD56bright within the affected lymph node 
compared to the male MCL patients. At the same time NK activation receptors 
on these cells could be analysed by flow cytometry to determine whether they 
have a greater expression compared to the peripheral blood NK cells and 
whether there is a difference between the genders. This may provide some 
insight into whether female MCL patients have more activated NK cells in the 
microenvironment compared to the male MCL patients.  
6.2. T regulatory Cells 
There was a trend towards female MCL patients exhibiting greater number of T 
regulatory cells in the peripheral blood and lymph node biopsies compared to 
male MCL patients (chapters 3 and 5). There are no studies to date that have 
examined the difference of T regulatory cells between the genders in MCL. 
However, studies with other B cell lymphomas have shown greater number of T 
regulatory cells to be associated with a better outcome (Eve et al, 2012; Kelley 
& Parker, 2010; Tzankov et al, 2008).  
T regulatory cells suppress their target cells by releasing inhibitory cytokines 
such as IL-10, TGF-β (inhibits T cell proliferation by disturbing IL-2) and IL-35 
(suppresses T cell proliferation and stimulates T regulatory cells to proliferate 
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and produce IL-10). Interleukin-10 induces suppression of both T helper and 
cytotoxic cells and down regulates the expression of co-stimulatory molecules, 
adhesion molecules and MHC-class II on APCs (Steinbrink et al, 2002). In 
some studies of B cell malignancies better survival has been shown when there 
is a high number of tumour-infiltrating T regulatory cells (Tzankov et al, 2008; 
Lee et al, 2008b). It may be that T regulatory cells have a double role in 
lymphoma. T regulatory cells on one hand could suppress the immune T cells 
therefore facilitating tumour growth but on the other hand they could act to 
suppress or even kill the tumour cells (Lindqvist & Loskog, 2012; Lindqvist et al, 
2011; Mittal et al, 2008). A study by Mittal et al, demonstrated autologous 
malignant B cells to promote T regulatory cell proliferation. They incubated 
malignant B cells from lymphoma patients with CD25- T cells. This resulted in a 
strong induction of the CD25- T cells to develop into T regulatory cells 
(CD4+CD25+FOXP3+) and subsequently expansion of T regulatory cell numbers 
was observed. This study suggested that the presence of the lymphoma 
stimulated the expansion of the T regulatory cells perhaps in order to inhibit the 
T helper cells allowing the lymphoma to proliferate (Mittal et al, 2008).  
In contrast a study reported by Lim et al, demonstrated direct suppression of B 
cells by incubating T regulatory cells with B cells in an otherwise T cell free 
condition. This study demonstrated reduction of IgG and IgA production from B 
cells as a result of the action of T regulatory cells. However it was highlighted in 
this study that direct T regulatory contact was needed in order to suppress the 
activity of the B cells (Lim et al, 2005b). Another study reported by Likuni et al, 
demonstrated direct cytotoxicity action of T regulatory cells on B cells. They co-
cultured T regulatory cells with autologous B cells from patients with systemic 
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lupus erythematosus and demonstrated B cell death by flow cytometry using 
Annexin V and 7-AAD staining (Likuni et al, 2009). 
If the role of T regulatory cells in MCL lymphoma involves direct killing of 
lymphoma cells then it could be that the higher number of T regulatory cells in 
the peripheral blood and lymph node biopsies of female MCL patients 
compared to the male patients could in part explain why females do better than 
males. Further investigations are needed to clarify the role and function of T 
regulatory cells in patients with MCL and to determine whether they influence 
the gender bias. 
6.3. Healthy controls exhibit greater cell mediated cytotoxicity compared 
to MCL patients 
 
After the enumeration of the immune cells in the peripheral blood, the functional 
activity of these cells was evaluated by examining the cell mediated cytotoxicity. 
The major finding was an overall reduced cytotoxic activity of the effector cells 
from MCL patients when compared to the healthy controls on Granta 519 target 
cells (chapter 4). One of the possible reasons for this could be the presence of 
inhibitory ligands produced by cancerous cells to evade or inhibit the immune 
response. A study reported by Wang et al, demonstrated the presence of B7-H1 
ligand which is a member of the B7 co-inhibitory / co-stimulatory ligand in MCL. 
The presence of B7-H1 inhibited T cell proliferation, impaired antigen specific T 
cell response and inhibited T cell mediated cytolysis. Blocking the action of the 
B7-H1 ligand allowed for the restoration of T cell function. (Wang et al, 2013a). 
Other studies of B cell malignancies have also demonstrated ligands to activate 
PD-1 inhibitory receptors on T cells. For example in a study of CLL the tumour 
cells exhibited a marked increase in PD-1 ligand (PG-L1)  compared to non-
malignant B cells from healthy controls (Ramsay et al, 2012). Activation of the 
251 
 
PD-1 (anti-programmed cell death 1) results in immunosuppressive signals that 
inhibit the kinases that are involved in the activation of T cells through 
phosphatase SHP2. These ligands also have been known to inhibit NK cells 
(Paulos & June, 2010; Nunes et al, 2012; Ramsay, 2013).  
Inhibitory ligands on T cells such as the B7-H1 ligand mentioned above could 
be potential future targets for therapy. If other ligands such as Anti-cytotoxic T 
lymphocyte associated antigen (CTLA4 / CD152)  could be identified in MCL, 
then these could potentially be inhibited by an antagonistic CTLA4-targeted 
antibody (ipilimumab) which has shown promising clinical responses in NHL 
(Ansell et al, 2009). Anti-PD-1 monoclonal antibody such as the CT011 antibody 
is currently being explored in haematological malignancies with some promising 
results. In addition, antibodies and small molecule inhibitors targeting numerous 
immune molecules which include inhibitory ligands B7-H3, B7-H4 (VTCN1), T- 
cell immunoglobulin and mucin domain containing molecule 3 (TIM-3) are now 
entering clinical trials (Ramsay, 2013).  
6.4. No significant difference was observed in the cell mediated 
cytotoxicity of effector cells from male and female MCL patients 
 
In examining the cell mediated cytotoxicity of effector cells from male and 
female MCL patients, there was no significant difference observed. In addition 
to the potential reasons for this observation described in chapter 4, this result 
could also be due to the effect of the lymphoma itself. Once the lymphoma has 
managed to escape the immune surveillance any gender difference could be 
diminished by inhibitory ligands produced by the tumours. One of the limitations 
of this study is the small number of participants. To fully evaluate and validate 
these results, studies with larger number of participants are needed. There are 
plans to continue recruitment of MCL patients by collaborating with multiple 
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sites which would result in a larger number of participants. Also the imminent 
launch of the MCL observational and Biobank national study coordinated by the 
University of Plymouth, Clinical Trials Unit will allow further participants for 
these studies to be recruited. 
6.5. Incubation with IL-2 results in increased cell mediated cytotoxicity 
 
Expectedly, incubation of PBMCs with IL-2 demonstrated a significant increase 
in cell mediated cytotoxicity in all groups except female MCL patients, where the 
rise in cell mediated cytotoxicity was not as pronounced as in the other groups 
(chapter 4). The increase in cell mediated cytotoxicity was probably in part due 
to the activation of NK cells by IL-2 which was supported by the results that 
demonstrated increased expression of NK cell activating receptors (NKp44, 
NKp30, NKG2) (chapter 4). 
The increase in cell mediated cytotoxicity observed largely in male MCL 
patients correlates to a study by Carter et al, which demonstrated murine T cells 
inhibited by PD-1 ligands overcame their inhibition by exogenous IL-2. This 
study suggested that the inhibition of T cell activity was due to the low 
production of indigenous IL-2  which was thought to be secondary to the 
inhibitory pathways activated by the PD-1 ligand (Carter et al, 2002). However, 
there is no clear explanation as to why the female MCL patients exhibited a 
lower cell mediated cytotoxicity compared to the male MCL patients when 
exogenous IL-2 was added. It is possible that the lower number of immune cells 
present in the PBMCs of female MCL patients may have resulted in the lower 
cell mediated cytotoxicity observed in these patients (chapter 4). In addition 
there was a greater number of T regulatory cells in female MCL patients 
samples which in turn could have had an inhibitory effect on the cytotoxic T 
cells if the IL-2 effect on the T regulatory cells would have caused a 
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disproportionate expansion.  The results observed in MCL patients could also 
be due to the clinical subtype of MCL present in the patients. The effector cells 
from male MCL patients that were examined were from patients with clinically 
less aggressive MCL compared to the female MCL patients. Although these 
‘less aggressive’ patients did not meet the strict definition of clinically indolent 
disease (MCL in asymptomatic patients who did not require immediate therapy 
and were observed for more than one year) they did have an initial period of 
monitoring without requiring immediate therapy. 
Either way this observation is worth following up with further larger studies. If it 
can be demonstrated that the activity of the immune cells is enhanced with 
exogenous IL-2 in all MCL patients, this could be exploited as an additional 
therapy for selected patients. A phase one trial in which relapsed / refractory 
NHL patients received weekly rituximab (an anti-CD20 antibody) therapy with 
IL-2 infusions demonstrated an overall 29.4% clinical response. They also 
demonstrated an expansion of the NK cell numbers and an increase in antibody 
dependent cellular cytotoxicity (ADCC) activity which was sustained with IL-2 
administrations (Gluck et al, 2004).  
6.6. Lenalidomide and Oestrone did not alter cell mediated cytotoxicity in 
male and female MCL patients 
 
Addition of lenalidomide or oestrone or a combination of lenalidomide and 
oestrone to effector cells did not result in a significant difference in cell mediated 
cytotoxicity between the genders. These results were in contrast to other 
studies in which there was an increase in cell mediated cytotoxicity and number 
of effector cells after incubation with lenalidomide (Davies et al, 2001; 
Richardson et al, 2010; Chanan-Khan et al, 2006). One of the main reasons for 
these observations is probably the shorter incubation time (24 hours) and 
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differing doses when compared to other studies. Additional plans to extend the 
incubation time and repeat the cell mediated cytotoxicity experiments should be 
considered to further investigate these observations. 
6.7. Oestrogen receptor β is present on MCL 
 
The presence of ERβ on MCL as described in chapter 5 correlates to other 
studies exploring oestrogen receptors on lymphoid malignancies and MCL 
(Yakimchuk et al, 2014, 2011b, 2013). ERβ is thought to have an anti-
proliferative and apoptotic effect when activated (Yakimchuk et al, 2011a; 
Nilsson & Koehler, 2005), but as yet the exact role of ERβ in MCL has not been 
fully defined or described. However, a recent study has provided some useful 
insights. Using the ERβ agonist DPN, they demonstrated that it could inhibit 
Granta 519 cell proliferation when engrafted in mouse models. They also 
showed inhibition of vascularisation of the lymphoma with a reduction of 
vascular endothelial growth factors (VEGFs) and LYVE-1; a lymphatic 
endothelial marker (Yakimchuk et al, 2014).  
To further explore whether ERβ has a role in influencing the gender difference 
observed in MCL, it would be interesting to investigate the effects of the other 
female hormones such as oestradiol and oestriol on the proliferation of MCL. 
This could be achieved by incubating Granta 519 cells over a period of time with 
varying concentrations of these hormones and utilising CSFE to monitor Granta 
519 cell proliferation by flow cytometry. Subsequently mouse models could be 
utilised to further explore this. Male mice engrafted with Granta 519 cells could 
be injected with the female hormones (oestrone, oestradiol and oestrial) at 
varying concentrations and time periods to determine whether they have an 
effect on the lymphoma growth. Klanavo et al, described their method of 
255 
 
engrafting established MCL cell lines like G519 cells in immunodeficeint non 
obese diabetic mouse models with success (Klanova et al, 2014). This model 
with ERβ-/- mouse models could be utilised. However it has to be acknowledged 
that the availability of this type of mouse model would be difficult to source, but 
collaboration with other research groups could potentially aid this research 
which have successfully engrafted MCL cells onto mouse models (Iyengar et al, 
2015). 
As mentioned before ERβ could prove to be a potential therapeutic target. 
Further studies with ERβ agonist such as DPN and KB9520 and antagonists 
like PHTPP (4-[2-Phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-
yl]phenol) are needed to establish the role of ERβ receptor on MCL (Yakimchuk 
et al, 2013). 
ERβ presents an area that could be explored further. A study with mouse 
models has demonstrated suppression of engrafted Burkitts lymphoma (which 
express ERβ)  in non-obese diabetic SCID mice by treatment with ERβ agonist 
DPN compared to vehicle control treated mice (Yakimchuk et al, 2013). In the 
context of clinical applications further studies are needed but initial data from 
studies already carried out is promising. 
6.8 Further Studies 
As already addressed earlier, acquisition of more samples from MCL patients 
would be critical to pursue this work further. It would also be interesting to group 
the patients in two groups, with one group having clinically indolent MCL and 
the other clinically aggressive MCL, followed by comparing the gender 
difference in the respective clinically indolent and aggressive groups. This 
would be possible by the recently approved National Cancer Research Network 
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(NCRN) UK mantle cell lymphoma observational trial where access to 
diagnostic materials from MCL patients would be available for further research. 
This study was limited in the number of immune cells that were investigated. 
Other immune cells such as NKT cells, macrophages and T cells such as TFH 
cells could also be analysed between the genders to develop a more complete 
description of the immune cells between the MCL genders. It would also be 
beneficial to explore the difference of the NK inhibitor receptors (KIR, KIRL) 
between the groups as it was done for the activating receptors NKp46, NKp44, 
NKp30 and NKG2D. Unfortunately due to the limited diagnostic and patient 
material it was not possible to pursue the isolation of NK and various T cells 
from the peripheral blood. With further patient material this is an area that would 
benefit from further investigation as PBMCs do not produce accurate data on 
individual immune cells.  
This study used peripheral blood for analysis, as this was easy to access and 
minimally invasive for the patients and control.  However, cells from the 
microenvironment i.e aspiration form the affected nodes would be interesting to 
analyse. Plans for this were in place, but due to the rarity of this disease and 
more so the availability of patients with safely accessible lymph nodes to 
aspirate was difficult. Nonetheless it is an area which would be interesting to 
research. Furthermore at the same time cytokines and chemokines (IL-2, IFN-γ, 
IL-6, IL-13, CXCR5, CXCR7) from patient serum should also be analysed from 
MCL patients and between genders to ascertain and gender difference. 
One of the key investigations needed here is to simulate the microenvironment 
by creating an in-vitro microenvironment followed by analyses of the MCL cell 
growth when exposed to various oestrogen, ERβ agonists such as DPN, and 
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treatments with lenalidomide. This would provide a closer data to the in-vivo 
environment of MCL. This may be achieved by either growing MCL cell lines or 
primary MCL on pre-stablished confluent of stromal or fibroblast cells. Once 
established further research may be done by introducing various cells like NK 
cells, T cells or treatments as described above to analyse the effects (Medina et 
al, 2012). This would also provide the basis of the first research paper with this 
work. 
Having shown that Granta 519 cells and MCL cells from patients exhibited ERβ 
receptor additional experiments with ERβ agonists and antagonist would be 
interesting as described above. This would provide initial data on whether ERβ 
is functional on these cells and subsequently down-stream proteins as 
discussed earlier in chapter 1 could be analysed to demonstrate further their 
functionality.  
 
 
6.9. Final Conclusion 
 
This study has demonstrated a significantly higher number of circulating T cells 
in male patients with MCL. The significance of this finding needs to be 
investigated further through larger studies. 
Although there was no significant difference in the cell mediated cytotoxicity 
demonstrated by effector cells between male and female MCL patients, the 
overall cell mediated cytotoxicity was impaired in patients with MCL compared 
to healthy control subjects, suggesting MCL could have an overall suppressive 
effect on the immune system.  
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The difference in prevalence of MCL between the genders could be related to 
the presence of ERβ on the MCL cells. However, this is only a suggestion and 
is an area which would particularly benefit in further research as it may provide 
another pathway to target when treating MCL. 
An area of increasing interest is the epigenetics in MCL and cancer. This is an 
area that could be explored further at the same time as the other suggested 
studies. Epigenetics are heritable changes in gene expression that are not due 
to an alteration in the DNA sequence (Esteller, 2008). The most common 
epigenetic marker is DNA methylation (Esteller, 2008). Studies which have 
included genome-wide screening have addressed the potential inactivation of 
specific tumour suppressor genes by methylation in MCL (Leshchenko et al, 
2010). A recent study identified five frequently methylated genes in primary 
MCL cells (SOX9, HOXA9, AHR, NR2F2 and ROBO1). This study 
demonstrated methylated SOX9 or HOXA9 was associated with a high 
proliferation index Ki-67 (p<0.002) and a shorter overall survival. This suggests 
that epigenetics changes may play an important role in the pathogenesis of 
these tumours (Enjuanes et al, 2011). This concept can be used to identify 
whether different epigenetics between male and female MCL patients occur. 
With the development of rapid sequencing technology this can be done rapidly 
and more economically (Morozova & Marra, 2008). If a difference is found this 
may provide further insight into the gender difference in MCL and potential 
targets for new tailored therapies.    
In conclusion the greater prevalence of MCL in males compared to females 
remains to be explained. The processes involved in the development and 
elimination of lymphoma are extremely complex and are continued to be studied 
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and understood. However this thesis provides an insight into a few of the 
possible mechanisms that may be involved. 
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Publications during the MD study period 
(copies of the publications are in the pouch at the back) 
 
 
International Journal of Hematologic Oncology. 2014; 3(1): 31-40  
Management perspective for mantle cell lymphoma 
Shah N, Rule S. 
 
Abstract: 
Mantle cell lymphoma (MCL) is genetically characterized by the t(11;14) (q13;q32) translocation 
resulting in the overexpression of cyclin D1. It generally has an aggressive clinical course with a 
poor prognosis. However, there is now a recognized subgroup with clinically indolent MCL. 
Management of MCL can be challenging. Early recognition of young and fit patients for potential 
intensive therapy and autologous stem cell transplant is important. Combination of rituximab 
with high-dose cytarabine should be used in upfront therapy for appropriate patients. In elderly 
and/or less fit patients, chemoimmunotherapy may be considered. Novel agents offer promising 
potential in the management of MCL and are likely to change the way it is treated. 
 
 
Expert Rev Hematol. 2014 Oct; 7(5):521-31 
Ibrutinib for the treatment of mantle cell lymphoma. 
Shah N, Hutchinson C, Rule S. 
 
Abstract: 
Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin’s lymphoma. It 
can follow a heterogeneous clinical course but generally patients relapse early after standard 
immunochemotherapy regimens and develop resistance to subsequent therapies. For younger 
patients, intensive approaches followed by autologous stem cell transplantation offer excellent 
long-term disease control but with the possible exception of an allogenic stem cell transplant, 
MCL is an incurable condition. As MCL principally affects older individuals, the majority of 
patients are not candidates for such intensive approaches. Ibrutinib is an orally active, 
Bruton’s tyrosine kinase inhibitor. It inhibits signaling pathways downstream of Bruton’s 
tyrosine kinase that appear critical for the proliferation and survival of MCL. As a single agent 
it has shown extremely promising activity in relapsed and refractory MCL patients with an 
excellent side-effect profile. The exact role for ibrutinib in the treatment of MCL is yet to be 
established; however, it is likely to fundamentally change the way we treat this disease. 
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Leuk Lymphoma. 2014 Nov 20:1-12 epub ahead of print. 
How applicable is fludarabine, cyclophosphamide and rituximab to the elderly? 
Shah N, Tam C, Seymour JF, Rule S. 
 
Abstract: 
The combination of fludarabine, cyclophosphamide and rituximab (FCR) has been widely used 
in the treatment of lymphoproliferative disorders, and is now considered as the standard first-
line therapy for fit, young patients with chronic lymphocytic leukemia (CLL). However, in routine 
practice, the majority of patients with lymphoproliferative disease are over the age of 70 years, 
and most studies involving FCR have included younger, "fitter" patients, on average in their 
sixth decade of life. It is not easy to extrapolate the results of these studies to routine practice. 
In general, the impression is that FCR is less well tolerated in more elderly patients (> 70 years) 
with good organ function. However, there is a relative paucity of evidence to support this. In this 
review we aimed to critically examine evidence of the efficacy and toxicity of FCR in the elderly 
patient 
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Presentations at Scientific meetings during the MD study period 
Significant gender differences in the number and distribution of T cells in patients with 
Mantle Cell Lymphoma. 
NK Shah
1,2
, S. Richardson
3
, N Crosbie
2
, S Rule
1,2
 
1
Peninsula Schools of Medicine and Dentistry, University of Plymouth, UK;  
2
Derriford Hospital, Plymouth Hospitals NHS Trust, UK 
3 Institute of Biomedical and Clinical Sciences, University of Exeter Medical School 
 
Mantle cell lymphoma (MCL) is a rare B cell neoplasm that accounts for approximately 4-8% of 
non-Hodgkin’s lymphomas (NHLs). The median age at diagnosis is 65 years with a male to 
female predominance of 3:1. T cells are central to the adaptive immune system which is part of 
the initial defence against cancerous cells. It is perceived that females mount a greater immune 
response compared to males. As part of our investigations to account for the gender difference 
in MCL, we examined the T cells (CD3+) and their subsets; Helper (CD3+CD4+) and cytotoxic T 
cells (CD3+CD8+). 
Peripheral blood of twelve untreated MCL patients (6 male and 6 female patients) was 
evaluated using flow cytometry to enumerate the T cells and the subsets.  
The male patients exhibited a significantly greater total mean number of T cells compared to the 
female patients (2488 cells/µl vs.1245 cells/µl, respectively)(P=0.04) and both the helper T cells 
(1229 vs 737 cells/µl, male vs females, respectively) and cytotoxic T cells (789 vs 375 cells/µl, 
males vs. females, respectively) were observed to be higher in the male patients (p>0.05). We 
subsequently analysed T cells numbers in the lymph node biopsies from a clinically 
homogeneous group of 3 male and 3 female treatment naive MCL patients. Conversely, the 
female MCL patients had a greater total number of T cells in the lymph nodes compared to male 
patients (5032 cells vs 3322 cells, respectively)(p>0.05). 
These findings suggest that female patients may be able to mount a greater immune response 
compared to male patients by exhibiting greater number of T cells within the tumour 
microenvironment. Further larger studies are needed to correlate these findings with clinical 
parameters. 
 
Accepted as a poster presentation at the British Society of Haematology Annual Scientific 
Meeting April 2015. 
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Single centre outcome of mantle cell lymphoma over the past decade 
NK Shah
1,2
, M Furtado
1,2
, N Crosbie
2
, S Rule
1,2
 
1
Peninsula Schools of Medicine and Dentistry, University of Plymouth, UK;  
2
Derriford Hospital, Plymouth Hospitals NHS Trust, UK 
Mantle Cell lymphoma (MCL) accounts for 6–8% of all non-Hodgkin lymphomas. It has a 
heterogeneous clinical course with poor prognosis and a challenge to treat. We retrospectively 
analysed 51 MCL patients diagnosed and managed in Plymouth between 2000 and 2010. 45/51 
patients were included. Patient characteristics, therapies and biological markers were evaluated 
with regards to overall survival rate (OS). Up-front treatment regimens were categorised into 
treatment within clinical trials or physician’s choice. The median age was 68 years (range: 40–
88) and 58% (26/45) of the patients were older than 65 years (45% and 95% OS at 3 years in 
patients >65 and <65 years, respectively, p = 0.0001). There was a 3:1 predominance of male 
to female patients. The median follow up  as 5 years and the median OS was 59 months. The 
OS at 2, 4 and 6 years were 71%, 57% and 38%, respectively. 15% (7/45) patients had initial 
treatment deferred resulting in a 57% OS at 3 years. 38% (17/45) of the patients were treated 
up-front within a trial. The OS at 3 years was 65% vs. 60%, p = 0.603, in patients treated within 
and outside clinical trials,  respectively. There was no difference in the 3 year OS between 
patients with a monocyte count greater or less than 0.5 9 10*9/l (p = 0.873). However, there is a 
significant difference in OS at 3 years when correlated to MCL Prognostic Index (MIPI). 100% 
and 45% OS with low plus intermediate and high MIPI, respectively (p = 0.004). In 2004, a 
specialist service for MCL was developed. The 3 year OS for patients diagnosed and managed 
after this date showed a significant improvement (82% vs. 47%, p = 0.04). This unselected 
group of patients demonstrate significant improvement in OS over the past decade correlating 
to advances made in available treatment and notably development of specialised services for 
MCL. 
Poster presentation at British Society of Haematology Annual Scientific Meeting April 2014. 
Br J Haematol. 2014 April; 165 (s1) 
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A phase I study of the oral Btk inhibitor ONO-4059 in patients with relapsed/refractory 
B-cell lymphoma 
NK Shah
1
 ,S Rule
1
, G Salles
2
, L Karlin
2
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3
, L Terriou
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, M Dyer
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, C Hutchinson
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1
Department of Haematology, Derriford Hospital, Plymouth, UK; 
2
Department of Hematology, 
Hospices Civiles de Lyon, Centre Hospitalier Lyon Sud, Lyon, France; 
3
Service Maladies du 
Sang, CHRU – Hospital Claude Huriez, Lille, France; 
4
Department of Cancer Studies and 
Molecular Medicine, University of Leicester, UK; 
5
Department of Haematology, Cardiff 
University, UK; 
6
Departement d’Hematologie Clinique, CHU Montpellier, Montpellier, France; 
7
Wright Dose Limited, Manchester, UK; 8Linden Oncology, Edinburgh, UK; 
9
ONO Pharma UK 
Ltd, London, UK; 
10 
ONOPharmaceutical Co. Ltd, Osaka, Japan. 
 
Bruton’s tyrosine kinase (Btk) is a critical kinase in B-cell receptor (BCR) signal transduction and 
recent studies support that targeting Btk is effective in the treatment of B-cell malignancies. 
ONO-4059 is a selective, highly potent oral Btk inhibitor that has demonstrated anti-tumour 
activity in pre-clinical models. This Phase I study was initiated to determine the safety, 
tolerability, dose-limiting toxicity (DLT), pharmacokinetics and pharmacodynamics of ONO-4059 
given as monotherapy (QD) to patients with relapsed/refractory NHL. We present the safety and 
efficacy data on 14 evaluable patients (mantle cell lymphoma n = 7, follicular lymphoma n = 3, 
plasmablastic-DLBCL n = 1, ABC-DLBCL n = 1, small lymphocytic lymphoma n = 1 and 
Waldenstrom’s macroglobulinaemia n = 1), with a median age 64 years (range 48–88). Patients 
received a median of 3 prior therapies (range 2–8) and 93% (13/14) having prior exposure to a 
rituximab- containing regimen. Patients received ONO-4059 at doses ranging from 20–160 mg 
(cohorts 1–4). ONO-4059 was well tolerated, with no DLTs. A total of 18 ONO-4059-related 
adverse events were reported in 6 out of 14 patients; 15 adverse events were CTCAE-V4.0 G1 
(n = 10) and G2 (n = 5). Three G3 haematological toxicities were reported in 2 patients; 
thrombocytopenia(x2) and anemia. No ONO-4059-related G4 events, or SAEs or infections 
were reported. Responses have occurred at doses of 40, 80 and 160 mg, with a best overall 
response rate of 42%; with 5 PR, 4 SD, 2 PD (both 
MCL). Three MCL patients have achieved PR resulting in a best ORR of 50%. Almost all 
patients experienced clinically meaningful rapid reductions in lymphadenopathy observed within 
the first cycle. 10/14 patients are still on study with a median progression-free survival 
of 93.5 days [Range 8–268]. In conclusion, ONO-4059 is a selective, highly potent oral Btk 
inhibitor showing a favourable safety profile with promising efficacy in this difficult-to-treat 
patient population. The study is currently ongoing with additional dose escalation cohorts. 
Br J Haematol. 2014 April; 165 (s1) 
Poster presentation at British Society of Haematology Annual Scientific Meeting April 2014. 
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The bruton’s tyrosine kinase (BTK) inhibitor ono-4059: promising single agent activity in 
patients with relapsed and refractory NHL 
F Morschhauser, L Terriou, M Dyer, C Hutchinson, S Rule, N Shah, G Salles, L Karlin, C Fegan, 
J Bagshawe, G Cartron, H Honda, A Nishimura, J Sharpe, T Ohno, T Yoshizawa, T Yasuhiro, J 
Birkett 
Haematologica 2014: 99 (s1) - Poster presentation at European Hematology Annual meeting 
2014. 
 
A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory 
B-Cell Lymphoma 
Simon Rule, Nimish Shah, Gilles Andre Salles, Lionel Karlin, Franck Morschhauser, Louis 
Terriou, Martin JS Dyer, Claire Hutchinson, Chris Fegan, Guillaume Cartron, Tomasz 
Knurowski, James G Wright, Andrew J Saunders, Hideyuki Honda, Andrew Mazur, Toshio 
Yoshizawa, Kazuhito Kawabata, Joseph TP Birkett 
Blood 2013; 122 (21):4397 
Poster presentation at the American Society of Heamatology Annual meeting 2013 
 
A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory 
and High Risk Chronic Lymphocytic Leukaemia (CLL). 
Gilles Andre Salles, Lionel Karlin, Simon Rule, Nimish Shah, Franck Morschhauser, Louis 
Terriou, Martin JS Dyer, Claire Hutchinson, Chris Fegan, Guillaume Cartron, Tomasz 
Knurowski, Andrew J Saunders, James G Wright, Hideyuki Honda, Bsc, Andrew Mazur, Toshio 
Yoshizawa, Kazuhito Kawabata, Joseph TP Birkett 
Blood 2013 122 (21):676 
Presentation at the American Society of Heamatology annual meeting 2013 
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Natural killer cells and their clinical correlation in mantle cell lymphoma (MCL) 
N Shah, M Furtado, H Eve, S Rule 
Department of Haematology, Derriford Hospital, Plymouth, UK 
Natural Killer cells (NK) are essential for innate immunity with evidence that they can recognise 
and control some tumour growth. We have shown that in MCL, the activity of the 
immunomodulatory 
drug lenalidomide, correlates with NK cell numbers. As such we undertook an observational 
study monitoring NK cells in unsolicited patients with MCL, over a 5 year period and 
retrospectively correlated this with clinical findings. Using flow cytometry (BDmultikit CD3  
CD16+ CD56+), peripheral blood was used to identify NK count (normal range 160–660 
cells/lL). Patients with more than two sequential NK counts were selected. A total of 19 patients 
(median age 65 years, 1:5-female to male ratio) where evaluated. Eighty-nine percent (17/19) of 
patients had relapsed MCL (1–4 prior regimens, including rituximab, ofatumamab, thalidomide, 
lenalidomide and one patient had an allogenic stem cell transplant). Eleven percent (2/19) had 
clinically indolent MCL were treatment naive with normal baseline NK counts. Forty-two percent 
(8/19) of the patients had a significant drop in the NK cell count 
(<100 cells/lL) at relapse, of which 50% had no therapy prior to relapse for at least 2 months (1–
8) and 50% relapsed while on treatment with lenalidomide or Ibrutinib. Patient who responded 
clinically 
to therapy after relapse showed a rise in NK cell numbers. Twenty-five percent of the patients 
with reduced NK cells had refractory disease. Twenty-one percent (4/19) of the patients 
presented 
with massive splenomegaly, of which 75% had NK counts greater than 1000cells/lL. These 
patients showed a normalisation of NK cell counts in response to treatment. This unique data 
correlating NK counts with clinical findings suggests that in a significant number of patients, 
relapse can be heralded 
by a fall in NK cell number. This opens the possibility of using this as a simple means to monitor 
disease activity. 
Br J Haematol. 2013 April; 161 (s1) 
Poster presentation at British Society of Haematology Annual Scientific Meeting April 2013. 
 
 
 
 
